text stringlengths 65 123k | url stringlengths 25 420 | crawl_date timestamp[us, tz=UTC]date 2022-04-01 01:00:57 2022-09-19 04:34:04 |
|---|---|---|
Sapiens Reinsurance solution will improve efficiency and enable auditable processing to better serve partners
RALEIGH, N.C., Sept. 6, 2022 /PRNewswire/ -- Sapiens International Corporation (NASDAQ: SPNS) (TASE: SPNS), a leading global provider of software solutions for the insurance industry, announced today that AEGIS, a leading mutual insurance company, has selected Sapiens ReinsurancePro to enhance their internal controls processes, automated calculations and reporting. Sapiens ReinsurancePro replaces AEGIS' complex combination of disparate custom applications and spreadsheets to streamline and optimize processes.
"Implementing Sapiens Reinsurance solution will help us manage the increasing volume and complexity of our ceded reinsurance strategy and quickly respond to new reinsurance offerings," said Scott Schenker, AEGIS Senior VP & CIO. "Sapiens' solution stands out in the industry for its proven ability to automate complex reinsurance requirements and improve efficiency. The solution will expand our capabilities to manage complex structures and total capacity, within a competitive cost structure."
"We are very pleased to empower AEGIS in their quest for full financial control of the reinsurance processes and to enable them to increase efficiency by streamlining the process," said Jamie Yoder, Sapiens North America President & General Manager. "Our platform enables AEGIS to take ownership of their data and proactively conduct analysis on that data instead of relying on IT or external parties, so they can better serve their customers."
Sapiens ReinsurancePro supports all types of reinsurance processing, regardless of volume, in one comprehensive and powerful reinsurance system, empowering insurance companies to manage and automate the underwriting and administration of reinsurance, including treaty and facultative, ceded, assumed and retroceded reinsurance.
About AEGIS
AEGIS is a leading mutual insurance company that provides liability and property coverage, as well as related risk management services, to the energy industry. Its policyholders represent virtually the entire energy infrastructure in North America, including electric and natural gas utilities, related energy companies, oil & gas exploration and production companies, water utilities, and transmission & distribution companies. For more information, visit www.aegislink.com/
About Sapiens
Sapiens International Corporation (NASDAQ and TASE: SPNS) empowers the financial sector, with a focus on insurance, to transform and become digital, innovative, and agile. Backed by 40 years of industry expertise, Sapiens offers a complete insurance platform, with pre-integrated, low-code solutions and a cloud-first approach that accelerates customers' digital transformation. Serving over 600 customers in 30 countries, Sapiens offers insurers across property and casualty, workers' compensation and life markets the most comprehensive set of solutions, from core to complementary, including Reinsurance, Financial & Compliance, Data & Analytics, Digital, and Decision Management. For more information, visit www.sapiens.com or follow us on LinkedIn.
Media Contact
Shay Assaraf
Chief of Marketing, Sapiens
Shay.assaraf@sapiens.com
Investor's Contact
Dina Vince
Head of Investor Relations, Sapiens
dina.vince@sapiens.com
Forward Looking Statements
Certain matters discussed in this press release that are incorporated herein by reference are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words "anticipate," "believe," "estimate," "expect," "may," "will," "plan" and similar expressions. Such statements reflect our current views with respect to future events and are subject to pandemic risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers' systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the recent novel coronavirus pandemic, which adversely affected our results of operations, or fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company.
While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.
Logo: http://mma.prnewswire.com/media/585787/Sapiens_Logo.jpg
View original content:
SOURCE Sapiens International Corporation | https://www.whsv.com/prnewswire/2022/09/06/aegis-selects-sapiens-automate-modernize-its-reinsurance-processes/ | 2022-09-06T12:54:44Z |
Members of BTS already received a special deferment. Instead of serving the mandatory 18 months by the time they turn 28, they can wait until they're 30. The two oldest members are now 29.
Copyright 2022 NPR
Members of BTS already received a special deferment. Instead of serving the mandatory 18 months by the time they turn 28, they can wait until they're 30. The two oldest members are now 29.
Copyright 2022 NPR | https://www.wyomingpublicmedia.org/2022-09-06/will-south-koreans-get-a-say-in-whether-a-boy-band-is-exempt-from-military-service | 2022-09-06T12:54:48Z |
PASADENA, Calif., Sept. 6, 2022 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE) today announced that its Board of Directors declared a quarterly cash dividend of $1.18 per common share for the third quarter of 2022. The dividend is payable on October 14, 2022, to shareholders of record on September 30, 2022. The common stock dividend for the 12 months ending September 30, 2022, of $4.66 per common share represents an increase of 24 cents, or 5 percent, over the 12 months ended September 30, 2021.
The dividend allows the company to share its continued high-quality, strong and increasing net cash provided by operating activities with its common shareholders while retaining a significant portion for reinvestment into its highly leased pipeline of new Class A development and redevelopment projects. For the 10-year period ending December 31, 2022, the company expects an aggregate $2.0 billion of cash flows from operating activities after dividends will have been generated for reinvestment. Additionally, its funds from operations (FFO) payout ratio (quarterly common stock dividends divided by quarterly funds from operations) remains favorably low at 56 percent for the three months ended June 30, 2022. Growth in the company's net cash flows provided by operating activities continues to generate opportunities to increase the company's quarterly cash dividend per common share while maintaining a low FFO payout ratio.
About Alexandria Real Estate Equities, Inc.
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® urban office real estate investment trust, is the first, longest-tenured and pioneering owner, operator and developer uniquely focused on collaborative life science, agtech and technology campuses in AAA innovation cluster locations. Founded in 1994, Alexandria pioneered this niche and has since established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland and Research Triangle. For more information, please visit www.are.com.
This press release contains "forward-looking statements" within the meaning of the federal securities laws. Actual results might differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained in the company's Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission.
CONTACT: Sara Kabakoff, Vice President – Communications, (626) 788-5578, skabakoff@are.com
View original content:
SOURCE Alexandria Real Estate Equities, Inc. | https://www.whsv.com/prnewswire/2022/09/06/alexandria-real-estate-equities-inc-declares-cash-dividend-118-per-common-share-3q22-an-aggregate-466-per-common-share-12-months-ending-september-30-2022-up-24-cents-or-5-percent-over-12-months-ended-september-30-2021/ | 2022-09-06T12:54:50Z |
Ani Banerjee, a Canadian, 30-year leader in Human Resources in the technology sector has joined the KnowBe4 team as CHRO.
TAMPA BAY, Fla., Sept. 6, 2022 /PRNewswire/ -- Ani Banerjee has joined KnowBe4, provider of the world's largest security awareness training and simulated phishing platform, as Chief Human Resources Officer (CHRO). A leader in Human Resources for the global technology sector, Banerjee will oversee KnowBe4's HR operations across 11 countries, and will be responsible for developing new initiatives to enhance the company's organizational culture, its recruitment channels, and its diversity, inclusion, and equity (DIE) strategies.
Banerjee's 30 years' experience in innovation and global HR leadership has been at Dell, Yahoo and AOL, throughout North America, Asia and Europe. Prior to joining KnowBe4, he was at VMware for 8 years in a variety of international HR leadership roles, which culminated in his most recent one, as the company's Global HR Head for SaaS Transformation Business Units.
"I came to KnowBe4 in part because the company has a strong, innovative culture, and extremely high caliber staff," Banerjee said. "I saw that within the company people operate as business partners to achieve common goals, which is something of a brass ring for HR. KnowBe4 is clearly one of the leaders contributing to Tampa Bay's emergence as a vibrant high tech hub. It's an exciting time to be involved."
KnowBe4's CEO, Stu Sjouwerman, emphasized the care that went into the choice of Banerjee. "KnowBe4's company culture is a point of pride among our execs and staff. Ani's experience and input have shown us that he is a leader who can further our accomplishments and strengthen our exemplary team. His record of HR leadership in global markets is a particularly strong asset as we launch our next phase of expansion. He is one more example of KnowBe4 attracting the best, the creative experts."
About KnowBe4
KnowBe4, the provider of the world's largest security awareness training and simulated phishing platform, is used by more than 52,000 organizations around the globe. Founded by IT and data security specialist Stu Sjouwerman, KnowBe4 helps organizations address the human element of security by raising awareness about ransomware, CEO fraud and other social engineering tactics through a new-school approach to awareness training on security. Kevin Mitnick, an internationally recognized cybersecurity specialist and KnowBe4's Chief Hacking Officer, helped design the KnowBe4 training based on his well-documented social engineering tactics. Tens of thousands of organizations rely on KnowBe4 to mobilize their end users as their last line of defense.
CONTACT:
Kathy Wattman
727 474 9950
pr@knowbe4.com
View original content to download multimedia:
SOURCE KnowBe4 | https://www.whsv.com/prnewswire/2022/09/06/ani-banerjee-joins-knowbe4-chief-human-resources-officer/ | 2022-09-06T12:54:57Z |
COPPELL, Texas, Sept. 6, 2022 /PRNewswire/ -- Arcline Investment Management ("Arcline"), a growth-oriented private equity firm, today announced the acquisition of Kings III of America ("Kings III"), a leading third-party provider of elevator and pool emergency monitoring solutions in North America, from Rockbridge Growth Equity and Thayer Street Partners.
Arcline commented, "Kings III demonstrates all of the traits that we look for in our portfolio companies in providing contractually recurring, non-discretionary safety solutions to a large installed base of critical infrastructure. Kings III has an excellent reputation among customers and employees, and is led by a strong, experienced management team that has enabled it to become a true market leader. The growth-oriented culture at Kings III will fit well within the Arcline portfolio, and we are excited to partner with the management team for the company's next chapter of growth."
Dennis Mason, CEO of Kings III, added, "Arcline's passion for growth, innovation and culture is a perfect match with our management team, employees, and customers. Our success would not have been possible without the dedication and excellence of the entire team at Kings III, and this acquisition is a testament to their hard work. We look forward to working with Arcline to continue our incredible trajectory and we are excited to leverage Arcline's deep experience in the elevator industry to accelerate our growth."
Piper Sandler served as financial advisor to Arcline.
Arcline Investment Management is a growth-oriented private equity firm with $4.4 billion in cumulative capital commitments. Arcline seeks to invest in technology-driven, meaningful to the world industrial businesses that enable a better future. For more information visit www.arcline.com.
Kings III of America, LLC is headquartered in Coppell, Texas, and is a provider of all-inclusive emergency monitoring solutions for elevators and pools across North America. Kings III designs, engineers, and manufactures its monitoring equipment, as well as runs a state-of-the-art 24/7 emergency dispatch center staffed with certified emergency responders. With over three decades of service, Kings III is a critical enabler of the elevator infrastructure in the U.S. and Canada.
Contact Information:
contact@arcline.com
www.arcline.com
Contact (For Press Inquiries Only):
Tim Ragones
Joele Frank, Wilkinson Brimmer Katcher
(212) 355‐4449
View original content:
SOURCE Arcline Investment Management | https://www.whsv.com/prnewswire/2022/09/06/arcline-investment-management-acquire-kings-iii-america/ | 2022-09-06T12:55:03Z |
PARIS, Sept. 6, 2022 /PRNewswire/ -- Global turnover from Fine Art auction sales increased by 8.8% in H1 2022, despite another wave of Covid-19 in China. Artprice counted a record number of auction transactions around the world and observes a growing enthusiasm for works by artists from the second half of the 20th and the beginning of the 21st century, whose prices are highly volatile.
Four indicators of the health of global Fine Art auction activity in H1 2022
Infographic - https://mma.prnewswire.com/media/1891851/Artmarket_Fine_Art_Infographic.jpg
thierry Ehrmann, President, and Founder of Artmarket.com: "A comprehensive study of the results of public auctions reveals growing competition between New York, London, and Hong Kong. This competition is rapidly inflating the prices of works by young artists to levels usually reserved for great masters. On the occasion of the Frieze London and Paris+ fairs (the latter run by Art Basel), Artprice will be publishing an exclusive report dedicated to 'Ultra Contemporary' Art: a term that designates a dynamic that is developing around artists under 40 years old, like Matthew Wong, Avery Singer, and Refik Anadol.
The analysis of the Art Market presented in this H1 2022 Report is based on the Fine Art public auction results recorded by Artprice and only concerns paintings, sculptures, drawings, photographs, prints, videos, installations, tapestries as well as NFTs, and excludes antiquities, anonymous cultural property, and furniture. All prices indicated in this Report refer to public auction results, including buyers' fees, and the $ sign refers to the US dollar.
H1 2022 KEY FIGURES
- Global Fine Art auction proceeds reached $7.49 billion.
- The art market's 5th most prosperous H1 period ever recorded.
- An increase of 8.8% versus H1 2021.
- A record 326,000 lots sold in H1 2022 versus 313,400 in H1 2021
- Christie's hammered the 2nd best art auction result of all time at $195 million.
- The unsold rate rose to 31% versus 27% in H1 2021.
- With a turnover of $3.27 billion, New York was clearly the world's leading marketplace.
- In second and third place, London hammered $1.43 billion and Hong Kong took $610 million.
- Not far behind, the Parisian art market generated $518 million and has attracted a growing number of international institutions.
- Christie's and Sotheby's account for 38% of global fine art turnover.
- The Macklowe Collection became the most expensive collection ever sold in the world, generating $922 million.
- 180 NFTs sold at auction generating $8.5 million.
ORGANIZATION AND STRUCTURE OF THE ART MARKET
As the health crisis wanes worldwide, Fine Art auctions settled down to an unsold rate of 31%, almost one in three works offered for sale. This level corresponds to a stable average over the last twenty years, fluctuating between 36% in 2009 and 27% in 2021. Indeed, this key market indicator has reacted quite differently compared with how it reacted in the last major crisis that affected the global art market, the 2009 financial crisis. Back then, collectors decided to take less financial risk, whereas the health crisis of 2021 prompted buyers to switch to a new entirely dematerialized sales channel.
In the first half of 2022, the market found a new balance thanks to the coexistence of two different and complementary sales channels (one physical, the other digital), which allowed auction transactions to continue at a healthy pace reaching a historic number of 326,000 Fine Art lots in six months. In H1 2022 this volume further increased to an unprecedented intensity, despite the postponement of many auctions in China (whose turnover volume is down 53%) due to an additional wave of Covid-19.
The United States (up 42% vs. H1 2021) and the UK (up 26%) have driven growth. The two powerful Anglo-Saxon markets alone accounted for exactly two-thirds of global Fine Art auction turnover. China, for its part, only accounted for 12% of global fine art auction turnover, a result that it owes in large part to Hong Kong which accounted for 70% of the value of the entire Chinese art market (including Hong Kong, Macao, and Taiwan).
France continued to grow (+14%) consolidating its 4th place ahead of Germany (-5%) after a sensational performance in 2021. In addition to the presence of Christie's and Sotheby's, several Parisian auction operators posted exceptionally strong performances: Artcurial (+42%) and Aguttes (+154%), among others. Meanwhile, The French capital is attracting a growing number of major international players like David Zwirner, while the Gagosian and Continua galleries have opened new spaces in France. Paris is delighted to see the upcoming arrival of Hauser & Wirth as well as the opening of a Phillips auction room. Bonhams has acquired the French house Cornette de Saint-Cyr (operating in Paris and Brussels). Lastly, the Art Basel company will henceforth be the official organizer of the international autumn art fair organized at the Grand Palais in Paris, entitled Paris+, which will replace the FIAC.
Japan and Switzerland also had an excellent start to 2022 with increases of 74% and 145% in their respective auction turnover totals. Without directly competing with Hong Kong (which still weighs seven times more), Tokyo is positioning itself on the Asian continent as a hub for major contemporary artists, including Andy Warhol, Yoshitomo Nara, Yayoi Kusama, but also young talents like Mr Doodle and Ayako Rokkaku (born in 1982), whose auction sales have already exceeded $18.6 million this year. For its part, Switzerland is continuing to carve out a place for itself in the Post-Impressionist and Modern Art market, with sales of important works by Ferdinand Hodler, Alberto Giacometti, and Marc Chagall.
Ferdinand Hodler, Der Brienzersee von Breitlauenen aus (1906); sold for CHF 2,875,000 (~$3 million) on 17 June 2022 by Galerie Kornfeld in Bern
Photo - https://mma.prnewswire.com/media/1891852/Artmarket_Ferdinand_Hodler.jpg
TRENDS: NFTs AND ULTRA CONTEMPORARY ART
Propelled to center stage in March 2021 with a first public auction result at $69.4 million, NFTs (non-fungible tokens) have created something of a revolution in the art market, with a new type of work, new collectors, and a new currency.
Of the 277 NFTs auctioned in H1 2022, 65% sold for an average price of $47,000. This situation is very different from H2 2021 in which 225 NFTs were offered for sale, of which 86% sold at an average price of $520,000. Beeple's Human One (2021) fetched nearly $29 million last November at Christie's, whereas the best NFT result in H1 2022 was just $1.38 million for Living Architecture: Casa Batlló (2022) by Refik Anadol.
The 104 CryptoPunks that Sotheby's announced in February 2022 were finally withdrawn on the eve of their scheduled sale. The withdrawal of such a lot, estimated between $20 and $30 million, underscores the extent to which NFT market players remain somewhat skeptical about the service provided by traditional intermediaries. Not only are they expensive (transaction costs amount to an average of 20% compared with around 2% to 3% via NFT platforms) but they also are governed by a much less flexible schedule. The major auction houses are nevertheless continuing their efforts to participate in this emerging market, although they only very rarely sell major NFT collections (BAYC, WoW, etc.). For the time being, such projects no longer seem to need the marketing efforts or the legitimacy of regulated auction houses.
At the same time, the volatility of cryptocurrencies, has exacerbated the mistrust of traditional collectors vis-à-vis this disruptive market. Fortunately, this lull will provide a good number of artists, dealers, collectors, and institutions – starting with museums – an opportunity to take an interest in digital works and to consider acquiring NFTs without the pressure of record sales and over-mediatization.
The NFT phenomenon stems from the same enthusiasm that Artprice is observing for the work of young artists, some of whom are eliciting record multi-million dollar results even before their work has been exhibited in a major museum or before they have even enjoyed a solo show in a gallery. The recent auction records for works by artists under 40 (whose very recent works are already trading on the secondary market) will be analyzed by the next Artprice Ultra Contemporary Art Report to be published in October 2022. This will notably be an opportunity to highlight the growing success and influence of young female painters.
Top 10 personal records for living artists under 40 at auction in H1 2022
©artprice.com
1. Avery Singer (1987): $5,253,000
2. Christina Quarles (1985): $4,527,000
3. Jennifer Packer (1984): $2,349,000
4. María Berrio (1982): $1,562,500
5. Robbie Barrat (1999): $841,317
6. Robert Nava (1985): $639,401
7. Issy Wood (1993): $588,042
8. Lauren Quin (1992): $588,042
9. Louis Fratino (1993): $365,400
10. Jordy Kerwick (1982): $277,200
FIVE EXCEPTIONAL RESULTS IN H1 2022
Andy Warhol's Shot Sage Blue Marilyn elicited the second highest ever art auction bid. For the first time since Leonardo Da Vinci's Salvator Mundi in November 2017 (four and a half years ago), the ultra-high-end market is back with a result that once again questions the notion of an absolute masterpiece and its value. The charity sale that produced this result was guaranteed by Christie's and ended with a result of $195 million (including fees). The 'painting' was acquired by Larry Gagosian himself, the powerful gallery owner who had already sold the canvas to Thomas Ammann in the early 1980s.
The French auction house Artcurial had the honor of presenting an exceptional still-life by Jean-Baptiste Chardin, Le panier de fraises des bois, painted in 1761 and exhibited the same year at the Grand Salon in Paris. While this was the first appearance of this painting at auction, art expert Eric Turquin insists on the immense historical importance of the work, importance to which the labels on the back of the painting attest, having been included in many prestigious exhibitions around the world. A gentle and magic painting, the Jean-Baptiste Chardin masterpiece was estimated between $13 and $16 million and finally sold for $26.8 million.
The biggest sensation of the year was undoubtedly created by the canvas The Sugar Shack (1976) by Ernie Barnes (1938 - 2009). Last year, the African-American painter set a new auction record at $550,000. But on 12 May this year, Christie's proposed his painting The Sugar Shack (1976) in New York with an estimate of $150,000 - $200,000. The work finally sold for $15,275,000, more than 100 times the low estimate. In the days and weeks that followed, six more important Ernie Barnes paintings were offered at Christie's and Bonhams, and they all sold well beyond their estimates.
Last year, the Japanese artist Yayoi Kusama became the first female artist to enter the world's Top 10 performing artists as calculated by Artprice (all periods of creation combined). She was also the third best performing living artist of the year behind Gerhard Richter and Banksy. This year, Yayoi Kusama has repeated that performance with 208 lots sold worldwide for more than $115 million. She also set a new auction record when her Untitled (Nets) (1959) reached $10.5 million at Phillips on 18 May 2022.
Matthew Wong would have been 38 if he hadn't taken his own life in 2019. Since his death, his paintings have enjoyed stunning success in auction rooms. On 19 May 2022, his Night Watcher (2018) was acquired for $5.9 million at Christie's New York. In H1 2022, Matthew Wong ranked 52nd in the global ranking of artists by auction turnover (all periods of creation combined), a success that has a certain Basquiat flavor to it, even if Wong's place in art history has not yet been recognized.
Read Artprice.com's H1 2022 Global Art Market Report online at:
The information and econometric studies produced by Artmarket.com are presented uniquely for the purpose of analyzing and understanding the statistical realities of the art market and should in no way be considered as advice or a suggestion or a solicitation to invest in the art market.
[https://imgpublic.artprice.com/img/wp/sites/11/2022/08/image2-Ferdinand-Hodler.jpeg]
Copyright 1987-2022 thierry Ehrmann www.artprice.com - www.artmarket.com
Don't hesitate to contact our Econometrics Department for your requirements regarding statistics and personalized studies: econometrics@artprice.com
Try our services (free demo): https://www.artprice.com/demo
Subscribe to our services: https://www.artprice.com/subscription
Artmarket.com is listed on Eurolist by Euronext Paris, SRD long only and Euroclear: 7478 - Bloomberg: PRC - Reuters: ARTF.
Discover Artmarket and its Artprice department on video: www.artprice.com/video
Artmarket and its Artprice department was founded in 1997 by its CEO, thierry Ehrmann. Artmarket and its Artprice department is controlled by Groupe Serveur, created in 1987.
See certified biography in Who's who ©:
Biographie_thierry_Ehrmann_2022_WhosWhoInFrance.pdf
Artmarket is a global player in the Art Market with, among other structures, its Artprice department, world leader in the accumulation, management and exploitation of historical and current art market information in databanks containing over 30 million indices and auction results, covering more than 787,000 artists.
Artprice by Artmarket, the world leader in information on the art market, has set itself the ambition through its Global Standardized Marketplace to be the world's leading Fine Art NFT platform.
Artprice Images® allows unlimited access to the largest Art Market image bank in the world: no less than 180 million digital images of photographs or engraved reproductions of artworks from 1700 to the present day, commented by our art historians.
Artmarket with its Artprice department accumulates data on a permanent basis from 6300 Auction Houses and produces key Art Market information for the main press and media agencies (7,200 publications). Its 5.4 million ('members log in'+social media) users have access to ads posted by other members, a network that today represents the leading Global Standardized Marketplace® to buy and sell artworks at a fixed or bid price (auctions regulated by paragraphs 2 and 3 of Article L 321.3 of France's Commercial Code).
Artmarket with its Artprice department, has been awarded the State label "Innovative Company" by the Public Investment Bank (BPI) (for the second time in November 2018 for a new period of 3 years) which is supporting the company in its project to consolidate its position as a global player in the market art.
Artprice by Artmarket's 2020 Global Art Market Report published in March 2022:
https://www.artprice.com/artprice-reports/the-art-market-in-2021
Artprice's 2020/21 Contemporary Art Market Report by Artmarket.com:
https://www.artprice.com/artprice-reports/the-contemporary-art-market-report-2021
Index of press releases posted by Artmarket with its Artprice department:
serveur.serveur.com/Press_Release/pressreleaseEN.htm
Follow all the Art Market news in real time with Artmarket and its Artprice department on Facebook and Twitter:
www.facebook.com/artpricedotcom/ (over 5.9 million followers)
Discover the alchemy and universe of Artmarket and its artprice department https://www.artprice.com/video headquartered at the famous Organe Contemporary Art Museum "The Abode of Chaos" (dixit The New York Times): https://issuu.com/demeureduchaos/docs/demeureduchaos-abodeofchaos-opus-ix-1999-2013
- L'Obs - The Museum of the Future: https://youtu.be/29LXBPJrs-o
- www.facebook.com/la.demeure.du.chaos.theabodeofchaos999 (4.3 million followers)
- https://vimeo.com/124643720
Contact Artmarket.com and its Artprice department - Contact: Thierry Ehrmann, ir@artmarket.com
Logo - https://mma.prnewswire.com/media/1009603/Art_Market_logo.jpg
View original content to download multimedia:
SOURCE Artmarket.com | https://www.whsv.com/prnewswire/2022/09/06/artmarketcom-presents-artprice-2022-half-year-report-art-market-returns-strong-growth-west/ | 2022-09-06T12:55:10Z |
This follow-up trial builds on AtriAN's initial safety and feasibility study and aims to assess the efficacy of its cardioneuroablation treatment in patients with atrial fibrillation.
GALWAY, Ireland, Sept. 6, 2022 /PRNewswire/ -- AtriAN Medical today announced that it has completed enrollment of a second study using its selective pulsed field ablation (PFA) technology for the treatment of atrial fibrillation.
The Neural AF-2 study has enrolled cardiothoracic surgery patients with paroxysmal AF, utilizing AtriAN's unique cardiac autonomic ablation technology to provide selective ablation of neuronal structures on the outside of the heart. A total of 12 patients were treated at Tbilisi Heart and Vascular Clinic (Georgia), with Prof Tamaz Shaburishvili as the Principal Investigator. Patients will be followed out to 1 year for AF recurrence.
The new study builds on AtriAN's initial Neural-AF study that focused on safety, feasibility and acute outcomes, in twenty four patients undergoing concomitant coronary artery bypass grafting. The initial study was performed at Na Homolce Hospital in Prague (Czech Republic) and Tbilisi Heart and Vascular Clinic (Georgia). Data from that study was presented by Prof Vivek Reddy MD (Mount Sinai Hospital, NY) at the 2022 AF Symposium and by Prof Joris de Groot (Amsterdam UMC) at the European Heart Rhythm Association (EHRA) 2022 conference.
The original Neural-AF study was an all-comers design for CABG patients that did not focus specifically on patients with atrial fibrillation. The findings indicate that selective epicardial PFA of ganglionated plexi is feasible and safe. An acute extension in atrial tissue refractoriness was also recorded; this is a well recognized indicator of resistance to atrial fibrillation.
"The promising results from our first study have given us the confidence and momentum to expand into this second trial looking specifically at clinical outcomes in patients with AF" said AtriAN CEO Ken Coffey. "This will be a challenging cohort of patients but we look forward to providing them with improved outcomes and demonstrating the potential of our novel approach."
The AtriAN system includes catheters designed for use within the pericardial space and a generator for providing low energy pulsed electric fields. In the near future, the company plans to conduct clinical studies to assess delivery of the treatment using sub-xiphoid minimally invasive access.
For more information about AtriAN Medical, please visit: www.atrianmedical.com
Contact Details:
Ken Coffey (CEO)
ken.coffey@atrianmedical.com
+353 85 761 5506
View original content:
SOURCE AtriAN Medical | https://www.whsv.com/prnewswire/2022/09/06/atrian-medical-completes-enrollment-second-study-cardioneuroablation-using-pfa/ | 2022-09-06T12:55:17Z |
Published: Sep. 6, 2022 at 8:30 AM EDT|Updated: 25 minutes ago
VANCOUVER, BC and HYDERABAD, India, Sept. 6, 2022 /PRNewswire/ - Ballard Power Systems (NASDAQ: BLDP) (TSX: BLDP) today announced a fuel cell module order from Medha Servo Drives, a leading rail system integrator, who has been contracted by Indian Railways to develop India's first hydrogen powered trains.
The two retrofitted diesel-electric commuter trains will integrate 8 units of 100 kW FCmoveTM-HD+, Ballard's latest fuel cell technology, which offers improved efficiency and power density than previous module generations.
The contract to provide the hydrogen-powered trains was awarded to Medha as a first step in Indian Railways' path to achieve their net zero ambitions. The fuel cell modules are expected to be shipped in 2023, with trains scheduled to go into service in 2024, with potential for additional retrofits following the initial deployment.
Indian Railways estimate their investment in the hydrogen fuel cell project to have a payback of less than two years as the cost of hydrogen is now less than diesel. These conversions are not only expected to be more economic than their diesel counterpart, but also reduce annual carbon dioxide emissions by over 11 metric tons and eliminate nearly a metric ton particulate matter per year.
"We are thrilled to be partnering with Ballard in the development of India's first hydrogen powered trains. Rail transportation is a critical piece of infrastructure across India and we are proud to be taking the first steps to decarbonize this facet of our economy. With leading technology and strong project economics, we are optimistic about the future of zero emission rail transport," said Mr. Kasyap Reddy, Managing Director of Medha Servo Drives.
"Our progress in decarbonizing the rail market is just beginning, as we work with leading rolling stock manufacturers, integrators and operators globally. This announcement with Medha exemplifies the growing need and progress being made to decarbonize global mobility. We are excited to grow our fuel cell business in India, and to power the first hydrogen powered, zero emission passenger trains in the Indian market," said David Mucciacciaro, Ballard Chief Commercial Officer.
About Ballard Power Systems
Ballard Power Systems' (NASDAQ: BLDP; TSX: BLDP) vision is to deliver fuel cell power for a sustainable planet. Ballard zero-emission PEM fuel cells are enabling electrification of mobility, including buses, commercial trucks, trains, marine vessels, and stationary power. To learn more about Ballard, please visit www.ballard.com.
This release contains forward-looking statements concerning anticipated product performance and other characteristics, product deliveries and deployments. These forward-looking statements reflect Ballard's current expectations as contemplated under section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any such forward-looking statements are based on Ballard's assumptions relating to its financial forecasts and expectations regarding its product development efforts, manufacturing capacity, and market demand.
These statements involve risks and uncertainties that may cause Ballard's actual results to be materially different, including general economic and regulatory changes, detrimental reliance on third parties, successfully achieving our business plans and achieving and sustaining profitability. For a detailed discussion of these and other risk factors that could affect Ballard's future performance, please refer to Ballard's most recent Annual Information Form. Readers should not place undue reliance on Ballard's forward-looking statements and Ballard assumes no obligation to update or release any revisions to these forward-looking statements, other than as required under applicable legislation.
About Medha Servo Drives Pvt.Ltd.
Medha is an R&D focused company dedicated to design, development, manufacture, supply and service of Railway products. It has been established in 1984 and has been supplying various products to Indian Railways since 1990. Medha has designed and manufactured various world-class high-tech electronics products for application on locomotives, trainsets, coaches, railway stations and yards. Medha's strength lies in designing, customizing and integrating systems that involve multiple functional domains such as control electronics, power electronics, fail safety and mechanical construction.
Further Information
Ballard Power Systems: Kate Charlton – VP Corporate Finance & Investor Relations +1.604.453.3939 or investors@ballard.com
The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc. | https://www.whsv.com/prnewswire/2022/09/06/ballard-power-indias-first-hydrogen-trains/ | 2022-09-06T12:55:23Z |
BDR University's Creating the Next Generation of Company Managers will be held in Raleigh, N.C., in November
SEATTLE, Sept. 6, 2022 /PRNewswire/ -- Business Development Resources (BDR), the training and business coaching authority for home services industry professionals, will host its first in-person BDR University event in more than two years, in Raleigh, North Carolina, in November.
Creating the Next Generation of Company Managers, a two-day live training scheduled for Nov. 2-3, is designed to help HVAC contractors position new leaders for success by preparing them for the transition from employee to management.
"Becoming a new manager is a challenge that requires new skills, new learning, and a new approach," said BDR head coach Chris Koch, who will lead Creating the Next Generation of Company Managers. "Simply promoting your top-performing technician, installer, or salesperson without training will not get the job done and only sets the employee and company up to fail. New relationships and dynamics demand new skill sets and strategies. Implementing steps to help new managers understand and embrace their new role offers long-term benefits that more than make up for the minor investment involved."
During Creating the Next Generation of Company Managers, Koch will introduce essential skills and principles that help employees successfully navigate the transition to management, including how to:
- Understand the difference between employees and managers and their roles in a company.
- Manage new expectations from employees, co-workers, and business owners.
- Implement time management, delegation, and prioritization strategies.
- Develop an improved understanding of the profit and loss statements and how to calculate break-even and gross profit rates.
- Measure success using the key financial metrics of installation and service.
- Build a positive team culture.
Koch is a team-building leader with nearly three decades of vital hands-on experience in the HVAC industry, ranging from startups to companies with $60 million in sales.
For more information on BDR, visit https://www.bdrco.com. For information about Creating the Next Generation of Company Managers, visit https://www.bdrco.com/upcoming-bdr-events/.
About Business Development Resources (BDR)
BDR (Business Development Resources) is the premier provider of business training and coaching to HVAC contractors and distributors, established in 1998. BDR's Profit Coach program has a membership of 600 leading contractors. Ten thousand HVAC professionals across North America attend BDR training courses annually. Nearly 1,000 industry professionals attend Profit Launch, BDR's planning workshop. For more information, please visit www.bdrco.com.
MEDIA CONTACT:
Heather Ripley
Ripley PR
(865) 977-1973
hripley@ripleypr.com
View original content to download multimedia:
SOURCE Business Development Resources (BDR) | https://www.whsv.com/prnewswire/2022/09/06/bdr-helps-hvac-companies-prepare-management-transition-with-live-training-event/ | 2022-09-06T12:55:29Z |
HONG KONG, Sept. 6, 2022 /PRNewswire/ -- The Blockchain-based Service Network (BSN) announced the beta launch of the BSN Spartan Network, a public infrastructure network that will provide non-cryptocurrency blockchain services to any IT system globally. The network initially launched with three non-cryptocurrency public chains, including non-crypto versions of Ethereum, Cosmos and PolygonEdge. Leading enterprises such as HSBC, Emperor Group, and Lan Kwai Fong Group presented BSN Spartan Network use cases at the BSN Spartan Global Summit, held in Hong Kong today. Known for its earlier initiatives in China, the BSN's Spartan Network is only available outside China.
"99% of the world's IT systems do not use cryptocurrency-based public chains to avoid being involved in unregulated and volatile cryptocurrencies. The BSN Spartan Network provides an infrastructure that integrates non-cryptocurrency public blockchains that can be used by any traditional IT system to leverage the capabilities of the underlying blockchain technology in an easier and more cost-effective way," said Yifan He, CEO of Red Date Technology, the technical architect of the BSN.
"We are excited about the possibilities the BSN Spartan Network opens up for Hong Kong corporates to digitize, tokenize, and automate their business processes. We look forward to exploring how our HSBC DLT Settlement Utility (HDSU) solution can streamline payment processes for business partners on the network, and help our customers benefit from this next wave of business and financial innovation," said Vincent Lau, Regional Head of International Payments for Asia Pacific at HSBC.
The BSN Spartan Network is an infrastructure to serve all traditional IT systems, not for issuing and trading cryptocurrencies, and consists of virtual data centers which are open source and free to download from GitHub. Individuals and businesses can set up data centers on the BSN Spartan Network anonymously and pay gas fees on non-cryptocurrency public chains using fiat currency or fiat-backed stablecoins such as USDC. The cost of using public chain technologies is also dramatically reduced. As an example, the cost of minting a standard ERC721 NFT on Spartan-I Chain (the non-cryptocurrency version of Ethereum) is fixed at 3 cents USD, several orders of magnitude lower than minting on cryptocurrency-based Ethereum.
"Out of the many use cases in blockchain technology, most of the general public would usually only think of those related to digital assets with the common examples of cryptocurrencies, NFT digital art, and metaverses. As one of the retail market leaders, we are keen to explore the opportunities to introduce and leverage blockchain technology for broader accessibility, in which this digital access could also create great value to our customers, the retail markets, and the general public. We are of like mind with the BSN about the ability to commercialize this technology," commented Leo Tsang, Group CIO for Emperor Group, a diversified group of businesses that includes Property, Financial Services, Watch and Jewellery, Entertainment & Culture, Hospitality, Digital Media and Home Living.
"With blockchain and Web3, I see many possibilities to enrich the LKF experience for visitors and operators alike. LKF Group's DNA for 40+ years is about embracing community and making the most out of lifestyle experiences, and BSN Spartan Network is a great enabler for the next generation," said Jonathan Zeman, CEO of Lan Kwai Fong Group, the diversified property development group.
The BSN Spartan Network is a decentralized network governed by the BSN Foundation (https://spartan.bsn.foundation/), with each member operating a governance data center that hosts all the validator nodes of non-cryptocurrency public chains. Any matters related to the governance of the BSN Spartan Network, such as adding a new chain or gas fee adjustments, will be decided by the BSN Foundation members. The BSN Foundation will start with five members, growing to 10 by the end of 2022, and 30 by the end of 2023.
"We are building the next layer of the internet, a public layer serving public IT systems that has the benefit of greater transparency, easy connectivity, and individual ownership of data compared to private IT systems today," said Tim Bailey, VP of Global Sales for Red Date Technology.
About Red Date Technology
Red Date Technology is a technology company headquartered in Hong Kong that is dedicated to building next-generation Public IT System infrastructures for internet communications, digital economies, and metaverses.
View original content:
SOURCE BSN | https://www.whsv.com/prnewswire/2022/09/06/bsn-launches-global-open-source-spartan-network-enable-public-it-systems/ | 2022-09-06T12:55:35Z |
HOUSTON, Sept. 6, 2022 /PRNewswire/ -- Callon Petroleum Company (NYSE: CPE) today announced the publication of the Company's 2021 Sustainability Report, titled Shaping Our Future. This report is the Company's third report and provides a comprehensive overview of Callon's continued progress on its sustainability initiatives as well as its partnership with the communities where it operates.
"I am proud to share Callon's tangible improvements that highlight our ongoing commitment to top-tier ESG performance," said Joe Gatto, President and Chief Executive Officer. "Our efforts are marked by clear action plans and a dedication to meaningful, quantifiable goals, coupled with critical linkages to executive and broader corporate compensation plans. I am confident that this report will provide readers with a deeper understanding of how we embrace sustainability in all facets of our business.
"Callon welcomes the challenge to meet the world's growing energy needs in ways that are innovative, safe, and environmentally and socially responsible. Addressing the evolving needs of our stakeholders and employees will be an important element of being a well-regarded operator and delivering long-term value for our shareholders," concluded Mr. Gatto.
Callon appreciates the importance of transparency and is proud to continue expanding ESG disclosures by adopting frameworks that best align with stakeholder interests. The 2021 Sustainability Report is aligned with the Sustainability Accounting Standards Boards (SASB), the Taskforce on Climate-related Financial Disclosures (TCFD), the American Exploration and Production Council (AXPC) ESG metrics framework, and the United Nations Sustainable Development Goals (UN SDGs).
Achievements and highlights from Callon's 2021 Sustainability Report include:
2021 Achievements:
- 11% Reduction in GHG emissions intensity for legacy Callon1
- 2% reduction in overall GHG emissions intensity, including initial impact of acquired Delaware Basin assets1
- 49% reduction in flare rate
- 24% reduction in total fluid spill rate
- 19% reduction in hydrocarbon spills to the environment
- 65% of new hires identified as female, racially or ethnically diverse, or both
- 83% participation rate in new Employee Development Plan
- 21% increase in percent of women in above-field workforce
Additional Report Highlights:
- Announced updated and accelerated emission reduction goals in early 2022, including a new methane emissions reduction target
- Continued board refreshment by welcoming the Company's third female director
- Expanded the Company's TCFD disclosures, including discussion of the resiliency of the Company's strategy under various climate-related scenarios
- Redesigned the executive compensation program in 2021 to align with investor priorities including ESG, and further enhanced the program in 2022 by adding a long-term GHG reduction incentive
- Formalized a Management Committee on Sustainability to support the Company's on-going commitment to various ESG matters
- Adopted a formal Human Rights Policy and Contractor Code of Conduct
- Expanded corporate philanthropy program to focus on building sustainable communities
For more information about Callon's sustainability efforts and to download the 2021 Sustainability Report, please visit www.callon.com/sustainability.
About Callon Petroleum
Callon Petroleum Company is an independent oil and natural gas company focused on the acquisition, exploration and development of high-quality assets in the leading oil plays of South and West Texas.
Kim Pinyopusarerk
Sustainability and Communications
corpcomm@callon.com
Kevin Smith
Director of Investor Relations
ir@callon.com
1 GHG emissions intensity is calculated as metric tons of Scope 1 CO2e/thousand equivalent barrels produced. Legacy Callon GHG emissions refers to 2021 Callon standalone emissions excluding emissions for the assets acquired in the Delaware Basin from Primexx Resource Development, LLC and BPP Acquisition, LLC (the "Primexx Acquisition"). Overall GHG emissions intensity includes emissions from the Primexx Acquisition assets.
View original content:
SOURCE Callon Petroleum Company | https://www.whsv.com/prnewswire/2022/09/06/callon-petroleum-company-publishes-2021-sustainability-report/ | 2022-09-06T12:55:42Z |
NEW YORK, Sept. 5, 2022 /PRNewswire/ -- Color Star Technology Co., Ltd. (Nasdaq: CSCW) ("Color Star" or the "Company"), an entertainment technology company with a global network that focuses on the application of technology and artificial intelligence in the entertainment industry, has recently signed an official strategic partnership agreement with Global Digital Club ("GDC"). From now on, the focus of this partnership will be on the metaverse digital economy, and both parties will jointly develop a series of related digital businesses in [Color World_Metaverse].
Global Digital Club is a world-renowned professional digital investment club, with members including global elites and top executives from leading companies around the world. Every year, the GDC holds major industry summits and organizes regular invite-only member meetings to more accurately and effectively enhance the globalization of the digital economy, providing the most accurate and representative outlook analysis for the industry, and to help corporate members establish effective cooperation with each other. As an authority in the digital economy industry, Color Star and GDC will utilize their respective advantages and resources to actively cooperate on the metaverse platform [Color World_Metaverse], connecting relevant NFTs, metaverses and other relevant content together.
CEO of Color Star, Farhan Qadir said: "Color Star has always viewed smart intelligence as its technical core, and while we continue to develop the entertainment metaverse, we expect to further develop more industrial content, the digital economy and artificial intelligence since they will certainly be profitable developments for the company. The partnership with GDC will not only allow us to progress further with our digital economy, but also allow Color Star to attract more partners, which is a very good thing. Next, we will partner with more corporate organizations, which suggests that the future developments of Color Star will be more diversified and comprehensive, bringing our partners and investors more guaranteed revenue."
Forward-Looking Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantee of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development, including the development of the metaverse project; product and service demand and acceptance; changes in technology; economic conditions; the growth of the educational and training services market internationally where CSCW conducts its business; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations or rules.
View original content:
SOURCE Color Star Technology Co., Ltd. | https://www.whsv.com/prnewswire/2022/09/06/color-star-technology-global-digital-club-forms-strategic-partnership-with-metaverse-digital-economy-focus/ | 2022-09-06T12:55:48Z |
LATHAM, N.Y. and RESEARCH TRIANGLE PARK, N.C., Sept. 6, 2022 /PRNewswire/ -- CommerceHub, an industry-leading commerce network connecting supply, demand and delivery for the world's leading retailers and brands, and ChannelAdvisor Corporation (NYSE: ECOM), a leading provider of cloud-based e-commerce solutions that enable brands and retailers to increase global sales, today announced they have entered into a definitive agreement for CommerceHub to acquire the outstanding shares of ChannelAdvisor in a transaction led by global software investor and current shareholder of CommerceHub, Insight Partners. Under the terms of the agreement, ChannelAdvisor stockholders will receive $23.10 per share in cash, representing a premium of approximately 57% over the company's closing stock price on September 2, 2022, the last full trading day prior to this announcement. The boards of directors of both companies have unanimously approved the transaction.
The complementary combination of CommerceHub and ChannelAdvisor expands capabilities for brands and retailers:
- Brands will be able to manage their public and private marketplaces alongside their retailer connections with a single vendor, improving efficiency by unifying first-party, dropship, and third-party integrations.
- Retailers will be able to access an even larger pool of brands, with over 18,000 customers transacting more than $50 billion in gross merchandise value (GMV) and more than $500 million in digital marketing and retail media ad spend annually across the combined network.
- Companies across the network will be able to save on delivery costs and improve delivery experiences with Delivery Suite, and improve their consumer experience with Shoppable Media and Brand Analytics.
"CommerceHub and ChannelAdvisor have both established themselves as leading solutions for different segments of online retailers and brands. By coming together, we can provide an even broader network, enabling our combined customers to grow their businesses by discovering new products, new brands, and new channels," said Bryan Dove, CEO, CommerceHub.
"This is a tremendous opportunity for our customers, for our team members and our shareholders. This transaction positions the combined company to accelerate innovation and help shape the future of commerce," said David Spitz, CEO, ChannelAdvisor.
Investors that participated in this transaction include Insight Partners, GTCR, Sycamore Partners, and Goldman Sachs Asset Management. Financing for the transaction is being provided by Sixth Street and Golub Capital LLC (the "Financing Sources").
The proposed transaction is not subject to a financing condition and is expected to close in 2022. The transaction is subject to customary closing conditions, including receipt of regulatory approvals and approval by ChannelAdvisor's stockholders. The companies will operate independently until the proposed transaction is finalized.
Upon completion of the transaction, ChannelAdvisor will become a privately held company and shares of ChannelAdvisor common stock will no longer be listed on any public market.
Advisors
Baird is serving as financial advisor to ChannelAdvisor and Cooley LLP is acting as legal counsel to ChannelAdvisor.
Stifel and District Capital Partners are serving as financial advisors to CommerceHub. Willkie Farr & Gallagher LLP is acting as legal advisor to CommerceHub and Paul, Weiss, Rifkind, Wharton & Garrison LLP are acting as debt financing legal advisor to CommerceHub. Kirkland & Ellis LLP served as legal advisor to GTCR and Sycamore Partners and Simpson Thacher & Barlett LLP served as legal advisor to Goldman Sachs Asset Management.
Latham & Watkins LLP are acting as legal advisors to the Financing Sources.
CommerceHub is a Software as a Service (SaaS) provider with a commerce network connecting the world's leading retailers and brands with drop ship, marketplace, and delivery solutions. Since 1997, CommerceHub has helped the largest retailers expand their online businesses to expand selection, meet consumer demand, and improve margins. For more information visit www. commercehub.com.
ChannelAdvisor (NYSE: ECOM) is a leading multichannel commerce platform whose mission is to connect and optimize the world's commerce. For over two decades, ChannelAdvisor has helped brands and retailers worldwide improve their online performance by expanding sales channels, connecting with consumers across the entire buying cycle, optimizing their operations for peak performance, and providing actionable analytics to improve competitiveness. Thousands of customers depend on ChannelAdvisor to securely power their e-commerce operations on channels such as Amazon, eBay, Google, Facebook, Walmart, and hundreds more. For more information, visit www.channeladvisor.com.
This communication is being made in respect of the proposed transaction involving ChannelAdvisor and CommerceHub, Inc. In connection with the proposed transaction, ChannelAdvisor will be filing documents with the SEC, including preliminary and definitive proxy statements relating to and describing the proposed transaction. The definitive proxy statement will be mailed to ChannelAdvisor stockholders in connection with the proposed transaction. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE "SEC") IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SEC's web site at www.sec.gov, on ChannelAdvisor's website at www.channeladvisor.com or by contacting ChannelAdvisor Investor Relations at (919) 228-4817.
This communication does not constitute a solicitation of proxy, an offer to purchase, or a solicitation of an offer to sell any securities. ChannelAdvisor and its respective directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from ChannelAdvisor stockholders in connection with the proposed transaction. Information about ChannelAdvisor's directors, executive officers and employees in the proposed transaction will be included in the proxy statements described above. Additional information regarding these individuals is set forth in ChannelAdvisor's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, the definitive proxy statement on Schedule 14A for ChannelAdvisor's most recent Annual Meeting of Stockholders held on May 13, 2022, and ChannelAdvisor's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022. To the extent ChannelAdvisor's directors and executive officers or their holdings of ChannelAdvisor securities have changed from the amounts disclosed in those filings, to ChannelAdvisor's knowledge, such changes have been or will be reflected on initial statements of beneficial ownership on Form 3 or statements of change in ownership on Form 4 on file with the SEC. These documents are (or, when filed, will be) available free of charge at the SEC's website at www.sec.gov or at ChannelAdvisor's website at www.ChannelAdvisor.com.
This communication contains forward-looking statements which include, but are not limited to, all statements that do not relate solely to historical or current facts, such as statements regarding the Company's expectations, intentions or strategies regarding the future, or the completion or effects of the proposed transaction. In some cases, these statements include words like: "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. ChannelAdvisor's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: the ability of the parties to consummate the proposed transaction, satisfaction of closing conditions precedent to the consummation of the proposed transaction, potential delays in consummating the proposed transaction, the ability of ChannelAdvisor to timely and successfully achieve the anticipated benefits of the transaction and the impact of health epidemics, including the COVID-19 pandemic, on the parties' respective businesses and the actions the parties may take in response thereto. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" and elsewhere in ChannelAdvisor's most recent filings with the SEC, including ChannelAdvisor's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 and any subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. ChannelAdvisor assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
For Media and Analyst Inquiries:
Forrest Monroy
CommerceHub
fmonroy@commercehub.com
Caroline Riddle
ChannelAdvisor
caroline.riddle@channeladvisor.com
(919) 439-8026
View original content to download multimedia:
SOURCE ChannelAdvisor Corporation | https://www.whsv.com/prnewswire/2022/09/06/commercehub-acquire-channeladvisor-2310-per-share/ | 2022-09-06T12:55:55Z |
CHICAGO, Sept. 6, 2022 /PRNewswire/ -- Conagra Brands, Inc. (NYSE: CAG) will host a webcast and conference call to review its fiscal 2023 first quarter results on Thursday, October 6, 2022, at 9:30 a.m. ET. The company's news release will be issued at approximately 7:30 a.m. ET.
The live audio webcast and presentation slides will be available on conagrabrands.com/investor-relations under Events & Presentations. The conference call may be accessed by dialing 1-877-883-0383 for participants in the U.S. and 1-412-902-6506 for all other participants and using passcode 2011887. Please dial in 10 to 15 minutes prior to the call start time. Following the company's remarks, the conference call will include a question-and-answer session with the investment community.
A replay of the webcast will be available until October 13, 2022.
Conagra Brands, Inc. (NYSE: CAG), headquartered in Chicago, is one of North America's leading branded food companies. Guided by an entrepreneurial spirit, Conagra Brands combines a rich heritage of making great food with a sharpened focus on innovation. The company's portfolio is evolving to satisfy people's changing food preferences. Conagra's iconic brands, such as Birds Eye®, Marie Callender's®, Banquet®, Healthy Choice®, Slim Jim®, Reddi-wip®, and Vlasic®, as well as emerging brands, including Angie's® BOOMCHICKAPOP®, Duke's®, Earth Balance®, Gardein®, and Frontera®, offer choices for every occasion. For more information, visit www.conagrabrands.com.
For more information, please contact:
MEDIA: media@conagra.com
INVESTORS: IR@conagra.com
View original content to download multimedia:
SOURCE Conagra Brands, Inc. | https://www.whsv.com/prnewswire/2022/09/06/conagra-brands-announces-details-fiscal-2023-first-quarter-earnings-release-webcast-conference-call/ | 2022-09-06T12:56:02Z |
LOS ANGELES, Sept. 6, 2022 /PRNewswire/ -- Dave Inc. (NASDAQ: DAVE, DAVEW), a banking app on a mission to build products that level the financial playing field, today announced that Chien-Liang Chou has been named Chief Technology Officer, effective immediately.
Mr. Chou previously served as Executive Vice President of Engineering at Dave, a position he held since 2020. In this role, he led the engineering, data, infrastructure, security and information technology teams, spearheading various data initiatives resulting in greater efficiencies and a better member experience. He has brought to Dave more than 20 years of experience developing software and technology platforms, with significant expertise in infrastructure buildouts, automation, machine learning, and more.
"Chien-Liang has been one of our greatest assets, instrumental in the buildout not only of our technology platform, but in the products and services we have been able to offer our members," stated Dave Co-founder and CEO Jason Wilk. "He continues to take on an increasingly important role and will play a big part in shaping our technology architecture going forward as we grow and scale. His dedication to Dave and the millions of members served has not gone unnoticed and I look forward to working with him and his team as we deliver the best banking and customer experience for our members."
Before joining Dave, Mr. Chou served as Vice President of Engineering with Flexport, where he managed all technology hubs both domestically and abroad, driving next-generation tech platforms to help scale their business. Previously, he served as VP, Technology with LendingClub Corporation, where he led the Loan Services Platform and Investor groups. While with LendingClub, Mr. Chou was instrumental in the buildout and implementation of cloud migration and micro-services, and the Company's next-gen platform, LendingClub 2.0. Earlier in his career, he held leadership positions and various technology roles with Stockpile, LOYAL3, Salesforce.com, and FirstRain.
"I am grateful for this opportunity and the recognition of my peers and will continue to give my all to develop the best technology platform and tools in our industry that will benefit Dave and the members we serve," stated Mr. Chou. "Our mission is what drives my team and we will continue to collaborate with all departments to ensure we have the best infrastructure in place that can support our growth, while continuing to improve the member experience."
Mr. Chou will work closely with Dave's leadership to develop and execute the long-term plan and vision for Dave's technology architecture, scaling its software and systems, and building out the Company's technology team.
Dave is a banking app on a mission to build products that level the financial playing field. Dave's financial tools, including its debit card and spending account, help millions of customers bank, budget, avoid overdraft fees, find work and build credit. For more information, visit www.dave.com.
This press release includes forward-looking statements, which are subject to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "feel," "believes," expects," "estimates," "projects," "intends," "should," "is to be," or the negative of such terms, or other comparable terminology and include, among other things, the quotations of our Chief Executive Officer and statements regarding Dave's future performance and other future events that involve risks and uncertainties. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein due to many factors, including, but not limited to: the ability of Dave to compete in its highly competitive industry; the ability of Dave to keep pace with the rapid technological developments in its industry and the larger financial services industry; the ability of Dave to manage its growth as a public company; disruptions to Dave's operations as a result of becoming a public company; the ability of Dave to remediate material weaknesses in Dave's internal controls over financial reporting and maintain an effective system of internal control over financial reporting; the ability of Dave to protect intellectual property and trade secrets; changes in applicable laws or regulations and extensive and evolving government regulations that impact operations and business; the ability to attract or maintain a qualified workforce; level of product service failures that could lead Dave members to use competitors' services; investigations, claims, disputes, enforcement actions, litigation and/or other regulatory or legal proceedings; the effects of the COVID-19 pandemic on Dave's business; the possibility that Dave may be adversely affected by other economic, business, and/or competitive factors; and those factors discussed in Dave's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 25, 2022 and subsequent Quarterly Reports on Form 10-Q under the heading "Risk Factors," filed with the SEC and other reports and documents Dave files from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and Dave undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release.
Contacts
View original content to download multimedia:
SOURCE Dave Inc. | https://www.whsv.com/prnewswire/2022/09/06/dave-announces-appointment-chien-liang-chou-its-new-chief-technology-officer/ | 2022-09-06T12:56:08Z |
PALO ALTO, Calif., Sept. 6, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today provided an update on the status of its planned request for emergency use authorization (EUA) of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19 based on its most recent communications with the U.S. Food and Drug Administration (FDA).
Following a cooperative and extensive pre-EUA information exchange with FDA regarding the Phase 3 TOGETHER study of peginterferon lambda for COVID-19, the agency has indicated that it is not yet able to determine whether the criteria for the submission of an application and issuance of an EUA are likely to be met. FDA has indicated that it will consider any new information and data from the TOGETHER study to support an EUA as well as the company's plans for the further development of peginterferon lambda for COVID-19. Eiger remains in active dialogue with FDA and will provide additional information to the agency that the company believes could be supportive of an EUA.
"We appreciate the active dialogue with FDA and remain committed to continued engagement with the agency to obtain the necessary alignment to submit our EUA application for peginterferon lambda," said David Cory, President and CEO, Eiger. "Given its unique mechanism of action and the ongoing need for effective COVID-19 therapeutics, making peginterferon lambda available for patients remains a priority for Eiger."
The company has recently generated new data and analyses from the TOGETHER study that it plans to discuss with FDA, including further statistical modeling and efficacy analyses of the study's primary and secondary endpoints in patients treated within three days of symptom onset. The endpoint of hospitalization due to COVID-19 and all-cause mortality for patients treated within three days of symptom onset is consistent with the endpoint used to authorize other therapeutics for emergency use and is summarized below:
The original efficacy analysis of the data generated from the TOGETHER study was based on dosing peginterferon lambda within seven days of symptom onset.
In addition, Eiger plans to provide new additional analyses of long-term follow-up data, including rates of rebound and incidence of long COVID, as well as an indirect comparative analysis of mortality and hospitalizations in vaccinated patients when treated with peginterferon lambda compared to other therapeutics authorized for emergency use.
The company is working with the TOGETHER investigators on the publication of a manuscript in a peer reviewed journal.
About Peginterferon Lambda
Peginterferon lambda is an investigational late-stage, first-in-class, type III interferon (IFN) that stimulates immune responses that are critical for the development of host protection during viral infections and has been well-tolerated in clinical studies.
Peginterferon lambda is to be administered as a single subcutaneous injection so that it can be prescribed and administered at the first sign of infection or at first awareness of an exposure, potentially helping patients avoid severe illness that can lead to hospitalization and death.
IFN lambdas are critical for maintaining a balanced antiviral response in the respiratory tract. They are induced at lower viral burden before type I IFNs to limit the initial infection by inducing viral resistance to cells and helping them deal with the virus load. IFN lambda lacks the strong pro-inflammatory effects of type I IFNs and are tissue-protective and anti-inflammatory. Administration of IFN lambda has been shown to suppress viral replication while stopping 'cytokine storm' from developing.
Eiger is developing peginterferon lambda for the treatment of HDV infection. Peginterferon lambda has been administered to over 4,000 subjects in 28 clinical trials of HBV, HCV, HDV and COVID-19. Peginterferon lambda is an investigational agent and not yet approved for any indication. Eiger has received Orphan Designation by the U.S. Food and Drug Administration (FDA) and European Medicines Agency, and Fast Track and Breakthrough Therapy Designation by FDA for peginterferon lambda in HDV.
Eiger licensed worldwide rights to peginterferon lambda from Bristol-Myers Squibb.
About TOGETHER Study
TOGETHER is a multi-center, investigator-sponsored, randomized, placebo-controlled adaptive platform Phase 3 study evaluating therapeutics in newly diagnosed, high-risk, non-hospitalized patients with COVID-19. TOGETHER is the largest placebo-controlled study in COVID-19 and has evaluated 11 different therapeutic agents for non-hospitalized COVID-19 patients. This evaluation of peginterferon lambda versus placebo was the second largest study to date of a COVID-19 therapeutic. Eligibility criteria required that all patients had laboratory-confirmed mild-to-moderate COVID-19, and were randomized within seven days of symptom onset. High-risk criteria were defined by patients having at least one of the following, including but not limited to: > age 50, diabetes, hypertension, CV disease, lung disease, kidney disease, obesity, etc. The study enrolled patients regardless of vaccination status or variant strain of SARS-CoV-2. The primary endpoint was a clinical outcome comparing hospitalizations or emergency room visits greater than six hours after a single subcutaneous injection of peginterferon lambda versus placebo. The Data Safety Monitoring Board provided independent oversight for the trial and had previously discontinued other therapeutics due to observed futility. The TOGETHER study recruited from 12 sites in Brazil and 5 sites in Canada.
For more information, please visit www.clinicaltrials.gov (NCT04727424) and www.togethertrial.com.
About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib and peginterferon lambda for HDV, Zokinvy for progeria, and avexitide for both congenital hyperinsulinism and post-bariatric hypoglycemia.
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including statements regarding our planned request for emergency use authorization of peginterferon lambda for the treatment of COVID-19, further development of peginterferon lambda, future interactions with FDA, our future financial condition, timing for and outcomes of clinical results, prospective products, preclinical and clinical pipelines, regulatory objectives, business strategy and plans and objectives for future operations, are forward-looking statements. Forward-looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the timing of our ongoing and planned clinical development; the sufficiency of our cash, cash equivalents and investments to fund our operations; the likelihood of obtaining an emergency use authorization from FDA for peginterferon lambda for COVID-19; our capability to provide sufficient quantities of any of our product candidates, including peginterferon lambda, to meet anticipated full-scale commercial demands; our ability to finance the continued advancement of our development pipeline; and the potential for success of any of our products or product candidates. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including additional applicable risks and uncertainties described in the "Risk Factors" sections in the Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 and Eiger's subsequent filings with the SEC. The forward-looking statements contained in this press release are based on information currently available to Eiger and speak only as of the date on which they are made. Eiger does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.
Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com
View original content to download multimedia:
SOURCE Eiger BioPharmaceuticals, Inc. | https://www.whsv.com/prnewswire/2022/09/06/eiger-biopharmaceuticals-provides-update-status-planned-peginterferon-lambda-covid-19-emergency-use-authorization-application/ | 2022-09-06T12:56:15Z |
Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Two Mini-Oral Presentations on the Pivotal Phase 3 CLEAR and Study 309/KEYNOTE-775 Trials Demonstrate the Clinical Benefit of Lenvatinib plus Pembrolizumab and the Combination's Potential Across Difficult-to-Treat Cancers
Post-Hoc, Pooled Analysis of Three Pivotal Phase 3 Studies on Eribulin's Efficacy in Newly-Defined HER2-low Metastatic Breast Cancer Showcases Eisai's Commitment to Advancing Understanding of Our Medicines
NUTLEY, N.J., Sept. 6, 2022 /PRNewswire/ -- Eisai announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place virtually and in-person in Paris, France from September 9 to 13.
A late-breaking oral presentation of detailed results from the LEAP (LEnvatinib And Pembrolizumab) clinical program including the final analysis of the Phase 3 LEAP-002 trial will be featured in a Proffered Paper session (NCT03713593; Presentation: #LBA34). The study evaluated the combination of lenvatinib plus Merck's anti-PD-1 antibody pembrolizumab versus lenvatinib monotherapy as a first-line treatment for patients with unresectable hepatocellular carcinoma. Additionally, two mini-oral presentations will feature updated efficacy and safety data from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial evaluating the combination in patients with advanced renal cell carcinoma (NCT02811861; Presentation: #1449MO) and Phase 3 Study 309/KEYNOTE-775 trial evaluating the combination in patients with advanced endometrial carcinoma (NCT03517449; Presentation: #525MO).
In addition, a new post-hoc analysis of three pivotal Phase 3 studies (Study 301/NCT00337103, Study 304/NCT02225470 and the EMBRACE trial/Study 305/NCT00388726) evaluating the efficacy of eribulin mesylate (HALAVEN®) versus other chemotherapies (capecitabine, vinorelbine and Treatment of Physician's Choice [TPC], respectively) in patients living with metastatic breast cancer whose tumors have low or no HER2-expression will be presented during a poster session (Presentation: #259P).
"We look forward to presenting data at ESMO, showcasing Eisai's latest research on both lenvatinib and eribulin, with the goal of continuing to help people living with various types of cancer," said Dr. Takashi Owa, Chief Scientific Officer, Deep Human Biology Learning, Senior Vice President, Eisai Co., Ltd. "Presentations on the LEAP clinical program as well as new analyses for eribulin reinforce our commitment to the ongoing research of our portfolio in an effort to better serve patients and healthcare providers."
In March 2018, Eisai and Merck (known as MSD outside the United States and Canada), through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib, both as monotherapy and in combination with pembrolizumab. To date, more than 15 trials have been initiated under the LEAP clinical program, which is evaluating the combination across multiple tumor types.
This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
The full list of Eisai presentations is included below. All regular abstracts are available. All late-breaking abstracts will be made available Wednesday, September 7, 2022, at 6:05 PM EDT (Thursday, September 8, 2022, at 12:05 AM CEST).
LENVIMA is indicated:
- For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC)
- In combination with pembrolizumab, for the first line treatment of adult patients with advanced renal cell carcinoma (RCC)
- In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy
- For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)
- In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR), as determined by an FDA-approved test, or not microsatellite instability-high (MSI-H), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
LENVIMA, discovered and developed by Eisai, is a multiple receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. Lenvatinib also exhibited antiproliferative activity in hepatocellular carcinoma cell lines dependent on activated FGFR signaling with a concurrent inhibition of FGF-receptor substrate 2α (FRS2α) phosphorylation. The combination of LENVIMA and everolimus showed increased anti-angiogenic and anti-tumor activity as demonstrated by decreased human endothelial cell proliferation, tube formation, and VEGF signaling in vitro and tumor volume in mouse xenograft models of human renal cell cancer greater than each drug alone. In syngeneic mouse tumor models, the combination of lenvatinib with an anti-PD-1 monoclonal antibody decreased tumor-associated macrophages, increased activated cytotoxic T cells, and demonstrated greater antitumor activity compared to either treatment alone.
Warnings and Precautions
Hypertension. In DTC (differentiated thyroid cancer), hypertension occurred in 73% of patients on LENVIMA (44% grade 3-4). In RCC (renal cell carcinoma), hypertension occurred in 42% of patients on LENVIMA + everolimus (13% grade 3). Systolic blood pressure ≥160 mmHg occurred in 29% of patients, and 21% had diastolic blood pressure ≥100 mmHg. In HCC (hepatocellular carcinoma), hypertension occurred in 45% of LENVIMA-treated patients (24% grade 3). Grade 4 hypertension was not reported in HCC.
Serious complications of poorly controlled hypertension have been reported. Control blood pressure prior to initiation. Monitor blood pressure after 1 week, then every 2 weeks for the first 2 months, and then at least monthly thereafter during treatment. Withhold and resume at reduced dose when hypertension is controlled or permanently discontinue based on severity.
Cardiac Dysfunction. Serious and fatal cardiac dysfunction can occur with LENVIMA. Across clinical trials in 799 patients with DTC, RCC, and HCC, grade 3 or higher cardiac dysfunction occurred in 3% of LENVIMA-treated patients. Monitor for clinical symptoms or signs of cardiac dysfunction. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.
Arterial Thromboembolic Events. Among patients receiving LENVIMA or LENVIMA + everolimus, arterial thromboembolic events of any severity occurred in 2% of patients in RCC and HCC and 5% in DTC. Grade 3-5 arterial thromboembolic events ranged from 2% to 3% across all clinical trials.
Among patients receiving LENVIMA with pembrolizumab, arterial thrombotic events of any severity occurred in 5% of patients in CLEAR, including myocardial infarction (3.4%) and cerebrovascular accident (2.3%).
Permanently discontinue following an arterial thrombotic event. The safety of resuming after an arterial thromboembolic event has not been established, and LENVIMA has not been studied in patients who have had an arterial thromboembolic event within the previous 6 months.
Hepatotoxicity. Across clinical studies enrolling 1327 LENVIMA-treated patients with malignancies other than HCC, serious hepatic adverse reactions occurred in 1.4% of patients. Fatal events, including hepatic failure, acute hepatitis, and hepatorenal syndrome, occurred in 0.5% of patients. In HCC, hepatic encephalopathy occurred in 8% of LENVIMA-treated patients (5% grade 3-5). Grade 3-5 hepatic failure occurred in 3% of LENVIMA-treated patients; 2% of patients discontinued LENVIMA due to hepatic encephalopathy, and 1% discontinued due to hepatic failure.
Monitor liver function prior to initiation, then every 2 weeks for the first 2 months, and at least monthly thereafter during treatment. Monitor patients with HCC closely for signs of hepatic failure, including hepatic encephalopathy. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.
Renal Failure or Impairment. Serious including fatal renal failure or impairment can occur with LENVIMA. Renal impairment was reported in 14% and 7% of LENVIMA-treated patients in DTC and HCC, respectively. Grade 3-5 renal failure or impairment occurred in 3% of patients with DTC and 2% of patients with HCC, including 1 fatal event in each study. In RCC, renal impairment or renal failure was reported in 18% of LENVIMA + everolimus–treated patients (10% grade 3).
Initiate prompt management of diarrhea or dehydration/hypovolemia. Withhold and resume at reduced dose upon recovery or permanently discontinue for renal failure or impairment based on severity.
Proteinuria. In DTC and HCC, proteinuria was reported in 34% and 26% of LENVIMA-treated patients, respectively. Grade 3 proteinuria occurred in 11% and 6% in DTC and HCC, respectively. In RCC, proteinuria occurred in 31% of patients receiving LENVIMA + everolimus (8% grade 3). Monitor for proteinuria prior to initiation and periodically during treatment. If urine dipstick proteinuria ≥2+ is detected, obtain a 24-hour urine protein. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.
Diarrhea. Of the 737 LENVIMA-treated patients in DTC and HCC, diarrhea occurred in 49% (6% grade 3). In RCC, diarrhea occurred in 81% of LENVIMA + everolimus–treated patients (19% grade 3). Diarrhea was the most frequent cause of dose interruption/reduction, and diarrhea recurred despite dose reduction. Promptly initiate management of diarrhea. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.
Fistula Formation and Gastrointestinal Perforation. Of the 799 patients treated with LENVIMA or LENVIMA + everolimus in DTC, RCC, and HCC, fistula or gastrointestinal perforation occurred in 2%. Permanently discontinue in patients who develop gastrointestinal perforation of any severity or grade 3-4 fistula.
QT Interval Prolongation. In DTC, QT/QTc interval prolongation occurred in 9% of LENVIMA-treated patients and QT interval prolongation of >500 ms occurred in 2%. In RCC, QTc interval increases of >60 ms occurred in 11% of patients receiving LENVIMA + everolimus and QTc interval >500 ms occurred in 6%. In HCC, QTc interval increases of >60 ms occurred in 8% of LENVIMA-treated patients and QTc interval >500 ms occurred in 2%.
Monitor and correct electrolyte abnormalities at baseline and periodically during treatment. Monitor electrocardiograms in patients with congenital long QT syndrome, congestive heart failure, bradyarrhythmias, or those who are taking drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. Withhold and resume at reduced dose upon recovery based on severity.
Hypocalcemia. In DTC, grade 3-4 hypocalcemia occurred in 9% of LENVIMA-treated patients. In 65% of cases, hypocalcemia improved or resolved following calcium supplementation with or without dose interruption or dose reduction. In RCC, grade 3-4 hypocalcemia occurred in 6% of LENVIMA + everolimus–treated patients. In HCC, grade 3 hypocalcemia occurred in 0.8% of LENVIMA-treated patients. Monitor blood calcium levels at least monthly and replace calcium as necessary during treatment. Withhold and resume at reduced dose upon recovery or permanently discontinue depending on severity.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS). Across clinical studies of 1823 patients who received LENVIMA as a single agent, RPLS occurred in 0.3%. Confirm diagnosis of RPLS with MRI. Withhold and resume at reduced dose upon recovery or permanently discontinue depending on severity and persistence of neurologic symptoms.
Hemorrhagic Events. Serious including fatal hemorrhagic events can occur with LENVIMA. In DTC, RCC, and HCC clinical trials, hemorrhagic events, of any grade, occurred in 29% of the 799 patients treated with LENVIMA as a single agent or in combination with everolimus. The most frequently reported hemorrhagic events (all grades and occurring in at least 5% of patients) were epistaxis and hematuria. In DTC, grade 3-5 hemorrhage occurred in 2% of LENVIMA-treated patients, including 1 fatal intracranial hemorrhage among 16 patients who received LENVIMA and had CNS metastases at baseline. In RCC, grade 3-5 hemorrhage occurred in 8% of LENVIMA + everolimus–treated patients, including 1 fatal cerebral hemorrhage. In HCC, grade 3-5 hemorrhage occurred in 5% of LENVIMA-treated patients, including 7 fatal hemorrhagic events. Serious tumor-related bleeds, including fatal hemorrhagic events, occurred in LENVIMA-treated patients in clinical trials and in the postmarketing setting. In postmarketing surveillance, serious and fatal carotid artery hemorrhages were seen more frequently in patients with anaplastic thyroid carcinoma (ATC) than other tumors. Safety and effectiveness of LENVIMA in patients with ATC have not been demonstrated in clinical trials.
Consider the risk of severe or fatal hemorrhage associated with tumor invasion or infiltration of major blood vessels (eg, carotid artery). Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.
Impairment of Thyroid Stimulating Hormone Suppression/Thyroid Dysfunction. LENVIMA impairs exogenous thyroid suppression. In DTC, 88% of patients had baseline thyroid stimulating hormone (TSH) level ≤0.5 mU/L. In patients with normal TSH at baseline, elevation of TSH level >0.5 mU/L was observed post baseline in 57% of LENVIMA-treated patients. In RCC and HCC, grade 1 or 2 hypothyroidism occurred in 24% of LENVIMA + everolimus–treated patients and 21% of LENVIMA-treated patients, respectively. In patients with normal or low TSH at baseline, elevation of TSH was observed post baseline in 70% of LENVIMA-treated patients in HCC and 60% of LENVIMA + everolimus–treated patients in RCC.
Monitor thyroid function prior to initiation and at least monthly during treatment. Treat hypothyroidism according to standard medical practice.
Impaired Wound Healing. Impaired wound healing has been reported in patients who received LENVIMA. Withhold LENVIMA for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of LENVIMA after resolution of wound healing complications has not been established.
Osteonecrosis of the Jaw (ONJ). ONJ has been reported in patients receiving LENVIMA. Concomitant exposure to other risk factors, such as bisphosphonates, denosumab, dental disease, or invasive dental procedures, may increase the risk of ONJ.
Perform an oral examination prior to treatment with LENVIMA and periodically during LENVIMA treatment. Advise patients regarding good oral hygiene practices and to consider having preventive dentistry performed prior to treatment with LENVIMA and throughout treatment with LENVIMA.
Avoid invasive dental procedures, if possible, while on LENVIMA treatment, particularly in patients at higher risk. Withhold LENVIMA for at least 1 week prior to scheduled dental surgery or invasive dental procedures, if possible. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk of ONJ.
Withhold LENVIMA if ONJ develops and restart based on clinical judgement of adequate resolution.
Embryo-Fetal Toxicity. Based on its mechanism of action and data from animal reproduction studies, LENVIMA can cause fetal harm when administered to pregnant women. In animal reproduction studies, oral administration of lenvatinib during organogenesis at doses below the recommended clinical doses resulted in embryotoxicity, fetotoxicity, and teratogenicity in rats and rabbits. Advise pregnant women of the potential risk to a fetus and advise females of reproductive potential to use effective contraception during treatment with LENVIMA and for at least 30 days after the last dose.
Adverse Reactions
In DTC, the most common adverse reactions (≥30%) observed in LENVIMA-treated patients were hypertension (73%), fatigue (67%), diarrhea (67%), arthralgia/myalgia (62%), decreased appetite (54%), decreased weight (51%), nausea (47%), stomatitis (41%), headache (38%), vomiting (36%), proteinuria (34%), palmar-plantar erythrodysesthesia syndrome (32%), abdominal pain (31%), and dysphonia (31%). The most common serious adverse reactions (≥2%) were pneumonia (4%), hypertension (3%), and dehydration (3%). Adverse reactions led to dose reductions in 68% of LENVIMA-treated patients; 18% discontinued LENVIMA. The most common adverse reactions (≥10%) resulting in dose reductions were hypertension (13%), proteinuria (11%), decreased appetite (10%), and diarrhea (10%); the most common adverse reactions (≥1%) resulting in discontinuation of LENVIMA were hypertension (1%) and asthenia (1%).
In RCC, the most common adverse reactions (≥20%) observed in LENVIMA + pembrolizumab-treated patients were fatigue (63%), diarrhea (62%), musculoskeletal pain (58%), hypothyroidism (57%), hypertension (56%), stomatitis (43%), decreased appetite (41%), rash (37%), nausea (36%), decreased weight (30%), dysphonia (30%), proteinuria (30%), palmar-plantar erythrodysesthesia syndrome (29%), abdominal pain (27%), hemorrhagic events (27%), vomiting (26%), constipation (25%), hepatotoxicity (25%), headache (23%), and acute kidney injury (21%). The most common serious adverse reactions (≥2%) were hemorrhagic events (5%), diarrhea (4%), hypertension (3%), myocardial infarction (3%), pneumonitis (3%), vomiting (3%), acute kidney injury (2%), adrenal insufficiency (2%), dyspnea (2%), and pneumonia (2%). Fatal adverse reactions occurred in 4.3% of patients receiving LENVIMA in combination with pembrolizumab, including cardio-respiratory arrest (0.9%), sepsis (0.9%), and one case (0.3%) each of arrhythmia, autoimmune hepatitis, dyspnea, hypertensive crisis, increased blood creatinine, multiple organ dysfunction syndrome, myasthenic syndrome, myocarditis, nephritis, pneumonitis, ruptured aneurysm and subarachnoid hemorrhage. Serious adverse reactions occurred in 51% of patients receiving LENVIMA and pembrolizumab. Serious adverse reactions in ≥2% of patients were hemorrhagic events (5%), diarrhea (4%), hypertension (3%), myocardial infarction (3%), pneumonitis (3%), vomiting (3%), acute kidney injury (2%), adrenal insufficiency (2%), dyspnea (2%), and pneumonia (2%). Permanent discontinuation of LENVIMA, pembrolizumab, or both due to an adverse reaction occurred in 37% of patients; 26% LENVIMA only, 29% pembrolizumab only, and 13% both drugs. The most common adverse reactions (≥2%) leading to permanent discontinuation of LENVIMA, pembrolizumab, or both were pneumonitis (3%), myocardial infarction (3%), hepatotoxicity (3%), acute kidney injury (3%), rash (3%), and diarrhea (2%). Dose interruptions of LENVIMA, pembrolizumab, or both due to an adverse reaction occurred in 78% of patients receiving LENVIMA in combination with pembrolizumab. LENVIMA was interrupted in 73% of patients and both drugs were interrupted in 39% of patients. LENVIMA was dose reduced in 69% of patients. The most common adverse reactions (≥5%) resulting in dose reduction or interruption of LENVIMA were diarrhea (26%), fatigue (18%), hypertension (17%), proteinuria (13%), decreased appetite (12%), palmar-plantar erythrodysesthesia (11%), nausea (9%), stomatitis (9%), musculoskeletal pain (8%), rash (8%), increased lipase (7%), abdominal pain (6%), and vomiting (6%), increased ALT (5%), and increased amylase (5%).
In RCC, the most common adverse reactions (≥30%) observed in LENVIMA + everolimus–treated patients were diarrhea (81%), fatigue (73%), arthralgia/myalgia (55%), decreased appetite (53%), vomiting (48%), nausea (45%), stomatitis (44%), hypertension (42%), peripheral edema (42%), cough (37%), abdominal pain (37%), dyspnea (35%), rash (35%), decreased weight (34%), hemorrhagic events (32%), and proteinuria (31%). The most common serious adverse reactions (≥5%) were renal failure (11%), dehydration (10%), anemia (6%), thrombocytopenia (5%), diarrhea (5%), vomiting (5%), and dyspnea (5%). Adverse reactions led to dose reductions or interruption in 89% of patients. The most common adverse reactions (≥5%) resulting in dose reductions were diarrhea (21%), fatigue (8%), thrombocytopenia (6%), vomiting (6%), nausea (5%), and proteinuria (5%). Treatment discontinuation due to an adverse reaction occurred in 29% of patients.
In HCC, the most common adverse reactions (≥20%) observed in LENVIMA-treated patients were hypertension (45%), fatigue (44%), diarrhea (39%), decreased appetite (34%), arthralgia/myalgia (31%), decreased weight (31%), abdominal pain (30%), palmar-plantar erythrodysesthesia syndrome (27%), proteinuria (26%), dysphonia (24%), hemorrhagic events (23%), hypothyroidism (21%), and nausea (20%). The most common serious adverse reactions (≥2%) were hepatic encephalopathy (5%), hepatic failure (3%), ascites (3%), and decreased appetite (2%). Adverse reactions led to dose reductions or interruption in 62% of patients. The most common adverse reactions (≥5%) resulting in dose reductions were fatigue (9%), decreased appetite (8%), diarrhea (8%), proteinuria (7%), hypertension (6%), and palmar-plantar erythrodysesthesia syndrome (5%). Treatment discontinuation due to an adverse reaction occurred in 20% of patients. The most common adverse reactions (≥1%) resulting in discontinuation of LENVIMA were fatigue (1%), hepatic encephalopathy (2%), hyperbilirubinemia (1%), and hepatic failure (1%).
In EC, the most common adverse reactions (≥20%) observed in LENVIMA and pembrolizumab–treated patients were hypothyroidism (67%), hypertension (67%), fatigue (58%), diarrhea (55%), musculoskeletal disorders (53%), nausea (49%), decreased appetite (44%), vomiting (37%), stomatitis (35%), decreased weight (34%), abdominal pain (34%), urinary tract infection (31%), proteinuria (29%), constipation (27%), headache (26%), hemorrhagic events (25%), palmar‐plantar erythrodysesthesia (23%), dysphonia (22%), and rash (20%). Fatal adverse reactions occurred in 4.7% of those treated with LENVIMA and pembrolizumab, including 2 cases of pneumonia, and 1 case of the following: acute kidney injury, acute myocardial infarction, colitis, decreased appetite, intestinal perforation, lower gastrointestinal hemorrhage, malignant gastrointestinal obstruction, multiple organ dysfunction syndrome, myelodysplastic syndrome, pulmonary embolism, and right ventricular dysfunction. Serious adverse reactions occurred in 50% of patients receiving LENVIMA and pembrolizumab. Serious adverse reactions with frequency ≥3% were hypertension (4.4%), and urinary tract infection (3.2%). Discontinuation of LENVIMA due to an adverse reaction occurred in 26% of patients. The most common (≥1%) adverse reactions leading to discontinuation of LENVIMA were hypertension (2%), asthenia (1.8%), diarrhea (1.2%), decreased appetite (1.2%), proteinuria (1.2%), and vomiting (1.2%). Dose reductions of LENVIMA due to adverse reactions occurred in 67% of patients. The most common (≥5%) adverse reactions resulting in dose reduction of LENVIMA were hypertension (18%), diarrhea (11%), palmar-plantar erythrodysesthesia syndrome (9%), proteinuria (7%), fatigue (7%), decreased appetite (6%), asthenia (5%), and weight decreased (5%). Dose interruptions of LENVIMA due to an adverse reaction occurred in 58% of these patients. The most common (≥2%) adverse reactions leading to interruption of LENVIMA were hypertension (11%), diarrhea (11%), proteinuria (6%), decreased appetite (5%), vomiting (5%), increased alanine aminotransferase (3.5%), fatigue (3.5%), nausea (3.5%), abdominal pain (2.9%), decreased weight (2.6%), urinary tract infection (2.6%), increased aspartate aminotransferase (2.3%), asthenia (2.3%), and palmar-plantar erythrodysesthesia (2%).
Use in Specific Populations
Because of the potential for serious adverse reactions in breastfed infants, advise women to discontinue breastfeeding during treatment and for at least 1 week after the last dose. LENVIMA may impair fertility in males and females of reproductive potential.
No dose adjustment is recommended for patients with mild (CLcr 60-89 mL/min) or moderate (CLcr 30-59 mL/min) renal impairment. LENVIMA concentrations may increase in patients with DTC, RCC, or EC and severe (CLcr 15-29 mL/min) renal impairment. Reduce the dose for patients with DTC, RCC, or EC and severe renal impairment. There is no recommended dose for patients with HCC and severe renal impairment. LENVIMA has not been studied in patients with end-stage renal disease.
No dose adjustment is recommended for patients with HCC and mild hepatic impairment (Child-Pugh A). There is no recommended dose for patients with HCC with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. No dose adjustment is recommended for patients with DTC, RCC, or EC and mild or moderate hepatic impairment. LENVIMA concentrations may increase in patients with DTC, RCC, or EC and severe hepatic impairment. Reduce the dose for patients with DTC, RCC, or EC and severe hepatic impairment.
LENVIMA (lenvatinib) is available as 10 mg and 4 mg capsules.
Please see Prescribing information for LENVIMA (lenvatinib) at http://www.lenvima.com/pdfs/prescribing-information.pdf.
HALAVEN® (eribulin mesylate) is a microtubule dynamics inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
Discovered and developed by Eisai, eribulin is a synthetic analog of halichondrin B, a natural product that was isolated from the marine sponge Halichondria okadai. First in the halichondrin class, eribulin is a microtubule dynamics inhibitor. Eribulin is believed to work primarily via a tubulin-based mechanism that causes prolonged and irreversible mitotic blockage, ultimately leading to apoptotic cell death. Additionally, in preclinical studies of human breast cancer, eribulin demonstrated complex effects on the tumor biology of surviving cancer cells, including increases in vascular perfusion resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with a change in phenotype, promoting the epithelial phenotype, opposing the mesenchymal phenotype. Eribulin has also been shown to decrease the migration and invasiveness of human breast cancer cells.
Warnings and Precautions
Neutropenia: Severe neutropenia (ANC <500/mm3) lasting >1 week occurred in 12% of patients with mBC and liposarcoma or leiomyosarcoma. Febrile neutropenia occurred in 5% of patients with mBC and 2 patients (0.4%) died from complications. Patients with mBC with elevated liver enzymes >3 × ULN and bilirubin >1.5 × ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal levels. Monitor complete blood cell counts prior to each dose, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting >7 days.
Peripheral Neuropathy: Grade 3 peripheral neuropathy occurred in 8% of patients with mBC (Grade 4=0.4%) and 22% developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25-662 days). Neuropathy lasting >1 year occurred in 5% of patients with mBC. Grade 3 peripheral neuropathy occurred in 3.1% of patients with liposarcoma and leiomyosarcoma receiving HALAVEN and neuropathy lasting more than 60 days occurred in 58% (38/65) of patients who had neuropathy at the last treatment visit. Patients should be monitored for signs of peripheral motor and sensory neuropathy. Withhold HALAVEN in patients who experience Grade 3 or 4 peripheral neuropathy until resolution to Grade 2 or less.
Embryo-Fetal Toxicity: HALAVEN can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with HALAVEN and for at least 2 weeks following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with HALAVEN and for 3.5 months following the final dose.
QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating HALAVEN and monitor these electrolytes periodically during therapy. Avoid in patients with congenital long QT syndrome.
Adverse Reactions
In patients with mBC receiving HALAVEN, the most common adverse reactions (≥25%) were neutropenia (82%), anemia (58%), asthenia/fatigue (54%), alopecia (45%), peripheral neuropathy (35%), nausea (35%), and constipation (25%). Febrile neutropenia (4%) and neutropenia (2%) were the most common serious adverse reactions. The most common adverse reaction resulting in discontinuation was peripheral neuropathy (5%).
Use in Specific Populations
Lactation: Because of the potential for serious adverse reactions in breastfed infants from eribulin mesylate, advise women not to breastfeed during treatment with HALAVEN and for 2 weeks after the final dose.
Hepatic and Renal Impairment: A reduction in starting dose is recommended for patients with mild or moderate hepatic impairment and/or moderate or severe renal impairment.
For more information about HALAVEN, click here for the full Prescribing Information.
In March 2018, Eisai and Merck, known as MSD outside the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck's anti-PD-1 therapy KEYTRUDA.
In addition to ongoing clinical studies evaluating the KEYTRUDA plus LENVIMA combination across several different tumor types, the companies have jointly initiated new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program and are evaluating the combination in multiple different tumor types across more than 15 clinical trials.
Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept [also known as our human health care (hhc) Concept], we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.
In addition, our continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), is demonstrated by our work on various activities together with global partners.
For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai, Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia, and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on Twitter (U.S. and global) and LinkedIn (for U.S. and EMEA).
LENVIMA® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
HALAVEN® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.
# # #
View original content to download multimedia:
SOURCE Eisai Inc. | https://www.whsv.com/prnewswire/2022/09/06/eisai-presents-new-data-its-oncology-portfolio-pipeline-esmo-congress-2022/ | 2022-09-06T12:56:22Z |
BEVERLY HILLS, Calif., Sept. 6, 2022 /PRNewswire/ -- EV Mobility, LLC., the leading all-electric vehicle car-sharing platform, provides electric vehicles on demand as an amenity to luxury hotels, multi-family apartment buildings, and commercial buildings through its easy-to-use mobile app. EV Mobility announced today recent expansion into properties in Florida, Washington, and Nevada.
EV Mobility initially launched its services in Los Angeles, San Diego, and the Bay Area. The expansion enables EV Mobility to start to build its national footprint and support its continued growth, aligning with property owner and consumer demand. In Florida, the expansion includes hotels in Stuart, Fort Lauderdale, and Palm Beach Gardens. In Washington, the expansion includes the tallest residential building in Seattle, the Modern. In Las Vegas, the company has deployed EVs at the English Hotel and will deploy at 3 additional hotels in the upcoming weeks.
As the multi-family apartment and hotel industry are starting to see the benefits of having EV Mobility as an amenity, the company is experiencing ever increasing demand for its services. Through partnerships with different property owner groups, EV Mobility will continue to expand strategically in cities across the country.
"The decision to expand our presence nationally was a logical next step in our business growth strategy" said Ramy El-Batrawi, CEO "In every city and area we expand in, we will deploy enough properties to create density and have a real presence. We are a technology-driven platform allowing us to scale rapidly and cost effectively."
EV Mobility is the leading all Electric Vehicle car-sharing platform that provides EVs on-demand through an easy-to-use mobile app 24/7. EV Mobility offers EVs as an amenity for luxury hotels, multi-family apartments, and commercial buildings. Through the app residents or guests access Electric Vehicles located in their building or hotel. Properties benefit from the added value they can now offer to residents or guests of a low-cost, zero emission Electric Vehicle on demand. Properties also generate an additional revenue stream, decreased parking needs, and improve resident retention. Residents benefit from having access to Electric Vehicles and by eliminating the cost of car ownership including car payments, insurance, maintenance, and cost of gas, while reducing their carbon footprint. Hotel guests benefit by not needing a rental car or paying for gas and overnight parking. EVs can be rented by the hour, daily, or with monthly incentive packages. The all-electric car-sharing service began in Los Angeles in 2021 and is expanding rapidly.
Learn more visit www.evmobility.com
View original content to download multimedia:
SOURCE EV Mobility | https://www.whsv.com/prnewswire/2022/09/06/ev-mobility-continues-expand-outside-california-florida-washington-nevada/ | 2022-09-06T12:56:28Z |
- Executive Chairman of the Board, Jeremy Frommer will assume the CEO seat.
- Creatd's board significantly amplifies its capabilities with the addition of Justin Maury, Creatd's COO and Co-founder.
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Creatd, Inc. (Nasdaq CM: CRTD) ("Creatd" or the "Company"), a creator-first holding company, and the parent company of Vocal, is pleased to announce a new appointment to its board of directors, Justin Maury, Creatd COO and co-founder, as well as the appointment of current Executive Chairman, Jeremy Frommer to the position of Chairman and CEO.
Justin Maury is Creatd's Chief Operating Officer and co-founder. Maury is a full-stack designer and product developer by training who first partnered with Creatd's Executive Chairman of the Board, Jeremy Frommer, in 2013 after building a decade of experience at numerous global creative agencies. Maury is credited with leading the early vision, design, and architecture of Vocal, the Company's flagship platform, which he brought to launch in 2016. Beyond Vocal, Maury oversees Creatd's broader technology roadmap and is instrumental in the creation and scale of Creatd's subsequent business segments, which encompass technology, agency partnership, e-commerce, and production activities.
Commented Creatd Executive Chairman Jeremy Frommer, "This addition to our board marks a significant boost to our company's collective strength on both a professional and personal level. As head of product, COO, and now, a member of Creatd's board, Justin has remained instrumental in leading the platform and the entire company. Our board will greatly benefit from his unique product perspective, and his direct input will be invaluable as we refine our technology roadmap and progress our Web 3.0 strategy."
Creatd, Inc. (Nasdaq CM: CRTD) is a company dedicated to unlocking creativity for creators, brands, and consumers. We accomplish this through Creatd's four business pillars: Creatd Labs, Creatd Partners, Creatd Ventures, and Creatd Studios.
Creatd: https://creatd.com;
Creatd IR: https://investors.creatd.com;
Vocal Platform: https://vocal.media;
Investor Relations Contact: ir@creatd.com
Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "intends," "plans," "believes" and "projects") may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release is qualified in its entirety by the cautionary statements and risk factor disclosure contained in our Securities and Exchange Commission filings.
View original content to download multimedia:
SOURCE Creatd, Inc. | https://www.whsv.com/prnewswire/2022/09/06/executive-chairman-jeremy-frommer-assume-chairman-ceo-position-additionally-creatd-inc-welcomes-founder-coo-justin-maury-board-directors/ | 2022-09-06T12:56:35Z |
Asian Insurance Giant Joins FinOps Foundation to Support its Rapid Cloud Adoption
PORTLAND, Ore., Sept. 6, 2022 /PRNewswire/ -- The FinOps Foundation, a part of The Linux Foundation's non-profit technology consortium focused on advancing the people and practice of cloud financial management, announced today that insurance giant, AIA Group, is joining as a Premier Member company.
As part of AIA's Premier Membership, Keith Austin, Associate Director of Cloud Services, leading the Cloud Centre of Excellence at AIA, will join the FinOps Governing Board as a voting member to help craft Foundation strategy and direction. The Governing Board sets the strategy of the program, including where to invest resources and funds in support of the Technical Advisory Council's work.
For more than a century, AIA has strived to make a significant, positive impact for customers and communities across Asia. As the largest independent publicly listed pan-Asian life insurance group—with a presence in 18 markets across Asia—how it evolves impacts millions of people every day.
Amid the growth of cloud computing, AIA's transition to the cloud has been enormous, increasing cloud adoption to 78%, ahead of the global average in the financial services and insurance industry. FinOps teams and practices enable companies to gain greater control over their cloud spend forecasting and migration planning. FinOps is now practiced in every major industry and AIA will lead the early growth of FinOps in the Asia-Pacific region, which is following North America and Europe in FinOps adoption, research shows.
"The common thread that unites our Technology, Digital, Analytics (TDA) team is that everybody is an expert in their respective fields. We bring together the best providers and hire top talent, and we empower our teams to build frictionless, world-class systems and products. This will now include the FinOps Foundation," said Marcel Malan, AIA Group's Head of Group IT Operations. "By leveraging the power of TDA to transform into a customer-centric, world-class digitally-enabled insurer, we enhance our resilience and abilities to capture the growth opportunities. This also deepens our purpose to help millions of people in Asia to live healthier, longer, better lives."
AIA's cloud first strategy is a fundamental pillar for AIA to be able to scale and modernize with the needs of customers, agencies and distributors, and it leads its peers in Asia in doing so.
"AIA's rapid cloud adoption takes courage, leadership and a committed team and partnership," said J.R. Storment, Executive Director of the FinOps Foundation. "We welcome AIA as a Premier Member. Its commitment to evolve to the cloud computing world is an example of how all companies, whether deeply established or brand new, can and must take advantage of technological advances to better meet their customer needs and stay ahead of competitors. AIA's membership in the FinOps Foundation will be a huge asset to the larger FinOps community as we develop and instill best practices across industries and continents."
The FinOps Foundation has continued its rapid expansion. It now serves over 7,500 community members from more than 2,500 organizations. End user members gain exposure in the FinOps community, have easy access to training and enhanced recruitment opportunities - accelerating the adoption, and are coached on the development of their FinOps practices.
The latest FinOps Foundation research indicates that large companies will continue to adopt FinOps, due to the complexity of their cloud environments, reporting requirements and the sheer number of disparate teams requiring collaboration. Also, the research found that financial services and IT industries practice FinOps most, followed by other industries.
With the explosive growth of cloud in recent years, organizations understand the critical need to ensure accountability for cloud spending in order to align cloud adoption and investment with business strategy and value.
To learn more about becoming a member of The FinOps Foundation visit https://www.finops.org/membership/
The FinOps Foundation (F2) is a non-profit trade association made up of FinOps practitioners around the world including Atlassian, Autodesk, Gannett, HERE Technologies, Just Eat, Nationwide and Spotify. Grounded in real world stories, expertise, and inspiration for and by FinOps practitioners, the FinOps Foundation is focused on codifying and promoting cloud financial management best practices and standards to help community members and their teams become better at cloud financial management.
AIA Group Limited and its subsidiaries (collectively "AIA" or the "Group") comprise the largest independent publicly listed pan-Asian life insurance group. It has a presence in 18 markets – wholly-owned branches and subsidiaries in Mainland China, Hong Kong SAR(1), Thailand, Singapore, Malaysia, Australia, Cambodia, Indonesia, Myanmar, New Zealand, the Philippines, South Korea, Sri Lanka, Taiwan (China), Vietnam, Brunei and Macau SAR(2), and a 49 per cent joint venture in India.
The business that is now AIA was first established in Shanghai more than a century ago in 1919. It is a market leader in Asia (ex-Japan) based on life insurance premiums and holds leading positions across the majority of its markets. It had total assets of US$340 billion as of 31 December 2021.
AIA meets the long-term savings and protection needs of individuals by offering a range of products and services including life insurance, accident and health insurance and savings plans. The Group also provides employee benefits, credit life and pension services to corporate clients. Through an extensive network of agents, partners and employees across Asia, AIA serves the holders of more than 39 million individual policies and over 16 million participating members of group insurance schemes.
AIA Group Limited is listed on the Main Board of The Stock Exchange of Hong Kong Limited under the stock code "1299" with American Depositary Receipts (Level 1) traded on the over-the-counter market (ticker symbol: "AAGIY").
Notes:
(1) Hong Kong SAR refers to the Hong Kong Special Administrative Region.
(2) Macau SAR refers to the Macau Special Administrative Region.
Contact: pr@linuxfoundation.org
View original content to download multimedia:
SOURCE FinOps Foundation | https://www.whsv.com/prnewswire/2022/09/06/finops-foundation-announces-aia-premier-member/ | 2022-09-06T12:56:42Z |
DALLAS, Sept. 6, 2022 /PRNewswire/ -- Generation Hemp, Inc., a Dallas/Fort Worth based midstream hemp company (OTCQB: GENH), and its wholly-owned subsidiary, GENH Halcyon Acquisition, LLC (collectively the "Company") in collaboration with Richard Rawlings' Gas Monkey Garage, today announced the official launch of its Gas Monkey Spill-Jack consumer goods hemp product line. Gas Monkey Spill-Jack is an all-natural, plant-based, sustainable, and biodegradable loose absorbent made from the hemp hurd byproduct that is produced by the Company's hemp processing operations. This is the second consumer goods product produced by Generation Hemp, adding to its hemp animal bedding line called Rowdy Rooster Hemp. Gas Monkey Spill-Jack is now being sold on spilljackusa.com and will soon be offered on Amazon.
There are several types of spill absorbents with varying characteristics within three general categories – mineral based, animal or vegetable based, and synthetic or organic polymers. The challenge in choosing an absorbent is finding an effective material that does not pose a threat to either health or the environment, whether that threat is posed when that material is procured or used. For example, a widely used spill absorbent material in products is Bentonite Clay. This is often a very dusty material and has warnings of containing unsafe levels of lead (FDA) and has been associated with a number of health complaints in humans.
When Generation Hemp's processing facility operations often led to thick and sticky hemp oil messes similar to spills in an automotive garage, the facility managers started to use hemp hurd to soak up those spills, because kitty litter and other chemical based products could not be used around the crops being processed. When they saw how well it worked, they took it to neighboring businesses to try out further. They found that it worked faster and better than the kitty litter stand by in other applications. Chairman and CEO of Generation Hemp, Inc. commented, "We began experimenting and testing hemp hurd's efficacy against all the industrial absorbent standard go-tos. Spill-Jack performed as well or better against every other material. Most of the current products used are not the best environmental options, and other eco-friendly options just don't perform as well. When we brought the milled hemp stalks to Richard Rawlings' Gas Monkey Garage, I think everyone was somewhat stunned at Spill-Jack's performance." Evans continued, "Our team was very excited to collaborate with Richard and Gas Monkey. Getting the stamp of approval from such a well known automotive brand is one thing, but to then have the founder put his brand behind our product was just unexpected. In fact, it was our visit to Gas Monkey Garage that inspired our product's name, Spill-Jack. If you can jack up a car, you can jack up a spill!"
The initial products in the Gas Monkey Spill-Jack line will come in three different sizes: a large 20 pound bag that can absorb approximately 24 gallons of oil, a medium sized bag that can absorb approximately 9 liters of oil, and mini-bag singles sold individually or in six-packs and can be kept in the purse or glove box to clean up any spills on the go, including pet messes.
Generation Hemp, Inc. is a Dallas/Fort Worth based hemp company that operates in the midstream sector. With operations in western Kentucky and Denver, Colorado, the company uses its proprietary technology to dry, clean, process and store hemp. In addition, Generation Hemp also owns and leases real estate to companies needing seed storage facilities located within the greater Denver area.
Richard Rawlings, owner and founder of Gas Monkey Garage, is the star of the international hit series "Fast N' Loud," "Garage Rehab," "Demolition Theatre," and more. Since the inception of Gas Monkey Garage in 2004, Richard Rawlings continues to be anything except ordinary. Having built two commissioned custom cars for Hot Wheels, setting numerous world records, and cementing Gas Monkey Garage as a household name, Richard does anything but blend in! Aside from his garage and television shows, Richard Rawlings is an innovative entrepreneur, turning Gas Monkey Garage into a household name and worldwide brand. Between owning multiple restaurants/venues, having his own Tequila and Energy Drink, selling merchandise worldwide, and sponsoring some of the top names in automotive racing, Richard Rawlings only knows one speed and its full throttle. You can learn more about Richard Rawlings and the Gas Monkey crew at GasMonkeyGarage.com, and see what the Monkeys are up to every Monday night at 8pm CDT on their YouTube Channel.
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as "believes", "expects", "anticipates", "intends", "plans", "estimates," "projects", "forecasts", "proposes", "should", "likely" or similar expressions, indicates a forward-looking statement. These statements and all the projections in this press release are subject to risks and uncertainties and are based on the beliefs and assumptions of management, and information currently available to management. The actual results could differ materially from a conclusion, forecast or projection in the forward-looking information. The identification in this press release of factors that may affect the company's future performance and the accuracy of forward-looking statements is meant to be illustrative and by no means exhaustive.
Contact:
Melissa M. Pagen
Generation Hemp, Inc.
Phone: (310) 628-2062
Email: mpagen@genhempinc.com
View original content:
SOURCE Generation Hemp Inc. | https://www.whsv.com/prnewswire/2022/09/06/generation-hemp-officially-launches-gas-monkey-spill-jack-hemp-product-line/ | 2022-09-06T12:56:48Z |
GMMI reaffirms its commitment to delivering high-quality care to members while managing client costs.
PEMBROKE PINES, Fla., Sept. 6, 2022 /PRNewswire/ -- GMMI – the U.S. cost containment entity of Generali Global Assistance – today announced that it has earned URAC accreditation for its Health Utilization Program. This year marks GMMI's 30th anniversary as the pioneer and leader of the U.S. and international cost containment landscape.
"This is yet another milestone to achieve our vision to be the most reliable care company in the world. GMMI's URAC accreditation is a testament of the quality of care all our client's members can experience as we bring them from distress to relief. Anytime, anywhere," said Chris Carnicelli, CEO.
URAC is the nation's leading health care accrediting organization and the undisputed leader in telehealth accreditation. Earning a URAC accreditation means that GMMI's Care Management Program follows the industry's most rigorous standards while reinforcing its commitment to quality improvement.
Zaydee Capo, RN., BSN., CCM., Vice President of Healthcare Services added: "GMMI's Health Utilization Management Program focuses on cost containment while ensuring our client's and members have accessibility, quality, and timeliness of care. GMMI maintains a critical role in improving patient care and health outcomes. Receiving the URAC 'Gold Star Standard' recognizes our commitment to quality and accountability."
Watch GMMI's Medical Team on URAC's accreditation of GMMI: https://youtu.be/NHAgcuq4504
About GMMI, Inc.
GMMI delivers industry-leading medical cost containment and medical risk management solutions that elevate standards of care. Through best-in-class provider networks, multilingual customer service, URAC accredited case management, and prompt and efficient claims administration worldwide, we provide members with exceptional care at the right time and the right place for the right cost.
To learn more, please visit: https://www.gmmi.com
About Generali Global Assistance
Generali Global Assistance (GGA) is a leading brand comprised of Travel Insurance & Assistance, Cost Containment, Identity & Cyber Protection, as well as other care services. GGA is part of the Generali Group, which for over 190 years has provided peace of mind to its clients and their customers and is now supported by more than 72,000 employees worldwide. Our success has been built on establishing trust by putting the customer at the core of everything we do, offering assistance and protection during our customer's most difficult and stressful situations.
To learn more, please visit: https://us.generaliglobalassistance.com/
CONTACT: Patrick Jordan, pjordan@mgroupsc.com, 9176762190
View original content to download multimedia:
SOURCE Generali Global Assistance | https://www.whsv.com/prnewswire/2022/09/06/gmmi-earns-urac-accreditation-its-health-utilization-management-program/ | 2022-09-06T12:56:54Z |
ISELIN, N.J., Sept. 6, 2022 /PRNewswire/ -- Hexaware Technologies, a fast-growing Global IT Consulting and Digital Solutions provider, today announced that it has achieved the Guidewire PartnerConnect specialization: Technical Upgrades.
Hexaware Technologies is a Guidewire PartnerConnect Consulting partner at the Advantage level and works with Guidewire in North America, EMEA, and Asia-Pacific.
Hexaware delivers state-of-the-art solutions to boost the digital capabilities of insurers and is a top choice for successful implementation with its customer-centric approach and domain expertise. The company offers quick, accurate, accessible, and reliable services at all touchpoints, exceeding user expectations. Hexaware always strives to provide tailor-made implementation and comprehensive management solutions for the Guidewire platform with its tools and technologies.
Specializations are both regionally and globally based and require partners to demonstrate skills, knowledge, and competency in a particular Guidewire product or solution area. The achievement of specializations enables insurers to have more clarity and insight into which partners have proven capabilities in a region. In addition, partners with specializations can better promote their capabilities across Guidewire products and solutions.
Molly Black, Senior Director, Partner Programs and Enablement, Global Alliances, Guidewire Software, says, "Congratulations to Hexaware on their most recent Technical Upgrades specialization within our PartnerConnect Consulting program. We're thrilled to recognize Hexaware for their expertise in Guidewire products and solutions and for continuing to provide successful implementations for our shared customers."
Milan Bhatt, Corporate Vice President, Healthcare & Insurance, Hexaware, said, "Hexaware believes in the 'Automation First Approach', and we have invested heavily in tools and technology to accelerate Guidewire upgrades. Hexaware is committed to helping customers take full advantage of the Guidewire platform for enhanced operational efficiencies. We already have multiple customer testimonials from Europe. Achieving the Guidewire Technical Upgrades specialization will be an important step in helping insurers around the world leverage our tools and services to bring down the upgrade-related cost significantly."
Please find more information about Guidewire specializations on the Guidewire website here.
About Hexaware
Hexaware is a global IT, BPS and consulting services company empowering businesses worldwide to realize digital transformation at scale and speed.
Learn more about Hexaware at http://www.hexaware.com. Take an immersive 360° virtual tour of our campuses worldwide at https://www.hexawareimmersive.com
Logo: https://mma.prnewswire.com/media/530945/Hexaware.jpg
View original content:
SOURCE Hexaware Technologies Ltd. | https://www.whsv.com/prnewswire/2022/09/06/hexaware-achieves-guidewire-partnerconnect-program-specialization/ | 2022-09-06T12:57:01Z |
BERLIN, Sept. 6, 2022 /PRNewswire/ -- At the ongoing IFA Consumer Electronics Show, Global technology brand HONOR stood on the IFA Keynote stage for the first time, presenting our vision of Embracing the Connected Future, and bringing the latest HONOR N-series products to global markets.
Featuring Sony's new IMX800 image sensor for the first time, the slim and stylish HONOR 70 has exceptional camera performance in this category. The new Solo Cut Mode, which gives a fresh new way of shooting vlogs, meets exactly what video creators are craving.
HONOR has won a total of 35 awards from global media this year, of which HONOR 70 has won 21 awards in various categories. A great number of global leading tech media have rated HONOR 70 as "Best of IFA". Global top-tier tech media TechRadar says that HONOR 70 is "One of the best Android phones of the year". Forbes, a leading international business media also said that HONOR 70 is "a strong all-rounder".
HONOR's other new products in the N series have also been recognized by global tech and vertical media. In Trusted Review's HONOR MagicBook 14 assessment, they said it's "a fantastic productivity laptop and a great alternative to the MacBook Air for those who want to stick with Windows." Notably, HONOR Pad 8, with its outstanding performance in audio and video entertainment, also took the Best of IFA award from the world-famous music and entertainment magazine Billboard.
The HONOR 70 is now available in select European markets for a starting price of EUR 549. The HONOR MagicBook 14 and the HONOR Pad 8 are also slated to arrive in select European markets with pre-orders open now.
About HONOR
HONOR is a leading global provider of smart devices. It is dedicated to becoming a global iconic technology brand and creating a new intelligent world for everyone through its powerful products and services. With an unwavering focus on R&D, it is committed to developing technology that empowers people around the globe to go beyond, giving them the freedom to achieve and do more. Offering a range of high-quality smartphones, tablets, laptops and wearables to suit every budget, HONOR's portfolio of innovative, premium and reliable products enable people to become a better version of themselves.
For more information, please visit HONOR online at www.hihonor.com or email newsroom@hihonor.com
http://community.hihonor.com/
https://www.facebook.com/honorglobal/
https://twitter.com/Honorglobal
https://www.instagram.com/honorglobal/
http://www.youtube.com/c/HonorOfficial
View original content to download multimedia:
SOURCE HONOR | https://www.whsv.com/prnewswire/2022/09/06/honor-70-recognized-best-ifa-with-numerous-media-awards/ | 2022-09-06T12:57:07Z |
Treatment with HT-004 significantly reduced lung inflammation after ovalalbumin (OVA) challenge in an asthma and allergy mouse model
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced development updates for its novel asthma and allergy maintenance therapeutic, HT-004.
Hoth's innovative approach employs a chemically-stable antisense oligonucleotide to eliminate cell surface high-affinity IgE receptor (FceRI) expression and function on mast cells and basophils, rendering mast cells unresponsive to IgE-mediated activation that occurs during asthma and allergy disorders.
Through a sponsored scientific research agreement with North Carolina State University, the team used the HT-004 FceRI mRNA frame-shifting approach to reduce lung inflammation induced by OVA in mice. OVA-induced inflammation mice treated with HT-004 via inhalation showed significantly reduced inflammatory cell recruitment in the bronchioles compared to vehicle control and oligonucleotide control OVA-induced mice; the reduction in bronchiolar inflammation in HT-004-treated mice was near the non-OVA stimulated mice. The results of these studies support the use of HT-004 as a novel inhalation maintenance therapy for asthma and allergic disorders.
The results of these studies are a continuation of the 2016 publication by Hoth Scientific Advisory Board member Dr. Glenn Cruse, "Exon skipping of FceRIβ eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy" (www.pnas.org/cgi/doi/10.1073/pnas.1608520113).
Hoth has filed several patent applications to protect this IP throughout the world.
Hoth is continuing to expand the HT-004 development program through investigating the therapeutic potential of HT-004 in other larger animal models (such as cats and/or dogs) that closely resemble human asthma and allergic diseases.
About Hoth Therapeutics, Inc
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates Hoth may develop, and the labeling under any approval Hoth may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of Hoth's products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on Hoth's business, its clinical trials, its research programs, healthcare systems or the global economy as a whole; Hoth's intellectual property; Hoth's reliance on third party organizations; Hoth's competitive position; Hoth's industry environment; Hoth's anticipated financial and operating results, including anticipated sources of revenues; Hoth's assumptions regarding the size of the available market, benefits of Hoth's products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding Hoth's goals, intentions, plans and expectations, including the introduction of new products and markets; and Hoth's cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place undue reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although Hoth believes that the expectations reflected in the forward-looking statements are reasonable, Hoth cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U.S. Securities and Exchange Commission. All such statements speak only as of the date of this press release. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:
SOURCE Hoth Therapeutics, Inc. | https://www.whsv.com/prnewswire/2022/09/06/hoth-therapeutics-mrna-frame-shifting-therapeutic-ht-004-shows-potential-reduce-lung-inflammation-asthma-allergy-disorders/ | 2022-09-06T12:57:14Z |
SAN FRANCISCO, Sept. 6, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Chief Executive Officer Piers Ingram, Ph.D., and Chief Financial Officer Josh House will participate in one-on-one investor meetings at Morgan Stanley's 20th Annual Global Healthcare Conference (September 12-14, 2022), held at the Sheraton New York Hotel in New York City.
About Hummingbird Bioscience
Hummingbird Bioscience is a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. We are currently developing two clinical-stage assets: HMBD-001, a humanized anti-HER3 monoclonal antibody targeting a novel epitope on HER3, and HMBD-002, a humanized anti-VISTA IgG4 monoclonal antibody. Both programs are currently in Phase 1 studies. At Hummingbird Bioscience, our commitment to rigorous science, teamwork and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic.
For more information, please visit www.hummingbirdbioscience.com, and follow Hummingbird Bioscience on LinkedIn, Twitter, and YouTube.
View original content:
SOURCE Hummingbird Bioscience | https://www.whsv.com/prnewswire/2022/09/06/hummingbird-bioscience-participate-morgan-stanley-20th-annual-global-healthcare-conference/ | 2022-09-06T12:57:20Z |
- Hyundai Mobis will exhibit more than 30 next-generation technologies, including its EV platform, lighting grille, integrated cockpit and AR HUD.
- Orders from NA automakers totaled $1.7B during 1H '22; Mobis expects further demand for its high-value products.
- Hyundai Mobis, the world's sixth largest automotive supplier, will hold a press conference to introduce expansion strategies and local marketing plans for the North American market.
SEOUL, South Korea , Sept. 6, 2022 /PRNewswire/ -- Hyundai Mobis (KRX 012330) is making its debut at the North American International Auto Show (NAIAS) 2022, which will be held at Huntington Place in Detroit, Mich. September 14-25. From September 14-16, the company will host a private room for its customers and exhibit more than 30 new technologies tailored for future mobility, including its electrification platform.
"We are discovering many new opportunities in the North American market, which is seeing heated competition for future mobility," said Axel Maschka, executive vice president and head of global OE sales at Hyundai Mobis. "It's important for us to join our customers in Detroit, the heart of the American automotive industry, to showcase our innovations and continue our expansion in the global market."
- Introducing new technologies available for mass production, in the most competitive EV and AV market.
At NAIAS, Hyundai Mobis will exhibit more than 30 new future mobility technologies in electrification, ADAS and IVI that are available for mass production. To be in line with the North American market, which has been leading the paradigm shift for EVs, the company will emphasize its electrification systems. One example of Hyundai Mobis's leading technology is its electric Complete Chassis Platform Module (eCCPM).
eCCPM, an optimized platform for EVs, combines braking, steering, suspension, driving and battery systems with scalable aluminum frames. Its ability to adjust its form makes it ideal for electric purpose-built vehicles (PBVs).
Lighting grille technology will be also introduced at the show, which enables automakers to utilize the entire front grille as a tool for lighting or for communication with vehicles or pedestrians. This technology showcases how a car grille, which provides the first impression of the car, can evolve in the era of EVs and AVs.
Hyundai Mobis will also exhibit many other future mobility technologies including a next-generation integrated cockpit (M.VICS 3.0), a hologram-based AR HUD, and a swivel display.
- With three consecutive years of rising North American orders, Mobis expects further demand for its high-value products.
For Hyundai Mobis, North America is the market where it wins the largest number of orders from automakers. During the first half of this year, Hyundai Mobis recorded $1.7 billion in orders from North American automakers, accounting for 45 percent of this year's global order target of $3.75 billion. The volume of orders from North American customers has steadily increased, with $0.66 billion in 2020, $1.4 billion in 2021, and $1.7 billion in the first half of 2022.
Adding to this momentum, Hyundai Mobis will announce its strategic plan for the North American market at its press conference on September 14 during the auto show. Axel Maschka will introduce the company's future strategies and core technological competencies as the sixth largest global auto supplier, as well as its plan to strengthen local marketing with its platform-based electrification components and high-value products.
- Hyundai Mobis Press Conference on NAIAS 2022 Press Day
- Date/Time: September 14, 3:30 p.m. to 3:55 p.m. ET
- Venue: AutoMobili-D Stage
- Presenter: Axel J. Maschka, Executive Vice President and head of Global OE Sales at Hyundai Mobis
About Hyundai Mobis
Hyundai Mobis is the global no. 6 automotive supplier, headquartered in Seoul, Korea. Hyundai Mobis has outstanding expertise in sensors, sensor fusion in ECUs and software development for safety control. The company's products also include various components for electrification, brakes, chassis and suspension, steering, airbags, lighting and automotive electronics. Hyundai Mobis operates R&D headquarter in Korea, with four technology centers in the United States, Germany, China and India.
For more information, please visit the website at http://www.mobis.co.kr/
Media Contact
Jihyun Han: jihyun.han@mobis.co.kr
Choon Kee Hwang: ckhwang@mobis.co.kr
Allen Nguyen (Ketchum): allen.nguyen@ketchum.com
View original content to download multimedia:
SOURCE Hyundai Mobis | https://www.whsv.com/prnewswire/2022/09/06/hyundai-mobis-makes-its-debut-naias-2022-showcase-future-mobility-technologies-ev-av/ | 2022-09-06T12:57:27Z |
- Abstract summarizing lemzoparlimab Phase 2 data selected for proffered paper presentation on September 10
- Investor conference call scheduled at 8:00 a.m. ET (English) on September 12
GAITHERSBURG, Md. and SHANGHAI, China, Sept. 6, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the results from its Phase 2 clinical study of lemzoparlimab (also known as TJC4) in combination with azacitidine (AZA) in patients with higher risk myelodysplastic syndrome (HR-MDS) will be featured in a proffered paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2022, on Saturday, September 10 at 2:45 p.m. CET. The Company will host a conference call with investors to provide an in-depth data analysis on Monday, September 12.
Presentation details:
The abstract is currently available on the ESMO website. Please visit the following link to read the full abstract.
I-Mab Conference Call Information:
Investors and analysts are invited to join the conference call at 8:00 a.m. Eastern Time for English session on September 12, 2022 via Zoom:
About CD47 and Lemzoparlimab
CD47 is a cell surface protein over-expressed in a wide variety of cancers and can act to protect tumors by delivering a "don't eat me" signal to otherwise tumor-engulfing macrophages. CD47 antibody blocks this signal and enables macrophages to attack tumor cells. However, development of CD47 antibody as a cancer therapy has been hampered by its hematologic side effects, such as severe anemia, caused by natural binding of CD47 antibody to red blood cells. Scientists at I-Mab discovered a novel CD47 antibody, lemzoparlimab, that is designed to target tumor cells while exerting a minimal untoward effect on red blood cells.
Multiple clinical studies of lemzoparlimab are ongoing to explore indications in treating patients with myelodysplastic syndrome (MDS), acute myelocytic leukemia (AML), non-Hodgkin's lymphoma (NHL), and advanced solid tumors in combination with chemotherapy and immune checkpoint inhibitors.
About I-Mab
I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon, commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-Proof-of-Concept and Fast-to-Market development strategies through internal R&D and global partnerships and commercial partnerships. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit http://www.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter, and WeChat.
I-Mab Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding data from the lemzoparlimab clinical studies, the potential implications of clinical data for patients, and I-Mab's advancement of, and anticipated clinical development, regulatory milestones, and commercialization of lemzoparlimab. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to I-Mab's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or NDA/BLA approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development, manufacturing and other services; I-Mab's limited operating history and I-Mab's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the COVID-19 pandemic on the Company's clinical development, commercial and other operations, as well as those risks more fully discussed in the "Risk Factors" section in I-Mab's most recent annual report on Form 20-F, as well as discussions of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with the US Securities and Exchange Commission. All forward-looking statements are based on information currently available to I-Mab, and I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
I-Mab Contacts
Investor Inquiries
View original content to download multimedia:
SOURCE I-Mab | https://www.whsv.com/prnewswire/2022/09/06/i-mab-announces-oral-presentation-phase-2-clinical-data-cd47-antibody-lemzoparlimab-esmo-congress-2022/ | 2022-09-06T12:57:33Z |
SAN DIEGO, Sept. 6, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), today received a decision from the European Commission prohibiting the company's acquisition of GRAIL. The company is reviewing the Commission's order and intends to appeal the decision. The EC decision follows last week's ruling by US Federal Trade Commission judge in favor of Illumina's acquisition of GRAIL.
"We are disappointed with the European Commission's decision prohibiting us from acquiring GRAIL back to Illumina," said Charles Dadswell, General Counsel of Illumina. "Illumina can make GRAIL's life-saving multi-cancer early detection test more available, more affordable, and more accessible – saving lives and lowering healthcare costs. As we continue to believe, this merger is pro-competitive and will accelerate innovation. Last week the Chief Judge of the US Federal Trade Commission issued a decision supporting Illumina acquiring GRAIL."
In addition, to prepare for the anticipated divestment order from the European Commission in the coming months, the company will begin reviewing strategic alternatives for GRAIL in the event the divestiture is not stayed pending Illumina's appeal.
The merger of Illumina and GRAIL would usher in a transformational phase in the detection and treatment of cancer by facilitating equal and affordable access to the life-saving early cancer detection Galleri test.
With a single blood test, Galleri can screen asymptomatic patients for more than 50 types of cancer, many of which have no other form of screening and are often caught too late to treat effectively. In addition, Galleri can identify the tissue in which a cancer has developed. Galleri is unique as a multicancer early detection test suitable for general population screening. There is no other test available for this purpose. Galleri is available today in the US and the UK, but not in the European Union.
Illumina would accelerate GRAIL's commercial entry into the EU at scale by at least five years, saving tens of thousands of lives in the EU and billions of euros in healthcare costs.
A combined Illumina and GRAIL is key to helping the European Union achieve the goals outlined in Europe's Beating Cancer Plan, which states: "Early detection through screening offers the best chance of beating cancer and saving lives." Today, 71% of cancer-related deaths are in cancers with no recommended screening. With limited screening, cancer is more likely to be detected in late stages but when we diagnose cancer too late, less than 20% of patients will survive more than 5 years. In contrast, if we diagnose cancer early, approximately 90% of patients are expected to survive beyond five years.1 The GRAIL merger would not only accelerate multicancer early detection in the EU but would also reduce inequity in cancer care by making early diagnosis affordable and widespread, another key priority of Europe's Beating Cancer Plan.
Illumina is separately appealing a July 2022 decision by the General Court of the European Union regarding the European Commission's jurisdiction to challenge the GRAIL deal.
Cautionary Notes on Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "may," "target," similar expressions and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the effects of the consummation of the transaction and the anticipated benefits thereof. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to: (i) the terms and conditions of any required divestiture of GRAIL, and the timing of and the risks, costs and business disruptions (including the diversion of management's attention) associated with any such divestiture, the announcement, pendency or implementation thereof or any associated legal or regulatory proceedings or obligations, and other uncertainties related to Illumina's compliance (or ability to comply) with a divestment order, which may adversely affect Illumina and its business, including current plans and operations; (ii) the possibility of other adverse consequences to, among other things, Illumina's reputation, its relationships with governmental or regulatory authorities or its ability to successfully complete future acquisitions and/or divestitures as a result of the acquisition, the prohibition decision or a divestment order; (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, dis-synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of Illumina's business following or in connection with any divestiture of GRAIL; (iv) potential adverse reactions or changes to business relationships or our ability to attract and retain employees resulting from the announcement, pendency or implementation of the prohibition decision and/or legal, regulatory and other proceedings related thereto; (v) any negative effects of the announcement, pendency or implementation of the prohibition decision or a divestment order and/or of any divestiture of GRAIL on the market price of Illumina's common stock and on Illumina's operating results; (vi) risks associated with third-party contracts or other agreements containing provisions that might be implicated by any divestiture of GRAIL, including Illumina's obligations with respect to certain GRAIL contingent value rights and the risk that Illumina will be unable to fully discharge such obligations in connection with a divestiture of GRAIL; (vii) the risk that Illumina will be unable to recover the costs and/or realize the economic benefits associated with its efforts to develop and commercialize GRAIL's products, including Galleri, the cancer screening test developed by GRAIL; (viii) the risk that Illumina's appeals of the prohibition decision or a divestment order and the EU General Court's ruling on the European Commission's jurisdiction to review the Acquisition and impose any decisions with respect thereto are unsuccessful and of other negative outcomes of legal, regulatory and other proceedings related thereto; (ix) the risk of adverse effects resulting from additional potential litigation associated with the acquisition; (x) the other risks described in Illumina's most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and (xi) management's response to any of the aforementioned factors.
While the list of factors presented here is, and the list of factors presented in Illumina's public filings are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Illumina's financial condition, results of operations, credit rating or liquidity. Illumina does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.
Investors:
Salli Schwartz
+1.858.291.6421
IR@illumina.com
Media:
Adi Raval
+1.202.629.8172
PR@illumina.com
1 Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov)
View original content:
SOURCE Illumina, Inc. | https://www.whsv.com/prnewswire/2022/09/06/illumina-intends-appeal-european-commissions-decision-grail-deal/ | 2022-09-06T12:57:40Z |
CALGARY, AB and LEHIGH VALLEY, Pa., Sept. 6, 2022 /PRNewswire/ -- Imperial (TSE: IMO) (NYSE American: IMO) today announced a long-term contract with Air Products (NYSE: APD) to supply low-carbon hydrogen for Imperial's proposed renewable diesel complex at its Strathcona refinery near Edmonton, Alberta. Air Products will provide pipeline supply from its hydrogen plant under construction in Edmonton.
"Our agreement with Air Products is an important milestone as we progress plans to build the largest renewable diesel manufacturing facility in Canada," said Jon Wetmore, Imperial's vice president of downstream. "This project highlights Imperial's commitment to investing in a lower carbon future. We continue to progress discussions with our business partners and governments as we work toward a final investment decision in the months ahead."
Imperial will use Air Products' low-carbon hydrogen to produce renewable diesel at Strathcona that substantially reduces greenhouse gas emissions relative to conventional production. The hydrogen and biofeedstock will be combined with a proprietary catalyst to produce premium low-carbon diesel fuel.
Air Products is increasing overall investment in its Edmonton hydrogen facility to CAD $1.6 billion to support the Imperial contract. The additional investment by Air Products will be used to facilitate integration with Imperial's proposed project that is expected to enable further significant emissions reductions at Air Products' overall complex. Air Products will supply Strathcona with approximately 50 percent of the low-carbon hydrogen output from the 165 million standard cubic feet per day hydrogen production complex.
"There is significant demand for low-carbon hydrogen, and as a first-mover, Air Products is ready to meet that demand from our Alberta Blue Hydrogen Hub," said Dr. Samir J. Serhan, chief operating officer at Air Products. "Canada is rapidly implementing an energy transition that emphasizes the use of low-carbon hydrogen, and Air Products is demonstrating that world-scale hydrogen facilities can be net-zero for carbon emissions. We continue to set the stage for a competitive, low-carbon-intensity hydrogen network, which includes increasing liquid hydrogen production capacity at our site to 35 metric tonnes per day, to provide clean hydrogen for the growing industrial and mobility markets across Canada."
Imperial's renewable diesel complex is expected to produce more than 1 billion litres per year of renewable diesel from locally sourced feedstocks. First announced in August 2021, the project is anticipated to realize about 3 million tonnes per year in emissions reductions in the Canadian transportation sector, which is estimated to be the equivalent to taking more than 650,000 vehicles off the road annually. The project is projected to create about 600 direct construction jobs, along with hundreds more through investments by business partners.
Third-party studies have shown renewable diesel from various non-petroleum feedstocks can provide life-cycle greenhouse gas emissions reductions of approximately 40 to 80 percent as compared to petroleum-based diesel.
After more than a century, Imperial continues to be an industry leader in applying technology and innovation to responsibly develop Canada's energy resources. As Canada's largest petroleum refiner, a major producer of crude oil, a key petrochemical producer and a leading fuels marketer from coast to coast, our company remains committed to high standards across all areas of our business.
Air Products (NYSE: APD) is a world-leading industrial gases company in operation for over 80 years. Focused on serving energy, environment and emerging markets, the Company provides essential industrial gases, related equipment and applications expertise to customers in dozens of industries, including refining, chemical, metals, electronics, manufacturing, and food and beverage. Air Products is also the global leader in the supply of liquefied natural gas process technology and equipment. The Company develops, engineers, builds, owns and operates some of the world's largest industrial gas projects, including: gasification projects that sustainably convert abundant natural resources into syngas for the production of high-value power, fuels and chemicals; carbon capture projects; and world-scale low- and zero-carbon hydrogen projects supporting global transportation and the energy transition.
The Company had fiscal 2021 sales of $10.3 billion from operations in over 50 countries and has a current market capitalization of over $55 billion. More than 20,000 passionate, talented and committed employees from diverse backgrounds are driven by Air Products' higher purpose to create innovative solutions that benefit the environment, enhance sustainability and address the challenges facing customers, communities, and the world. For more information, visit www.airproducts.com or follow us on LinkedIn, Twitter, Facebook or Instagram.
Cautionary statement: Statements of future events or conditions in this report, including projections, targets, expectations, estimates, and business plans are forward-looking statements. Forward-looking statements can be identified by words such as believe, anticipate, intend, propose, plan, project, target, estimate, expect, schedule, future, may, should, will and similar references to future periods. Forward-looking statements in this report include, but are not limited to, references to Imperial's proposed renewable diesel complex at its Strathcona refinery, including timing of a final investment decision, planned startup and production, potential emissions reductions and job creation; Imperial's commitment to the energy transition and investing in a lower carbon future; construction of Air Products' hydrogen plant, and the use of hydrogen to produce renewable diesel at Imperial's renewable diesel complex; reduction of greenhouse gas emissions relative to conventional production; Air Products' additional investment related to the hydrogen contract, including net negative emissions at its overall complex and estimated production and supply quantities; the ability for Air Products to operate a competitive, low carbon intensity hydrogen network; and third party studies regarding life-cycle greenhouse gas emissions reductions from non-petroleum feedstocks.
Forward-looking statements are based on the company's current expectations, estimates, projections and assumptions at the time the statements are made. Actual future financial and operating results, including expectations and assumptions concerning future energy demand, supply and mix; commodity prices, foreign exchange rates and general market conditions; project plans, timing, costs, technical evaluations and capacities, and the companies' ability to effectively execute on these plans and operate the refinery and cogeneration unit, and hydrogen complex; production rates, growth and mix across various assets; the availability of locally-sourced and grown feedstock; the adoption and impact of new facilities or technologies on capital efficiency, production and reductions to greenhouse gas emissions intensity, including Imperial's Strathcona's renewable diesel complex and Air Products' hydrogen plant in Edmonton; the amount and timing of emissions reductions; that any required support from policymakers and other stakeholders for various new technologies will be provided; applicable laws and government policies, including taxation, restrictions in response to COVID-19 and with respect to climate change and greenhouse gas emissions reductions; receipt of regulatory approvals; performance of third-party service providers; capital and environmental expenditures; and evolution of COVID-19 and its impacts on Imperial's ability to operate its assets could differ materially depending on a number of factors.
These factors include global, regional or local changes in supply and demand for oil, natural gas, petroleum and petrochemical products, feedstocks and other market or economic conditions and resulting demand, price, differential and margin impacts; the results of research programs and new technologies, including with respect to greenhouse gas emissions, the ability to bring new technologies to commercial scale on a cost-competitive basis, and the competitiveness of alternative energy and other emission reduction technologies; the receipt, in a timely manner, of regulatory and third-party approvals; project management and schedules and timely completion of projects; availability and allocation of capital; failure or delay of supportive policy and market development for emerging lower emission energy technologies; environmental regulation, including climate change and greenhouse gas regulation and changes to such regulation; environmental risks inherent in oil and gas activities; availability and performance of third-party service providers, including in light of restrictions related to COVID-19; political or regulatory events, including changes in law or government policy, applicable royalty rates, tax laws, and actions in response to COVID-19; third-party opposition to company and service provider operations, projects and infrastructure; unexpected technological developments; unanticipated technical or operational difficulties; management effectiveness and disaster response preparedness, including business continuity plans in response to COVID-19; general economic conditions, including the occurrence and duration of economic recessions; and other factors discussed in the companies' risk factors and management discussion and analysis of financial condition and results of operations in their most recent annual report on Form 10-K.
Forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties, some that are similar to other oil and gas and energy companies and some that are unique to Imperial Oil Limited and Air Products. The companies' actual results may differ materially from those expressed or implied by its forward-looking statements and readers are cautioned not to place undue reliance on them. The companies undertake no obligation to update any forward-looking statements contained herein, except as required by applicable law.
Cautionary Note Regarding Forward-Looking Statements: This release contains "forward-looking statements" within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's expectations and assumptions as of the date of this release and are not guarantees of future performance. While forward-looking statements are made in good faith and based on assumptions, expectations and projections that management believes are reasonable based on currently available information, actual performance and financial results may differ materially from projections and estimates expressed in the forward-looking statements because of many factors, including risk factors described in our Annual Report on Form 10-K for the fiscal year ended September 30, 2021. Except as required by law, we disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect any change in the assumptions, beliefs or expectations or any change in events, conditions or circumstances upon which any such forward-looking statements are based.
View original content:
SOURCE Air Products | https://www.whsv.com/prnewswire/2022/09/06/imperial-advances-renewable-diesel-plans-awards-hydrogen-contract-air-products/ | 2022-09-06T12:57:46Z |
BRIDGEWATER, N.J., Sep. 6, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor events:
- The Morgan Stanley 20th Annual Global Healthcare Conference in New York, NY on September 12, 2022 at 9:55 a.m. ET in a fireside chat
- The H.C. Wainwright 24th Annual Global Investment Conference in New York, NY on September 13, 2022 at 5:00 p.m. ET in a fireside chat
Each fireside chat will be webcast and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Each webcast will be archived for a period of 30 days following the respective presentation dates.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.
Contact:
Investors:
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download multimedia:
SOURCE Insmed Incorporated | https://www.whsv.com/prnewswire/2022/09/06/insmed-present-two-september-conferences/ | 2022-09-06T12:57:53Z |
IXL's new games provide engaging ways to help students gain a deeper understanding of fundamental math and language arts concepts
SAN MATEO, Calif., Sept. 6, 2022 /PRNewswire/ -- IXL, the personalized learning platform used by more than 13 million students, released more than 120 educational games covering math and English language arts skills for Pre-K through 5th grade. Each game provides a fun, new way to help students understand key grade level topics and spark a lasting love of learning.
IXL games teach the fundamental concepts necessary to help young learners grow. They provide students with hands-on practice in topics including the alphabet, parts of speech and contractions, multiplication and more.
Specially designed to fascinate young students, IXL's games include whimsical sounds and animations that immerse children in a joyful world of learning. Within each activity, learners interact with animations, unique characters and dynamic challenges as they race to answer questions, decipher clues and earn rewards. Because IXL games are both educational and entertaining, they can be implemented in various ways in the classroom, including within a lesson, as a reward for great work and for further enrichment. In addition, each game is kidSAFE COPPA certified, meeting the high standard of quality and safety that teachers and parents can trust.
"IXL's carefully crafted educational games give young students enjoyable ways to enhance their knowledge and grow confidence in their skills," said Kate Mattison, VP of Curriculum at IXL Learning. "Educators and parents now have more incredibly compelling resources that will instill a lasting eagerness to learn in children, regardless of whether they are in the classroom or at home."
IXL games can be accessed from the Learning section of IXL math and English language arts grade-level landing pages, and are currently available on the web version of IXL.com.
IXL's teaching and learning platform comprises a comprehensive PK-12 curriculum and personalized guidance, instructional resources and classroom engagement tools, a first-of-its-kind assessment suite and actionable analytics for districts, schools, classrooms and individual learners. Additionally, IXL offers district partnership, professional learning and implementation services. All integrated into a single offering, each component is designed to work together seamlessly to give educators the tools and insights they need to maximize learning for every single student. Research in 37 states has shown that IXL boosts academic achievement.
In Pre-K through 5th grade, IXL's curriculum and learning tools are tailored to help younger learners:
Develop a deeper understanding of math: IXL Math offers more than 2,200 standards-aligned skills for Pre-K through 5th grade to help students master essential skills through fun and interactive questions, built-in support and motivating awards. In addition, the IXL platform recently won the 2022 SIIA CODiE award for Best Math Instructional Solution for Grades PK-8 after undergoing a rigorous review by expert judges.
Build reading fluency: IXL offers more than 1,200 standards-aligned literacy skills for grades Pre-K through 5th grade that help students build fluency in phonics and reading, writing, vocabulary and grammar. With intriguing texts and engaging images, students interact with language in exciting new ways. IXL ELA was honored by the CODiE's in 2020 and 2021 as the best solution for developing foundational English language arts skills.
Media, please note: Screenshots of IXL may be downloaded at www.ixl.com/press. For demos and access to IXL, contact press@ixl.com.
Currently used by 13 million students and in all of the top 100 U.S. school districts, IXL is an all-inclusive educational platform that provides a comprehensive PK-12 curriculum and instructional resources, actionable analytics and a state-of-the-art assessment suite. IXL's end-to-end teaching and learning solution supports personalized instruction in math, English language arts, science, social studies and Spanish. With more than 100 billion questions asked and answered around the world, IXL is helping schools and parents successfully boost student achievement. The IXL Learning family of products also includes Rosetta Stone, Wyzant, Education.com, ABCya, Vocabulary.com and Curiosity Media. To learn more about IXL, visit www.ixl.com, facebook.com/IXL and twitter.com/IXLLearning.
Press Contact
Eric Bates
IXL Learning
press@ixl.com
View original content to download multimedia:
SOURCE IXL Learning | https://www.whsv.com/prnewswire/2022/09/06/ixl-introduces-educational-games-young-learners/ | 2022-09-06T12:57:59Z |
– – Largest Leaseholder in Northern DJ Basin – –
– – Substantial Current Production and Cash Flow with Years of High-Quality Inventory – –
HOUSTON, Sept. 6, 2022 /PRNewswire/ -- Juniper Capital ("Juniper") and Boomtown Oil & Gas Company ("Boomtown") today announced the formation of North Peak Oil & Gas LLC ("North Peak") through the combination of two existing Juniper portfolio entities (North Silo Resources and Longs Peak Resources) and the acquisition of assets from a private oil & gas company with complementary assets.
- Largest lease holder in the Wyoming DJ Basin with approximately 150,000 net acres
- Over 10,000 Barrels per Day of Gross Operated Oil production (over 11,000 Barrels of per Day of Oil Equivalent production) currently, generating substantial operational cash flow
- Drilling program scheduled to begin in September, which is expected to substantially grow future production
- Many years of high-quality inventory, with oil reserves per well in-line with Permian and Eagle Ford wells, and some of the lowest drilling and completion costs for long lateral horizontal wells in the U.S.
- F&D and cash operating cost each averaging less than $10.00/BOE are competitive with any basin
- Vast majority of the assets are fee leases located in Wyoming, one of the most constructive states in the U.S. for oil and gas development
- Owned produced water transportation and disposal infrastructure with scalable capacity reduces environmental footprint and allows for flexibility in development
- Oil and natural gas midstream infrastructure in place which allows for consistent operations and efficient pricing
Sean Fitzgerald, North Peak Co-President, commented, "We are honored to continue our partnership with Juniper Capital in putting together the premier operator in the oil-rich Northern DJ Basin, including now owning the horizontal well with the highest cumulative oil production ever in the entire DJ. The benefits of this consolidation into North Peak are very compelling, and we believe North Peak is one of the strongest private oil & gas companies in the U.S. We remain steadfast in our disciplined approach to running the business, and we continue to be committed to maximizing returns for investors and protecting the health, safety, and environment of our local communities. We look forward to demonstrating compelling results from our planned development program, which is scheduled to begin in the next few weeks."
Edward Geiser, Managing Partner of Juniper Capital, added, "Juniper currently owns assets in the Permian, Eagle Ford and other major basins, and we regularly review oil & gas investment prospects in all the major basins. Based on its strong operational cash flow, low costs, and attractive well-level economics with years of inventory, we believe North Peak represents one of the most attractive opportunities we have seen. We are proud to continue our partnership with Boomtown in this area, and we are excited about what the future holds for North Peak."
Juniper Capital is an energy investment firm based in Houston, Texas with over $1.3 billion of cumulative equity commitments and current investments in the Permian Basin, Eagle Ford Trend Area, DJ Basin, and Powder River Basin. Juniper is focused on working with high-quality management teams to provide transformational equity capital to demonstrate the value and productive potential of oil and gas properties located primarily in the continental United States.
Boomtown Oil is a privately-owned Exploration & Production company based in Houston, Texas. The principals of the company are entrepreneurs with decades of oil & gas operating experience that are focused on low-cost, safe, and technically sound operations. The company's goal is to be a value-added partner and friend whether you are a landowner, JV member, financial sponsor, or service provider.
View original content to download multimedia:
SOURCE Juniper Capital Advisors, LP | https://www.whsv.com/prnewswire/2022/09/06/juniper-capital-boomtown-announce-formation-north-peak-oil-amp-gas/ | 2022-09-06T12:58:06Z |
SAN FRANCISCO , Sept. 6, 2022 /PRNewswire/ -- Limbix is excited to announce a partnership with Children's Hospital Los Angeles (CHLA) for a research study to evaluate SparkRx, an adjunct treatment for adolescents with symptoms of depression, in specialty medical care settings. SparkRx is a self-guided, cognitive behavioral therapy (CBT)-based digital therapeutic intervention for adolescents, aged 13-22 years old. Research indicates that CBT is an effective treatment option for depression in adolescents. SparkRx brings an engaging, evidence-based program directly to teens' smartphones. This digital therapeutic helps teens understand their depression and learn coping skills to manage their symptoms.
Limbix and CHLA are testing SparkRx's feasibility and efficacy among adolescents with elevated depressive symptoms that are being treated in the Cardiology and Gastroenterology programs at CHLA. Teens that have chronic medical conditions, such as cardiovascular and gastrointestinal diseases, are often at higher risk for depression. Finding behavioral health care can be difficult and when left untreated, symptoms of depression can worsen other health conditions.
"At Limbix, we are committed to building digital therapeutics that are easily accessible to patients and give providers a safe and effective treatment option," said Aarthi Padmanabhan, PhD, Chief Research Officer at Limbix and Co-Principal Investigator of the study. "We are especially excited to partner with Children's Hospital Los Angeles to run this research study in specialty care settings to better understand the mental health needs of this patient population."
Eligible study participants complete interactive activities within the digital therapeutic intervention that are designed to help them learn the relationship between mood and behavior, identify activities that can help them feel better, and give them a sense of accomplishment. The goal of the study is to understand if these adolescents find SparkRx to be a convenient treatment option, if it can reduce the symptoms of depression in adolescents with chronic medical conditions, and to collect feedback on the participants' experience using SparkRx.
"We're excited about this opportunity to offer our patients a new resource for adolescent depression via a digital therapeutic that could help minimize barriers and increase access to mental health treatment," said Heather Bemis, PhD, Licensed Clinical Psychologist, Division of Comfort and Palliative Care, Department of Anesthesiology Critical Care Medicine at CHLA and Principal Investigator of the study.
To learn more about the study or to enroll as a participant, please visit https://project.limbix.com/sparkrx-study-a.
Limbix is on a mission to make mental health treatment accessible to young people who need it the most, when they need it the most. Limbix's diverse team of clinicians, product designers, researchers, and engineers are uniquely suited to developing mental health technology, as they understand the value of combining clinical expertise with technological innovation. The team is focused on giving all young people access to affordable, effective behavioral health care by building safe and evidence based treatment options that providers can offer to their patients. Through extensive research, Limbix built their first digital therapeutic, SparkRx, that delivers CBT-based treatment directly to each user's smartphone.
Intended Use: SparkRx is a digital therapeutic intended to provide a neurobehavioral intervention (Cognitive Behavioral Therapy - Behavioral Activation) in patients 13 to 22 years of age as adjunct treatment for symptoms of depression.
SparkRx has not been cleared or approved by the U.S. Food and Drug Administration. During the COVID-19 public health emergency, SparkRx is being made available without a prescription under the FDA's emergency guidance for digital health devices treating psychiatric disorders.
Warnings: SparkRx is not for emergency use. Please instruct patients to dial 911 or go to the nearest emergency room in the event of a medical emergency.
Patients should be clearly instructed not to use SparkRx to communicate severe, critical, or urgent information to their health care provider. Patients should also be informed that text they enter into SparkRx will not be monitored or reviewed by a health care provider.
SparkRx is not meant to be used as treatment without supervision of a health care provider. Please instruct your patients to contact you should they notice a worsening of symptoms or an increase in thoughts of suicide or self-harm.
SparkRx is not meant to be a substitution for any treatment or medication.
SparkRx is intended for patients whose primary language is English with a reading level of 5th grade or above, and who have access to an Android/iOS smartphone or tablet. SparkRx is intended only for patients who own a smartphone or tablet and are familiar with use of smartphone or tablet apps (applications).
SparkRx contains sensitive medical information. Please instruct patients to protect their information by password protecting their smartphone or tablet, and ensuring no one else may access their device.
SparkRx does not address concerns of active suicidal ideation with intent. SparkRx is not intended for the prevention of suicide attempts or self-harm behaviors. Patients with active suicidal ideation with intent or those who have had a past suicide attempt may still be given SparkRx to help treat depression but should not be given SparkRx to prevent, treat or mitigate active suicidal ideation with intent.
Patients with posttraumatic stress disorder (PTSD) who are currently experiencing marked alterations in arousal or reactivity associated with traumatic events may find that the level of exposure related to guided behavioral activation exacerbates symptoms.
View original content:
SOURCE Limbix | https://www.whsv.com/prnewswire/2022/09/06/limbix-partners-with-childrens-hospital-los-angeles-study-sparkrx/ | 2022-09-06T12:58:12Z |
Animals Make the Best Friends!
MAZATLÁN, Mexico, Sept. 6, 2022 /PRNewswire/ -- Mexican-based indie game developer and publisher EnsenaSoft is proud to announce the worldwide release of ISLA SINALOA, a relaxing open-ended social simulation game set on an island retreat inhabited by fun and engaging animal characters in a peaceful universe full of fun activities. Over two years in the making, ISLA SINALOA is available as a FREE-TO-PLAY download on iOS®, Android™, and the Windows® Store.
Launch Trailer: https://www.youtube.com/watch?v=XEnusZsAGNQ
ISLA SINALOA features a large cast of colorful, friendly neighbors and animal characters. Your character is fully customizable, and 100s of options are available from the clothing store. You can tailor the look, features, and body expressions as desired, and when you are ready, exciting adventures and exploration await.
ISLA SINALOA challenges you to complete a series of fun and rewarding tasks. In return, you are given fascinating attractions to place, such as the Zoo, the Museum, and the Botanical Garden, collectively featuring more than 500 items to collect and learn from. Donate the fish you catch to the Zoo and watch them swim in the aquarium. Visit a remote island by talking to Dolly Dolphin, who, in exchange for a ticket, will grant you access to unique locations with mines to scavenge, pyramids with underground temples to explore, and even volcanic caves with rare gems and gold to mine. Items you collect can be donated to the exhibits or sold for profit in the games store, from where you can buy and sell 100s of items over time. The Museum has a rather large collection of fun and unique artifacts that you need to collect. They provide entertaining stories and historical nuggets guaranteed to make you smile. A large painting room with world-famous artists eventually opens, but it is your task to populate it by digging up treasure on remote islands, treasures that you trade for artistic loot with the local pirate! When you need a break, you can visit the Botanical Garden and smell the beautiful and colorful flowers you have collected during your adventures.
ISLA SINALOA would not be complete without a farm from where you can plant crops and manage the garden. Harvest your crops for assigned tasks or resell your items and take care of the cows and chickens. No retreat is complete without great food and entertainment! Visit the restaurant and purchase the ingredients needed for tasty recipes. The disco sells delicious ice cream and has a dancing floor with different genres of music hosted by the fabulous Alex DJ. You can even go on a Hot Air Balloon ride and visit other players' islands, and when fatigue sets in, call Byron Bat for a ride home to take a well-deserved siesta.
ISLA SINALOA is a paradise for casual gamers with more than 15+ mini-games to try out: How about a solitaire game? Or mahjong with Piao Panda? Why not build your very own arcade cabinet and try it out? You can cook and serve food by running a food truck owned by Nacho Dog! When you are not playing, you can build upon and expand your house by decorating each room with interesting wall decor, rugs, and unique furniture you craft or purchase when available.
ISLA SINALOA celebrates your birthday, and the islanders will host you a party. 10 major international holidays like Christmas, Halloween and Cinco de Mayo are given special treatment in the game as buildings and houses are decorated according to season.
KEY FEATURES
- 15+ mini-games, including a food truck that you get to run
- Over 30+ animal characters to get to know and become friends with
- Over 500+ items to collect and donate for island building exhibits
- Beautiful and vibrant zoo, museum, and botanical gardens
- Customize your character with 100s of outfit and character combinations
- 100s of craft-able items to decorate your island and home
- Many holidays are celebrated on your island
- You can share your island with your friends
- Full of love and little surprises!
ISLA SINALOA supports English and Spanish with French, German, Italian and Portuguese translations in the works. There is even an excellent merchandise shop on ZAZZLE offering fantastic items featuring the characters expressing their personalities.
Isla Sinaloa is available from here:
Journalists interested in further information or additional assets may contact indie PR specialist Hans Olsen by sending an email to hans@hansfrederikolsen.dk. Members of the press are encouraged to check out the following Hotlinks for recent news and updates.
About EnsenaSoft
EnsenaSoft is an award-winning game developer and publisher founded in Mazatlán, Sinaloa, Mexico in 2009, and consists of a talented group of designers, artists, programmers (and musicians from around the world) all committed to creating high-quality digital games content across all major gaming platforms and technologies. With a portfolio spanning hundreds of released titles, it is our continued promise to produce entertaining digital games to audiences of all ages and gaming preferences.
View original content:
SOURCE EnsenaSoft | https://www.whsv.com/prnewswire/2022/09/06/live-harmony-with-nature-adventure-relaxation-await-you-tropical-island-paradise-isla-sinaloa/ | 2022-09-06T12:58:18Z |
New data layer creates a foundation for intelligent predictions about employee preferences and likely future actions based on insights from across the digital workplace
AUSTIN, Texas, Sept. 6, 2022 /PRNewswire/ -- LumApps, a leading Employee Experience Platform, is introducing the industry's first employee data layer, a dynamic digital data hub that organizations can tap into to drive hyper-personalization in the digital workplace.
"We're taking the power of consumer personalization, and applying it to the employee experience. Similar to how Netflix recommends movies, LumApps' employee data layer will enable highly targeted and personalized employee interactions that ultimately help engage, enable and retain great talent," said Chris McLaughlin, CMO at LumApps.
The employee data layer synchronizes information from various channels, devices and applications across the entire business and translates it into a secure, holistic view of each individual employee. This comprehensive employee profile gives organizations the power to execute hyper-personalization at scale. Leveraging AI, the employee data layer provides the foundation to orchestrate and deliver contextual communications across touchpoints and create tailored experiences along every step of the employee journey.
Over time, the system aggregates each individual's activities, interests, and preferences, including what they read, which content they liked, or with whom they interacted. This allows for greater segmentation and analysis to support an even deeper understanding of employees and their interests. As more data is added, the system will be able to provide intelligent predictions about likely future actions and events.
"We live in an era where people expect us to not only understand their wants and needs, but anticipate and exceed them. The digital workplace is no exception," said McLaughlin. "LumApps' employee data layer allows organizations to sift through vast amounts of information to make every employee interaction smarter and deliver a game-changing employee experience."
To learn more, visit here.
LumApps is a global Employee Experience Platform, transforming how companies engage, enable, and empower their workforces. The cloud-native solution is architected to tailor each experience to the individual needs of every employee, wherever and whenever they connect. With the industry's first unified employee data layer to drive hyper-personalization, LumApps is the only solution to deliver truly customized interactions for a game-changing employee experience. Since 2015, LumApps has been helping some of the world's largest and most innovative companies, such as Palo Alto, Publicis Sapient, Electronic Arts, Airbus, and Just Eat, revolutionize how they attract and retain great talent. Learn more at www.lumapps.com.
Media Contact:
Andrea LePain
On behalf of LumApps
andrea@emediajunction.com
617-275-8112
View original content to download multimedia:
SOURCE LumApps | https://www.whsv.com/prnewswire/2022/09/06/lumapps-delivers-key-hyper-personalization-with-industrys-first-employee-data-layer/ | 2022-09-06T12:58:24Z |
Sale makes this September the best time to create a backyard oasis
FORT WAYNE, Ind., Sept. 6, 2022 /PRNewswire/ -- Master Spas Global Hot Tub and Swim Spa Sale is nearly here! During this first-ever event, customers can SAVE BIG on a Master Spas hot tub or swim spa.
With additional savings up to $2,000, there's never been a better time to invest in your backyard. The event will be September 8 to September 18, with Master Spas global network of dealers participating.
Customers can get more information and download a coupon for additional savings up to $2,000 by visiting MasterSpas.com/globalsale.
Master Spas' entire range of hot tubs and swim spas will be on sale during the event. Customers can enjoy special pricing on the best-selling Twilight Series TS 7.2 hot tub and the H2X Trainer 15D swim spa. Or, they can choose from the luxurious Michael Phelps line, including the LSX 900 hot tub and MP Momentum Deep swim spa.
Customers won't want to miss the chance to take advantage of this special pricing. In addition, inventory will be available for immediate delivery.
As part of the event, Master Spas is giving back. Master Spas will be contributing a minimum of $50,000 to the Tunnel to Towers Foundation. The foundation helps America's heroes by providing mortgage-free homes to Gold Star and fallen first responder families with young children; by building custom-designed smart homes for catastrophically injured veterans and first responders; and working tirelessly to eradicate veteran homelessness.
For more information, visit MasterSpas.com/globalsale or your local Master Spas retailer.
Master Spas is based in Fort Wayne, Indiana. Operating out of a state-of-the-art, 45-acre campus, we are the largest swim spa manufacturer in the world, and largest portable spa and hot tub manufacturer that makes 100% of our product in the USA. Our management team has over 200 years of spa manufacturing success, and one of the strongest track records in the industry.
View original content to download multimedia:
SOURCE Master Spas | https://www.whsv.com/prnewswire/2022/09/06/master-spas-hosts-first-ever-global-hot-tub-swim-spa-sale/ | 2022-09-06T12:58:31Z |
Seasoned executive Katie Taylor joins Board of parent company of North America's largest privately owned homebuilder
TORONTO, Sept. 6, 2022 /PRNewswire/ - Mattamy Asset Management, a diversified asset management firm and parent company of Mattamy Homes, is pleased to announce the appointment of Kathleen (Katie) Taylor to its Board of Directors. Ms. Taylor is an experienced executive, corporate director and board chair for companies in both the public and private sectors, with deep experience in international business, corporate strategy, customer experience, risk management and corporate governance.
"We're thrilled that Katie has joined Mattamy's already highly experienced Board of Directors and look forward to benefiting from her advice on a range of strategic and business issues," says Peter Gilgan, Chairman & CEO of Mattamy Asset Management and Founder of Mattamy Homes. "Her diversity of knowledge, skills and experience will be invaluable on our Board as we continue to evolve and grow our organization."
Ms. Taylor is Chair of the Board of the Royal Bank of Canada, Vice-Chair of the Adecco Group and a director of the Canada Pension Plan Investment Board and Air Canada. She serves as Chair of Altas Partners, a private equity investment firm. Ms. Taylor is also Chair of the Board of Trustees for the Hospital for Sick Children. Ms. Taylor is the former President and Chief Executive Officer of Four Seasons Hotels and Resorts. During her 24-year career, she held a number of senior leadership roles and was instrumental in building the firm's global brand and its international portfolio of luxury properties.
Ms. Taylor is a member of the C.D. Howe Institute's National Council, Chair of their Human Capital Policy Council and a member of the Task Force on the Digital Economy. She serves on the Dean's Advisory Council of the Schulich School of Business and on the Principal's International Advisory Board at McGill University.
Her many accolades for business achievement include the Schulich School of Business Award for Outstanding Executive Leadership and the inaugural Medal for Career Achievement from the Hennick Centre for Business and Law at York University. She has been inducted into the Canadian Marketing Hall of Legends and was named to Canada's Most Powerful Women Hall of Fame by the Women's Executive Network (WXN) after being honoured by WXN in 2011, 2014, 2016 and 2017. In 2016, Ms. Taylor received the Governance Professionals of Canada Peter Dey Governance Achievement Award and was made a Member of the Order of Canada. Report on Business magazine named Ms. Taylor among the 50 most powerful people in Canadian Business in 2017.
Ms. Taylor holds an M.B.A. from the Schulich School of Business, a law degree from Osgoode Hall Law School and a Bachelor of Arts (Honours) from the University of Toronto. She has also received an Honorary Doctorate of Laws from the University of Toronto, McGill University, York University and Trent University; an Honorary Doctorate of Humane Letters from Mount Saint Vincent University; and an Honorary Doctorate of Divinity from Huron University College.
Privately owned Mattamy chose to establish an external Board of Directors of knowledgeable advisors in 2010 as a governance best practice. In addition to Ms. Taylor, the other external members of Mattamy's Board also have significant experience and expertise:
- Carol Stephenson, a highly respected CEO over a 40-year career, former Dean of the Ivey Business School at Western University as well as President and CEO of both Stentor Resource Centre and Lucent Technologies Canada, now a Corporate Director serving on the Boards of several leading companies including General Motors, Maple Leaf Foods and Ritchie Brothers Auctioneers.
- David Williams, a veteran executive with 35+ years of experience in the food and drug industry, former Executive Chair of Shoppers Drug Mart and CFO/President with Loblaw Companies, and the former board chair with Jamieson Wellness and Toronto Hydro and a former board member with PC Financial Bank and Mitel Networks.
- Larry Nicholson, currently Executive Chairman of Mattamy Homes, former President and CEO of CalAtlantic Group, the fifth largest homebuilder in the U.S., as well as President and CEO with The Ryland Group.
- Luke Gilgan, former educator, currently serving as board member with The Peter Gilgan Foundation, as well as director of programs at the Gilgan Family Office.
- Tim Hockey, former President and CEO of TD Ameritrade, former Group Head, Canadian Banking and Wealth Management at TD Bank Group, and President and CEO of TD Canada Trust, as well as a board member of Maple Leaf Foods and Chair of the Board of the CivicAction Leadership Foundation.
Mattamy Asset Management is an asset manager focused on building a diversified portfolio of investments across geographies, asset classes and the spectrum of risk and return. Mattamy Asset Management is the parent company of Mattamy Homes Canada and Mattamy Homes U.S., which together comprise the largest privately held homebuilding platform in North America. Mattamy Asset Management is committed to achieving the best-possible long-term risk-adjusted returns for its clients and functioning as a socially responsible corporate citizen.
View original content to download multimedia:
SOURCE Mattamy Asset Management | https://www.whsv.com/prnewswire/2022/09/06/mattamy-asset-management-appoints-new-board-member/ | 2022-09-06T12:58:37Z |
State-of-the-art digital platform simplifies COVID-19 test result management
MADISON, Wis., Sept. 6, 2022 /PRNewswire/ -- MicroGEM, a Virginia-based life sciences and molecular diagnostics company,and Workflow Services by ImageMover, a healthcare software company that provides solutions to capture point-of-care medical data through provider-focused digital workflows, have announced their partnership to streamline COVID-19 test result workflow. In this agreement designating MicroGEM as a premier partner for PCR point of care testing, Workflow Services by ImageMover now offers optional access to its fully-integrated reporting platform with the MicroGEM Sal6830 SARS-CoV-2 Saliva Test to automate and simplify data reporting requirements.
MicroGEM develops innovative point-of-need diagnostic devices based on its ground-breaking approach to sample preparation and nucleic acid extraction. The MicroGEM Sal6830 Point of Care PCR System is designed to capture intact virus, a key indicator of infectiousness. The Sal6830 is simple to operate with non-invasive saliva collection, no extra consumables or sample preparation steps, easy touchscreen instructions, and PCR results at the point of care in under 30 minutes.
"Our goal is to streamline test administration for providers and ensure secure test results for patients so that point-of-care COVID-19 testing can be implemented with ease and efficiency," said LeRoy Blake, Chief Commercial Officer at MicroGEM. "The Workflow Services solution enables our customers to quickly document point of care test results, communicate those automatically to the patient, and automatically report results to state and federal health authorities."
Since its founding in 2013, ImageMover has automated the management of millions of diagnostic images and grown to accommodate numerous clinical workflows and different care settings from pharmacies, to urgent cares, to universities and sports teams. Workflow Services by ImageMover employs an exclusive approach to securely capture and integrate point-of-care medical data, simplifying communication and enhancing patient care. The streamlined workflow reduces errors by capturing data elements through barcode scanning and optical character recognition, and securely stores captured results.
"The MicroGEM innovative saliva PCR test, paired with point-of-care operational support from Workflow Services, brings a compelling, fully integrated solution to the market. This type of combined offering makes high quality diagnostic testing more accessible and meets the demands of point of care service delivery now and into the future," said Kevin Houlihan, ImageMover President and CEO.
The MicroGEM Sal6830 SARS-CoV-2 Saliva Test has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories, including under a CLIA waiver. Find Sal6830 FDA EUA information here: https://microgembiocovid19.com/img/uploads/FDA%20language%20for%20website.pdf
MicroGEM democratizes molecular biology by moving complex molecular biology tools out of highly skilled laboratories to non-laboratory settings where they can be used quickly at the point of need. The company's innovative enzymatic approach to nucleic acid extraction provides the foundation for fast sample preparation suitable for PCR analysis. Coupled with its expertise in microfluidics and synthetic biology, MicroGEM is creating the next generation of person-portable diagnostic devices for the management of infectious diseases and other personalized medicine applications.
www.microgembio.com/covid-19
Contact: Lianne Landers, Sr. Director of Corporate Communications
l.landers@microgembio.com
Workflow Services by ImageMover is a healthcare software company that innovates seamless point-of-care medical workflow software solutions for healthcare professionals and patients. The company's solutions employ exclusive, patented approaches to securely capture and integrate medical data to simplify communication and enhance patient care.
www.workflowservices.com
Contact: Shannon Brenkendorff
Email: shannon@imagemovermd.com
View original content:
SOURCE ImageMoverMD | https://www.whsv.com/prnewswire/2022/09/06/microgem-workflow-services-by-imagemover-join-forces-provide-comprehensive-solution-fast-saliva-pcr-sars-cov-2-testing-point-care/ | 2022-09-06T12:58:44Z |
HOUSTON, Sept. 6, 2022 /PRNewswire/ -- Motiva Enterprises LLC ("Motiva") announced today that it has commenced a cash tender offer for any and all of its outstanding 6.85% senior notes due January 15, 2040 (CUSIP Nos. 61980AAD5 (144A) and U61999AC9 (Reg. S)) (the "Notes"), on the terms and subject to the conditions set forth in the Offer to Purchase, dated the date hereof (as it may be amended or supplemented from time to time, the "Offer to Purchase") and the related Notice of Guaranteed Delivery attached to the Offer to Purchase (the "Notice of Guaranteed Delivery"). As of September 6, 2022, there was $1,000,000,000 aggregate principal amount of the Notes outstanding. The tender offer is referred to herein as the "Offer." The Offer to Purchase and the Notice of Guaranteed Delivery are referred to herein collectively as the "Offer Documents."
Certain information regarding the Notes and the pricing for the Offer is set forth in the table below.
The Offer will expire at 5:00 p.m., New York City time, on September 12, 2022, unless extended (such date and time, as the same may be extended, the "Expiration Date") or earlier terminated. The "Tender Offer Consideration" for each $1,000 principal amount of Notes validly tendered and not validly withdrawn and accepted for purchase pursuant to the Offer to Purchase will be determined in the manner described in the Offer Documents by reference to the fixed spread for the Notes specified in the table above plus the yield based on the bid-side price of the U.S. Treasury Reference Security specified in the table above at 2:00 p.m., New York City time, on September 12, 2022, unless extended.
Holders must validly tender (and not validly withdraw) or deliver a properly completed and duly executed Notice of Guaranteed Delivery for their Notes at or before the Expiration Date in order to be eligible to receive the Tender Offer Consideration. In addition, holders whose Notes are purchased in the Offer will receive accrued and unpaid interest on the purchased Notes from the last interest payment date to, but not including, the Settlement Date (as defined in the Offer to Purchase). Motiva expects the Settlement Date to occur on September 14, 2022. Notes tendered by Notice of Guaranteed Delivery and accepted for purchase are expected to be purchased on September 16, 2022, the fourth business day after the Expiration Date, but payment of accrued interest on such Notes will only be made to, but not including, the Settlement Date.
Tendered Notes may be withdrawn prior to 5:00 p.m., New York City time, on September 12, 2022. The consummation of the Offer is neither conditioned upon any minimum amount of Notes being tendered nor is it subject to a financing condition, but is subject to, and conditioned upon, the satisfaction or waiver of certain conditions described in the Offer to Purchase. Motiva intends to use cash on hand to fund the aggregate consideration and accrued interest for all Notes validly tendered (and not withdrawn) pursuant to the Offer to Purchase and accepted for purchase by us, and to pay all fees and expenses incurred in connection with the Offer.
Motiva has retained D.F. King & Co., Inc. ("D.F. King") as the tender agent and information agent for the Offer. Motiva has retained J.P. Morgan Securities LLC as the dealer manager for the Offer.
Holders who would like additional copies of the Offer Documents may call or email the information agent, D.F. King, toll-free at (800) 488-8075, collect at (212) 269-5550 or motiva@dfking.com. Copies of the Offer to Purchase and the Notice of Guaranteed Delivery are also available at the following website: http:www/dfking.com/motiva. Questions regarding the terms of the Offer should be directed to J.P. Morgan Securities LLC at (866) 834-4666 (toll-free) or (212) 834-3554 (collect).
None of Motiva, its subsidiary guarantors, its board of directors, J.P. Morgan Securities LLC, D.F. King or the trustee for the Notes, or any of their respective affiliates, is making any recommendation as to whether holders of the Notes should tender their Notes pursuant to the Offer.
This press release does not constitute an offer to buy or a solicitation of an offer to sell any Notes. The Offer is being made solely pursuant to the Offer Documents. The Offer is not being made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. In any jurisdiction in which the securities laws or blue sky laws require the Offer to be made by a licensed broker or dealer, the Offer will be deemed to be made on behalf of Motiva by J.P. Morgan Securities LLC or one or more registered brokers or dealers that are licensed under the laws of such jurisdiction.
About Motiva
Headquartered in Houston, Texas, Motiva refines, distributes, and markets petroleum products throughout the Americas. The company's Port Arthur Manufacturing Complex is comprised of North America's largest refinery with a crude capacity of 630,000 barrels a day, the country's largest base oil plant, and an adjacent chemical plant. Under exclusive, long-term brand licenses with Shell and Phillips 66 (for the 76® brand), Motiva's marketing operations support more than 5,000 retail gasoline stations. A Delaware limited liability company, Motiva is wholly owned by Aramco.
Forward-Looking Statements
Certain statements herein or in the Offer Documents are "forward-looking statements," which are generally identifiable by words such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "likely," "may," "plan," "position," "possible," "potential," "probable," "project," "should," "strategy," "will," or similar language. Forward-looking statements reflect Motiva's views based on historical results, current information and assumptions related to future developments. Except as may be required by law, Motiva undertakes no obligation to update any forward-looking statements made herein or in the Offer Documents. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those projected or implied by the forward-looking statements. Please refer to the "Forward-Looking Statements" and "Risk Factors" sections in the Offer to Purchase for a description of these and other risks and uncertainties that could cause actual results to differ materially from those projected or implied by the forward-looking statements.
Investor Relations Contact:
Joan Wu, Treasurer
e-mail: motiva-debt@motiva.com, or
Reginald Hart, Treasury Manager (713) 427-3202
e-mail: motiva-debt@motiva.com
CONTACTS:
Amy Cole
Motiva Communications
mediadesk@motiva.com
Media Line: 713-427-3699
View original content:
SOURCE Motiva Enterprises LLC | https://www.whsv.com/prnewswire/2022/09/06/motiva-enterprises-llc-cash-tender-offer-any-all-its-outstanding-685-senior-notes-due-january-15-2040/ | 2022-09-06T12:58:51Z |
JUNO BEACH, Fla., Sept. 6, 2022 /PRNewswire/ -- NextEra Energy, Inc. (NYSE: NEE) and NextEra Energy Partners, LP (NYSE: NEP) today announced that Kirk Crews, executive vice president, finance and chief financial officer of NextEra Energy, and chief financial officer of NextEra Energy Partners, is scheduled to present on Sept. 7, 2022, at the 2022 Barclays CEO Energy-Power Conference in New York City, New York. The presentation is scheduled to begin at 9:10 a.m. ET. A live audio webcast will be available at www.NextEraEnergy.com/investors or www.NextEraEnergyPartners.com. For those unable to listen to the live webcast, a replay will be available for 90 days by accessing the links listed above.
NextEra Energy, Inc. (NYSE: NEE) is a leading clean energy company headquartered in Juno Beach, Florida. NextEra Energy owns Florida Power & Light Company, which is America's largest electric utility that sells more power than any other utility, providing clean, affordable, reliable electricity to approximately 5.8 million customer accounts, or more than 12 million people across Florida. NextEra Energy also owns a competitive clean energy business, NextEra Energy Resources, LLC, which, together with its affiliated entities, is the world's largest generator of renewable energy from the wind and sun and a world leader in battery storage. Through its subsidiaries, NextEra Energy generates clean, emissions-free electricity from seven commercial nuclear power units in Florida, New Hampshire and Wisconsin. NextEra Energy has been recognized often by third parties for its efforts in sustainability, corporate responsibility, ethics and compliance, and diversity. NextEra Energy is ranked No. 1 in the electric and gas utilities industry on Fortune's 2022 list of "World's Most Admired Companies," recognized on Fortune's 2021 list of companies that "Change the World" and received the S&P Global Platts 2020 Energy Transition Award for leadership in environmental, social and governance. For more information about NextEra Energy companies, visit these websites: www.NextEraEnergy.com, www.FPL.com, www.NextEraEnergyResources.com.
NextEra Energy Partners, LP (NYSE: NEP) is a growth-oriented limited partnership formed by NextEra Energy, Inc. (NYSE: NEE). NextEra Energy Partners acquires, manages and owns contracted clean energy projects with stable, long-term cash flows. Headquartered in Juno Beach, Florida, NextEra Energy Partners owns interests in geographically diverse wind, solar and energy storage projects in the U.S. as well as natural gas infrastructure assets in Texas and Pennsylvania. For more information about NextEra Energy Partners, please visit: www.NextEraEnergyPartners.com.
This news release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but instead represent the current expectations of NextEra Energy, Inc. (together with its subsidiaries, NextEra Energy) regarding future operating results and other future events, many of which, by their nature, are inherently uncertain and outside of NextEra Energy's control. Forward-looking statements in this news release include, among others, statements concerning long-term growth rate expectations. In some cases, you can identify the forward-looking statements by words or phrases such as "will," "may result," "expect," "anticipate," "believe," "intend," "plan," "seek," "potential," "projection," "forecast," "predict," "goals," "target," "outlook," "should," "would" or similar words or expressions. You should not place undue reliance on these forward-looking statements, which are not a guarantee of future performance. The future results of NextEra Energy and its business and financial condition are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, or may require it to limit or eliminate certain operations. These risks and uncertainties include, but are not limited to, those discussed in this news release and the following: effects of extensive regulation of NextEra Energy's business operations; inability of NextEra Energy to recover in a timely manner any significant amount of costs, a return on certain assets or a reasonable return on invested capital through base rates, cost recovery clauses, other regulatory mechanisms or otherwise; impact of political, regulatory, operational and economic factors on regulatory decisions important to NextEra Energy; disallowance of cost recovery based on a finding of imprudent use of derivative instruments; effect of any reductions or modifications to, or elimination of, governmental incentives or policies that support utility scale renewable energy projects or the imposition of additional tax laws, tariffs, duties, policies or assessments on renewable energy or equipment necessary to generate it or deliver it; impact of new or revised laws, regulations, interpretations or constitutional ballot and regulatory initiatives on NextEra Energy; capital expenditures, increased operating costs and various liabilities attributable to environmental laws, regulations and other standards applicable to NextEra Energy; effects on NextEra Energy of federal or state laws or regulations mandating new or additional limits on the production of greenhouse gas emissions; exposure of NextEra Energy to significant and increasing compliance costs and substantial monetary penalties and other sanctions as a result of extensive federal regulation of its operations and businesses; effect on NextEra Energy of changes in tax laws, guidance or policies as well as in judgments and estimates used to determine tax-related asset and liability amounts; impact on NextEra Energy of adverse results of litigation; effect on NextEra Energy of failure to proceed with projects under development or inability to complete the construction of (or capital improvements to) electric generation, transmission and distribution facilities, gas infrastructure facilities or other facilities on schedule or within budget; impact on development and operating activities of NextEra Energy resulting from risks related to project siting, planning, financing, construction, permitting, governmental approvals and the negotiation of project development agreements, as well as supply chain disruptions; risks involved in the operation and maintenance of electric generation, transmission and distribution facilities, gas infrastructure facilities, retail gas distribution system in Florida and other facilities; effect on NextEra Energy of a lack of growth or slower growth in the number of customers or in customer usage; impact on NextEra Energy of severe weather and other weather conditions; threats of terrorism and catastrophic events that could result from terrorism, cyberattacks or other attempts to disrupt NextEra Energy's business or the businesses of third parties; inability to obtain adequate insurance coverage for protection of NextEra Energy against significant losses and risk that insurance coverage does not provide protection against all significant losses; a prolonged period of low gas and oil prices could impact NextEra Energy's gas infrastructure business and cause NextEra Energy to delay or cancel certain gas infrastructure projects and could result in certain projects becoming impaired; risk of increased operating costs resulting from unfavorable supply costs necessary to provide full energy and capacity requirement services; inability or failure to manage properly or hedge effectively the commodity risk within its portfolio; effect of reductions in the liquidity of energy markets on NextEra Energy's ability to manage operational risks; effectiveness of NextEra Energy's risk management tools associated with its hedging and trading procedures to protect against significant losses, including the effect of unforeseen price variances from historical behavior; impact of unavailability or disruption of power transmission or commodity transportation facilities on sale and delivery of power or natural gas; exposure of NextEra Energy to credit and performance risk from customers, hedging counterparties and vendors; failure of counterparties to perform under derivative contracts or of requirement for NextEra Energy to post margin cash collateral under derivative contracts; failure or breach of NextEra Energy's information technology systems; risks to NextEra Energy's retail businesses from compromise of sensitive customer data; losses from volatility in the market values of derivative instruments and limited liquidity in over-the-counter markets; impact of negative publicity; inability to maintain, negotiate or renegotiate acceptable franchise agreements; occurrence of work strikes or stoppages and increasing personnel costs; NextEra Energy's ability to successfully identify, complete and integrate acquisitions, including the effect of increased competition for acquisitions; environmental, health and financial risks associated with ownership and operation of nuclear generation facilities; liability of NextEra Energy for significant retrospective assessments and/or retrospective insurance premiums in the event of an incident at certain nuclear generation facilities; increased operating and capital expenditures and/or reduced revenues at nuclear generation facilities resulting from orders or new regulations of the Nuclear Regulatory Commission; inability to operate any of NextEra Energy's owned nuclear generation units through the end of their respective operating licenses; effect of disruptions, uncertainty or volatility in the credit and capital markets or actions by third parties in connection with project-specific or other financing arrangements on NextEra Energy's ability to fund its liquidity and capital needs and meet its growth objectives; inability to maintain current credit ratings; impairment of liquidity from inability of credit providers to fund their credit commitments or to maintain their current credit ratings; poor market performance and other economic factors that could affect NextEra Energy's defined benefit pension plan's funded status; poor market performance and other risks to the asset values of nuclear decommissioning funds; changes in market value and other risks to certain of NextEra Energy's investments; effect of inability of NextEra Energy subsidiaries to pay upstream dividends or repay funds to NextEra Energy or of NextEra Energy's performance under guarantees of subsidiary obligations on NextEra Energy's ability to meet its financial obligations and to pay dividends on its common stock; the fact that the amount and timing of dividends payable on NextEra Energy's common stock, as well as the dividend policy approved by NextEra Energy's board of directors from time to time, and changes to that policy, are within the sole discretion of NextEra Energy's board of directors and, if declared and paid, dividends may be in amounts that are less than might be expected by shareholders; NextEra Energy Partners, LP's inability to access sources of capital on commercially reasonable terms could have an effect on its ability to consummate future acquisitions and on the value of NextEra Energy's limited partner interest in NextEra Energy Operating Partners, LP; effects of disruptions, uncertainty or volatility in the credit and capital markets on the market price of NextEra Energy's common stock; and the ultimate severity and duration of public health crises, epidemics and pandemics, and its effects on NextEra Energy's business. NextEra Energy discusses these and other risks and uncertainties in its annual report on Form 10-K for the year ended December 31, 2021 and other Securities and Exchange Commission (SEC) filings, and this news release should be read in conjunction with such SEC filings. The forward-looking statements made in this news release are made only as of the date of this news release and NextEra Energy undertakes no obligation to update any forward-looking statements.
This news release contains "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements are not statements of historical facts, but instead represent the current expectations of NextEra Energy Partners, LP (together with its subsidiaries, NEP) regarding future operating results and other future events, many of which, by their nature, are inherently uncertain and outside of NEP's control. Forward-looking statements in this news release include, among others, statements concerning long-term growth rate expectations. In some cases, you can identify the forward-looking statements by words or phrases such as "will," "may result," "expect," "anticipate," "believe," "intend," "plan," "seek," "aim," "potential," "projection," "forecast," "predict," "goals," "target," "outlook," "should," "would" or similar words or expressions. You should not place undue reliance on these forward-looking statements, which are not a guarantee of future performance. The future results of NEP and its business and financial condition are subject to risks and uncertainties that could cause NEP's actual results to differ materially from those expressed or implied in the forward-looking statements. These risks and uncertainties could require NEP to limit or eliminate certain operations. These risks and uncertainties include, but are not limited to, the following: NEP's ability to make cash distributions to its unitholders is affected by wind and solar conditions at its renewable energy projects; Operation and maintenance of renewable energy projects and pipelines involve significant risks that could result in unplanned power outages, reduced output or capacity, personal injury or loss of life; NEP's business, financial condition, results of operations and prospects can be materially adversely affected by weather conditions, including, but not limited to, the impact of severe weather; NEP depends on certain of the renewable energy projects and pipelines in its portfolio for a substantial portion of its anticipated cash flows; NEP may pursue the repowering of wind projects or the expansion of natural gas pipelines that would require up-front capital expenditures and could expose NEP to project development risks; Terrorist acts, cyberattacks or other similar events could impact NEP's projects, pipelines or surrounding areas and adversely affect its business; The ability of NEP to obtain insurance and the terms of any available insurance coverage could be materially adversely affected by international, national, state or local events and company-specific events, as well as the financial condition of insurers. NEP's insurance coverage does not provide protection against all significant losses; NEP relies on interconnection, transmission and other pipeline facilities of third parties to deliver energy from its renewable energy projects and to transport natural gas to and from its pipelines. If these facilities become unavailable, NEP's projects and pipelines may not be able to operate or deliver energy or may become partially or fully unavailable to transport natural gas; NEP's business is subject to liabilities and operating restrictions arising from environmental, health and safety laws and regulations, compliance with which may require significant capital expenditures, increase NEP's cost of operations and affect or limit its business plans; NEP's renewable energy projects or pipelines may be adversely affected by legislative changes or a failure to comply with applicable energy and pipeline regulations; Petroleos Mexicanos (Pemex) may claim certain immunities under the Foreign Sovereign Immunities Act and Mexican law, and the Texas pipeline entities' ability to sue or recover from Pemex for breach of contract may be limited and may be exacerbated if there is a deterioration in the economic relationship between the U.S. and Mexico; NEP does not own all of the land on which the projects in its portfolio are located and its use and enjoyment of the property may be adversely affected to the extent that there are any lienholders or land rights holders that have rights that are superior to NEP's rights or the U.S. Bureau of Land Management suspends its federal rights-of-way grants; NEP is subject to risks associated with litigation or administrative proceedings that could materially impact its operations, including, but not limited to, proceedings related to projects it acquires in the future; NEP's operations require NEP to comply with anti-corruption laws and regulations of the U.S. government and Mexico; NEP is subject to risks associated with its ownership interests in projects that are under construction, which could result in its inability to complete construction projects on time or at all, and make projects too expensive to complete or cause the return on an investment to be less than expected; NEP relies on a limited number of customers and is exposed to the risk that they may be unwilling or unable to fulfill their contractual obligations to NEP or that they otherwise terminate their agreements with NEP; NEP may not be able to extend, renew or replace expiring or terminated power purchase agreements (PPA), natural gas transportation agreements or other customer contracts at favorable rates or on a long-term basis; If the energy production by or availability of NEP's renewable energy projects is less than expected, they may not be able to satisfy minimum production or availability obligations under their PPAs; NEP's growth strategy depends on locating and acquiring interests in additional projects consistent with its business strategy at favorable prices; Reductions in demand for natural gas in the United States or Mexico and low market prices of natural gas could materially adversely affect NEP's pipeline operations and cash flows; Government laws, regulations and policies providing incentives and subsidies for clean energy could be changed, reduced or eliminated at any time and such changes may negatively impact NEP's growth strategy; NEP's growth strategy depends on the acquisition of projects developed by NextEra Energy, Inc. (NEE) and third parties, which face risks related to project siting, financing, construction, permitting, the environment, governmental approvals and the negotiation of project development agreements; Acquisitions of existing clean energy projects involve numerous risks; NEP may continue to acquire other sources of clean energy and may expand to include other types of assets. Any further acquisition of non-renewable energy projects may present unforeseen challenges and result in a competitive disadvantage relative to NEP's more-established competitors; NEP faces substantial competition primarily from regulated utilities, developers, independent power producers, pension funds and private equity funds for opportunities in North America; The natural gas pipeline industry is highly competitive, and increased competitive pressure could adversely affect NEP's business; NEP may not be able to access sources of capital on commercially reasonable terms, which would have a material adverse effect on its ability to consummate future acquisitions and pursue other growth opportunities; Restrictions in NEP and its subsidiaries' financing agreements could adversely affect NEP's business, financial condition, results of operations and ability to make cash distributions to its unitholders; NEP's cash distributions to its unitholders may be reduced as a result of restrictions on NEP's subsidiaries' cash distributions to NEP under the terms of their indebtedness or other financing agreements; NEP's subsidiaries' substantial amount of indebtedness may adversely affect NEP's ability to operate its business, and its failure to comply with the terms of its subsidiaries' indebtedness could have a material adverse effect on NEP's financial condition; NEP is exposed to risks inherent in its use of interest rate swaps; Widespread public health crises and epidemics or pandemics may have material adverse impacts on NEP's business, financial condition, liquidity, results of operations and ability to make cash distributions to its unitholders; NEE has influence over NEP; Under the cash sweep and credit support agreement, NEP receives credit support from NEE and its affiliates. NEP's subsidiaries may default under contracts or become subject to cash sweeps if credit support is terminated, if NEE or its affiliates fail to honor their obligations under credit support arrangements, or if NEE or another credit support provider ceases to satisfy creditworthiness requirements, and NEP will be required in certain circumstances to reimburse NEE for draws that are made on credit support; NextEra Energy Resources, LLC (NEER) or one of its affiliates is permitted to borrow funds received by NEP's subsidiaries and is obligated to return these funds only as needed to cover project costs and distributions or as demanded by NextEra Energy Operating Partners, LP (NEP OpCo). NEP's financial condition and ability to make distributions to its unitholders, as well as its ability to grow distributions in the future, is highly dependent on NEER's performance of its obligations to return all or a portion of these funds; NEER's right of first refusal may adversely affect NEP's ability to consummate future sales or to obtain favorable sale terms; NextEra Energy Partners GP, Inc. (NEP GP) and its affiliates may have conflicts of interest with NEP and have limited duties to NEP and its unitholders; NEP GP and its affiliates and the directors and officers of NEP are not restricted in their ability to compete with NEP, whose business is subject to certain restrictions; NEP may only terminate the Management Services Agreement among, NEP, NextEra Energy Management Partners, LP (NEE Management), NEP OpCo and NextEra Energy Operating Partners GP, LLC (NEP OpCo GP) under certain limited circumstances; If the agreements with NEE Management or NEER are terminated, NEP may be unable to contract with a substitute service provider on similar terms; NEP's arrangements with NEE limit NEE's potential liability, and NEP has agreed to indemnify NEE against claims that it may face in connection with such arrangements, which may lead NEE to assume greater risks when making decisions relating to NEP than it otherwise would if acting solely for its own account; NEP's ability to make distributions to its unitholders depends on the ability of NEP OpCo to make cash distributions to its limited partners; If NEP incurs material tax liabilities, NEP's distributions to its unitholders may be reduced, without any corresponding reduction in the amount of the IDR fee; Holders of NEP's units may be subject to voting restrictions; NEP's partnership agreement replaces the fiduciary duties that NEP GP and NEP's directors and officers might have to holders of its common units with contractual standards governing their duties and the NYSE does not require a publicly traded limited partnership like NEP to comply with certain of its corporate governance requirements; NEP's partnership agreement restricts the remedies available to holders of NEP's common units for actions taken by NEP's directors or NEP GP that might otherwise constitute breaches of fiduciary duties; Certain of NEP's actions require the consent of NEP GP; Holders of NEP's common units currently cannot remove NEP GP without NEE's consent and provisions in NEP's partnership agreement may discourage or delay an acquisition of NEP that NEP unitholders may consider favorable; NEE's interest in NEP GP and the control of NEP GP may be transferred to a third party without unitholder consent; NEP may issue additional units without unitholder approval, which would dilute unitholder interests; Reimbursements and fees owed to NEP GP and its affiliates for services provided to NEP or on NEP's behalf will reduce cash distributions from NEP OpCo and from NEP to NEP's unitholders, and there are no limits on the amount that NEP OpCo may be required to pay; Increases in interest rates could adversely impact the price of NEP's common units, NEP's ability to issue equity or incur debt for acquisitions or other purposes and NEP's ability to make cash distributions to its unitholders; The liability of holders of NEP's units, which represent limited partnership interests in NEP, may not be limited if a court finds that unitholder action constitutes control of NEP's business; Unitholders may have liability to repay distributions that were wrongfully distributed to them; The issuance of securities convertible into, or settleable with, common units may affect the market price for NEP's common units, will dilute common unitholders' ownership in NEP and may decrease the amount of cash available for distribution for each common unit; NEP's future tax liability may be greater than expected if NEP does not generate net operating losses (NOLs) sufficient to offset taxable income or if tax authorities challenge certain of NEP's tax positions; NEP's ability to use NOLs to offset future income may be limited; NEP will not have complete control over NEP's tax decisions; and, Distributions to unitholders may be taxable as dividends. NEP discusses these and other risks and uncertainties in its annual report on Form 10-K for the year ended December 31, 2021 and other Securities and Exchange Commission (SEC) filings, and this news release should be read in conjunction with such SEC filings made through the date of this news release. The forward-looking statements made in this news release are made only as of the date of this news release and NEP undertakes no obligation to update any forward-looking statements.
View original content to download multimedia:
SOURCE NextEra Energy, Inc.; NextEra Energy Partners, LP | https://www.whsv.com/prnewswire/2022/09/06/nextera-energy-nextera-energy-partners-present-2022-barclays-ceo-energy-power-conference/ | 2022-09-06T12:58:57Z |
Testing is designed around a simplified process flow sheet that could yield better results for Niobium and Titanium production and is expected to confirm previously achieved high recovery rates for Scandium
CENTENNIAL, Colo., Sept. 6, 2022 /PRNewswire/ -- NioCorp Developments Ltd. ("NioCorp" or the "Company") (TSX: NB; OTCQX: NIOBF) is pleased to announce that its demonstration-scale processing plant (the "demonstration plant") in Quebec, Canada is now processing ore samples from the Company's Elk Creek Critical Minerals Project (the "Project"). The demonstration plant project is intended to demonstrate that the Company can extract and separate rare earth elements from ore that NioCorp expects to mine from the Project site, subject to receipt of necessary project financing, and that its simplified process for potentially producing niobium, scandium, and titanium is technically and economically feasible.
The demonstration plant will process Elk Creek ore samples in three phases. Testing is expected to be completed over the next several weeks. NioCorp expects to publicly disclose testing results after each operational phase concludes.
- Phase 1 is designed to demonstrate a new approach to the initial processing of the ore that NioCorp expects to mine from the Project site, subject to receipt of necessary project funding, including calcination, initial leaching, and rare earth extraction.
- Phase 2 is designed to demonstrate an improved process for the second stage of leaching along with Niobium and Titanium separation.
- Phase 3 is designed to demonstrate the technical viability of separating high-purity versions of several target magnetic rare earth products from Elk Creek ore samples, as well as confirming previously achieved high recovery rates for high-purity Scandium trioxide. The potential magnetic rare earth products include Neodymium-Praseodymium ("NdPr") oxide, Dysprosium oxide, and Terbium oxide. NioCorp will utilize conventional solvent extraction ("SX") technology to test a rare earth separation approach developed by NioCorp and L3. NioCorp and L3 have years of collective experience in SX technology.
"Our team is very pleased to see the demonstration plant begin operations, and we intend to closely monitor every step of this process," said Scott Honan. "Many of these processes have already been successfully tested at the bench scale. Given our team's years of experience in hydrometallurgy, including rare earth separations, I expect that we will demonstrate positive results. I also look forward to potentially demonstrating how our simplified process flow sheet can more efficiently and cost-effectively produce Niobium, Scandium, and Titanium."
Honan added that once operations have concluded and data analyzed, work can then turn to the design and engineering of the new process flow sheet, which in turn is expected to be incorporated into an updated Elk Creek Project Feasibility Study that incorporates an economic analysis of separated rare earth oxide products and the simplified process flow sheet.
As no economic analysis has been completed on the rare earth mineral resource comprising the Project, further studies are required before determining whether extraction of rare earth elements can be reasonably justified and economically viable after taking account all relevant factors.
Eric Larochelle, B.Eng., Co-Owner, L3 Process Development, a Qualified Person as defined by National Instrument 43-101, has reviewed and approved the technical information contained in this news release.
Contact Jim Sims, Corporate Communications Officer, NioCorp Developments Ltd., 720-639-4650, jim.sims@niocorp.com
Source: NioCorp Developments Ltd.
@NioCorp $NB.TO $NIOBF $BR3 #Niobium #Scandium #rareearth #neodymium #dysprosium #terbium #ElkCreek #EV #electricvehicle
NioCorp is developing a critical minerals project in Southeast Nebraska that will produce niobium, scandium, and titanium. The Company also is evaluating the potential to produce several rare earths from the Project. Niobium is used to produce specialty alloys as well as High Strength, Low Alloy ("HSLA") steel, which is a lighter, stronger steel used in automotive, structural, and pipeline applications. Scandium is a specialty metal that can be combined with Aluminum to make alloys with increased strength and improved corrosion resistance. Scandium is also a critical component of advanced solid oxide fuel cells. Titanium is used in various lightweight alloys and is a key component of pigments used in paper, paint and plastics and is also used for aerospace applications, armor, and medical implants. Magnetic rare earths, such as neodymium, praseodymium, terbium, and dysprosium are critical to the making of Neodymium-Iron-Boron ("NdFeB") magnets, which are used across a wide variety of defense and civilian applications.
Certain statements contained in this document may constitute forward-looking statements, including but not limited to statements related to the Company's expectations that it will be able to complete operations of its demonstration plant; that the demonstration plant testing will show positive results; the expectation regarding the completion of a new Elk Creek Project Feasibility Study that incorporates an economic analysis of separated rare earth oxide products and the simplified process flow sheet; and the Company's expectations that the Project will reach production stage if it is able to secure project financing, and its ability to produce its planned products commercially, including potential production of rare earths. Such forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Readers are cautioned that such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause a change in such assumptions and the actual outcomes and estimates to be materially different from those estimated or anticipated future results, achievements or position expressed or implied by those forward-looking statements. Risks, uncertainties and other factors that could cause NioCorp's plans or prospects to change include risks related to NioCorp's ability to operate as a going concern; risks related to NioCorp's requirement of significant additional capital; changes in demand for and price of commodities (such as fuel and electricity) and currencies; changes or disruptions in the securities markets; legislative, political or economic developments; the need to obtain permits and comply with laws and regulations and other regulatory requirements; the possibility that actual results of work may differ from projections/expectations or may not realize the perceived potential of NioCorp's projects; risks of accidents, equipment breakdowns and labor disputes or other unanticipated difficulties or interruptions; the possibility of cost overruns or unanticipated expenses in development programs; operating or technical difficulties in connection with exploration, mining or development activities; the speculative nature of mineral exploration and development, including the risks of diminishing quantities of grades of reserves and resources; the risks involved in the exploration, development and mining business, and the risks set forth in the Company's filings with the SEC at www.sec.gov. NioCorp disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
View original content to download multimedia:
SOURCE NioCorp Developments Ltd. | https://www.whsv.com/prnewswire/2022/09/06/niocorps-demonstration-plant-begins-testing-process-improvements-rare-earth-recovery-operations/ | 2022-09-06T12:59:04Z |
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person company overview and share the Company's latest updates at the H.C. Wainwright 24th Annual Global Investment Conference, on September 13, 2022 in New York, NY.
Presentation Details:
H.C. Wainwright 24th Annual Global Investment Conference
Date: Tuesday, September 13, 2022
Time: 3:00 p.m. E.T.
Location: Lotte New York Palace, New York, NY
The presentation will be viewable starting Tuesday, September 13, 2022, at 3:00 p.m. Eastern time, and will be available for 90 days, through the following link: https://journey.ct.events/view/fbd3fb46-d695-4516-9e06-8d9247a157ab.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).
For more information, please visit www.oramed.com.
Logo - https://mma.prnewswire.com/media/1724339/Oramed_Logo.jpg
Company contact:
Zach Herschfus
+1-844-9-ORAMED
zach@oramed.com
View original content:
SOURCE Oramed Pharmaceuticals Inc. | https://www.whsv.com/prnewswire/2022/09/06/oramed-present-hc-wainwright-24th-annual-global-investment-conference/ | 2022-09-06T12:59:10Z |
DENVER, Sept. 6, 2022 /PRNewswire/ - Ovintiv Inc. (NYSE: OVV) (TSX: OVV) ("Ovintiv" or the "Company") today announced that Ralph Izzo has been named as an independent member of its Board of Directors, effective September 6, 2022, and that Bruce Waterman will retire from the Board of Directors effective December 31, 2022.
Mr. Izzo, 64, currently serves as the Executive Chair of Public Service Enterprise Group Incorporated ("PSEG"), having recently retired as their Chair, President and CEO. PSEG is a publicly traded diversified energy holding company, founded in 1903 and has a long history of providing infrastructure to access safe, affordable, reliable, and cleaner energy to customers in New Jersey and Long Island. Since joining PSEG in 1992, Mr. Izzo has held several significant executive positions within the PSEG family of companies. Mr. Izzo also serves on the Board of Directors of the Bank of New York Mellon.
Mr. Izzo is a member of the U.S. Department of Energy's Fusion Energy Sciences Advisory Committee and the former chair of the Nuclear Energy Institute. He is also on the Board of Directors for the Edison Electric Institute, Nuclear Electric Insurance Limited, the New Jersey Chamber of Commerce, the Liberty Science Center and the New Jersey Performing Arts Center. Mr. Izzo is on the advisory board for the University of Pennsylvania's School of Engineering and Applied Sciences Mechanical Engineering and Applied Mechanics Department, a member of the Board of Trustees of the Peddie School and Princeton University's Andlinger Center for Energy and the Environment Advisory Council, as well as a member of the Visiting Committee for the Department of Nuclear Engineering at Massachusetts Institute of Technology, the Columbia University School of Engineering Board of Visitors, and of the CEO Action for Diversity and Inclusion. In addition, he is a former chair of the Rutgers University Board of Governors and the New Jersey Chamber of Commerce.
Mr. Izzo received his Bachelor of Science and Master of Science degrees in mechanical engineering and his Doctor of Philosophy degree in applied physics from Columbia University. He also received a Master of Business Administration degree, with a concentration in finance, from the Rutgers Graduate School of Management.
"We are excited that Ralph is joining our Board. His significant senior leadership experience in operations, strategic planning, finance, risk management, environmental stewardship, and diversity leadership will enhance the board's strengths," said Ovintiv's Chair Peter Dea. "Mr. Izzo is a well-known leader within the utility industry, as well as the national energy policy arena and represents our ongoing Board refreshment process as our third new Director in the past 18-months."
Mr. Waterman joined the board in 2010 and served on various committees over his tenure including Audit Committee Chair from 2017 until 2022. Mr. Waterman's wealth of finance, energy industry and government relations experience benefited the Company immensely. "On behalf of the Board and leadership team, I would like to thank Bruce for his many contributions and wise counsel over the last 12 years," said Mr. Dea. Brendan McCracken, Ovintiv's President and CEO noted "the Company is grateful for Mr. Waterman's years of service and dedication and we wish him well in retirement."
Further information on Ovintiv Inc. is available on the Company's website, www.ovintiv.com, or by contacting:
View original content to download multimedia:
SOURCE Ovintiv Inc. | https://www.whsv.com/prnewswire/2022/09/06/ovintiv-names-ralph-izzo-its-board-directors/ | 2022-09-06T12:59:17Z |
AUSTIN, Texas, Sept. 6, 2022 /PRNewswire/ -- Pain Specialists of America (PSA) is pleased to announce that Padma Doniparthi, MD, DABA, DABPM, AAHPC, has joined their team to provide patient care in their Temple and Georgetown, Texas communities. Dr. Doniparthi is a best-in-class, triple board-certified interventional pain management physician with over 20 years of excellence. She has relocated to the Georgetown community from Brookfield, WI, where she practiced interventional pain medicine.
According to PSA's Clinical President, Pankaj Mehta, MD, DABA, DABPM, "We have been looking for a highly trained interventional pain doctor to join us in Temple and Georgetown to provide care for our growing patient base, and we couldn't be more pleased to have Dr. Doniparthi join our team" PSA has a state-of-the-art ambulatory surgery center in Killeen, TX, where Dr. Mehta offers the latest and most advanced therapies for treating chronic pain. Dr. Doniparthi will join him in performing minimally invasive procedures and surgeries at this center of excellence. "Training physicians across the US gives our company an advantage that not every practice gets to experience", says Dr. Mehta, "Dr. Doniparthi's passion for learning new skills and innovation makes her an asset to the growing team of experts in the interventional pain specialty".
Dr. Padma Doniparthi is a diplomate of the American Board of Anesthesiology, Pain Management and Hospice and Palliative Care. After attending medical school at the Medical College of Wisconsin, Milwaukee, WI, she trained at Baylor University Medical Center for her Internship and UT Southwestern in Dallas, Texas, for her Anesthesiology Residency. She completed her Interventional Pain Management residency and fellowship training at The Medical College of Wisconsin in Milwaukee, WI. With over twenty years of interventional pain management experience, Dr. Doniparthi offers a variety of treatment options with a patient-centric practice and multidisciplinary approach.
Dr. Doniparthi, her husband and their three children enjoy traveling together and outdoor activities. She is proud that all of her children are becoming physicians to serve the needs of the community. A leader in her field, she was named Patients' Choice and Compassionate Doctor - 10 years & running as the top 3% of U.S. physicians. This annual recognition reflects the difference she has made in the lives of her patients. The honor is bestowed to physicians who have received near-perfect scores, as voted by patients. The Compassionate Doctor Certification is granted to physicians who treat their patients with the utmost kindness. The honor is granted based on a physician's overall and bedside manner scores.
Pain Specialists of America is an interventional pain management group with highly educated, double and triple-board-certified pain physicians. Many of our physician leaders have trained at the nation's most prestigious medical centers in the country, like Harvard Medical School and the Cleveland Clinic. We offer services at 15 convenient office locations in Texas along the I-35 corridor from Waco to San Antonio. Our providers and their care teams develop treatment plans from a host of multidisciplinary approaches and offer the latest advanced interventional options available. Our Individualized treatment programs are designed to improve quality of life, allowing patients to return to normal daily functions as quickly as possible.
Visit Pain Specialists of America at www.psadocs.com and connect with us on Facebook at https://www.facebook.com/PainSpecialistsofAmerica
Contact
Amber Kerby
VP of Sales & Marketing
akerby@psadocs.com
View original content to download multimedia:
SOURCE Pain Specialists of America | https://www.whsv.com/prnewswire/2022/09/06/padma-doniparthi-md-daba-dabpm-aahpc-joins-pain-specialists-america-temple-georgetown-tx/ | 2022-09-06T12:59:23Z |
YOKNEAM ILLIT, Israel, Sept. 6, 2022 /PRNewswire/ -- PixCell Medical, innovator of rapid hematology testing solutions at the point-of-care, today announced a partnership with Insight Medical, a medical supply and service company based in Port Moresby, Papua New Guinea. Insight Medical will serve as the exclusive distributor of PixCell's HemoScreen™, a hematology analyzer designed for use at the point of care, across Papua New Guinea.
Insight Medical's mission is to enhancing the healthcare quality available in Papua New Guinea, with a commitment to providing quality health care access, including modern medical equipment and specialist care. Currently, most of Papua New Guinea's 9 million citizens live in rural communities, facing many healthcare and infrastructure challenges. HemoScreen was chosen for its suitability in meeting these challenges, delivering lab-grade blood diagnostics at the point-of-care, with no need for user maintenance or external reagents and requiring only minimal training.
"We see HemoScreen as a cutting-edge analyzer that can provide lab-grade diagnostics in remote regions of PNG where laboratories lack basic infrastructure and instrumentation, as well as qualified lab expertise" said Manas Sukumara Panicker, managing director at Insight Medical. "Being a tropical region, PNG has a high prevalence of vector borne diseases such as Malaria. Access to quality CBC results will certainly assist doctors in carrying out timely clinical interventions. We are confident HemoScreen will simplify the blood testing in PNG's rural settings."
"As our mission is to provide lad-quality blood diagnostics to anyone and anywhere, we have been striving to expand to more challenging and rural-centric regions, where HemoScreen can make a huge impact." stated Avishay Bransky, Ph.D., co-founder and CEO of PixCell Medical. "For this reason, we are extremely thrilled to form this partnership with Insight Medical who share our vision and provide services across the challenging Papua New Guinea healthcare network."
About PixCell Medical
PixCell Medical, an innovator of rapid hematology testing solutions at the point-of-care, has developed the only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked and TGA-approved for point-of-care use –the HemoScreen™. The portable, easy to use platform offers clinically proven lab-accurate readings of 20 standard blood count parameters within five minutes, with just one finger-prick of blood. This facilitates fast diagnostic results and data-driven disease management decisions. Leveraging a patented, disposable cartridge preloaded with all necessary reagents, the company's unique Viscoelastic Focusing technology and AI-powered machine vision, PixCell enables improved medical outcomes and patient quality of life and reduces costs for healthcare providers.
For more information: www.pixcell-medical.com
Follow PixCell Medical on LinkedIn and Twitter.
Media Contact:
PixCell Medical
Jake Jones
jake.jones@pixcell-medical.com
Logo - https://mma.prnewswire.com/media/1501459/PixCell_Medical_Logo.jpg
View original content to download multimedia:
SOURCE PixCell Medical | https://www.whsv.com/prnewswire/2022/09/06/pixcell-medical-partners-with-insight-medical-distribute-hematology-point-of-care-analyzer-hemoscreen-papua-new-guinea/ | 2022-09-06T12:59:29Z |
VANCOUVER, BC, Sept. 6, 2022 /PRNewswire/ - PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) ("PlantX" or the "Company"), the digital face of the plant-based community, operating a one-stop shop for plant-based products, today announced unaudited monthly financial metrics for August 2022.
PlantX generated monthly gross revenue of $1.381 million in August 2022, an increase of 32% compared to $1.048 million in August 2021. The increase was driven primarily by expansion of our distribution channels and retail footprint. Gross profit for August 2022 was $525,000, or 38% gross margin, compared to gross profit of $367,000, or 35% gross margin in August 2021. Notably, the Little West cold-pressed juice brand continues to generate strong sell-through across its retail distribution partners. Additionally, the Chicago Uptown location had its best month since it was acquired by PlantX in December 2021. This growth was driven by expanded selection and special events.
"PlantX continues to generate significant year-over-year growth, driven by positive market reception to the Little West cold-pressed juice brand and the success of live events at our retail locations to drive store traffic as we build loyal customers," said PlantX CEO, Lorne Rapkin. "Consumers increasingly see PlantX as the first stop for all things involved with the plant-based lifestyle, and this growing presence is resulting in revenue acceleration."
The financial metrics disclosed in this press release are management prepared and have not been audited or reviewed by the Company's auditors. Unless otherwise indicated, all amounts are expressed in Canadian dollars.
As the digital face of the plant-based community, PlantX's platform is a one-stop shop for plant-based products. With its fast-growing category verticals, the Company offers customers across North America more than 5,000 plant-based products. In addition to offering delivery service for meals and indoor plants, the Company currently has plans underway to expand its product lines to include a juice and coffee company. The Company uses its digital platform to build a community of likeminded consumers and, most importantly, to provide education. Its successful enterprise is being built and fortified on partnerships with the top nutritionists, chefs, and brands. The Company's digital presence works to eliminate the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier, and happier life.
Connect with PlantX: Email | Website | Facebook | LinkedIn | Twitter | Instagram | YouTube | TikTok
This press release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as "may," "will," "expect," "likely", "should," "would," "plan," "anticipate," "intend," "potential," "proposed," "estimate," "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen, or by discussions of strategy. The forward-looking information contained herein includes, without limitation, statements regarding the business and strategic plans of the Company.
By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release including, without limitation: receiving sufficient demand for the Offering; the Company's ability to comply with all applicable governmental regulations including all applicable food safety laws and regulations; impacts to the business and operations of the Company due to the COVID-19 epidemic; the conflict in eastern Europe; having a limited operating history; the ability of the Company to access capital to meet future financing needs; the Company's reliance on management and key personnel; competition; changes in consumer trends; foreign currency fluctuations; and general economic, market or business conditions.
Additional risk factors can also be found in the Company's continuous disclosure documents, which have been filed on SEDAR and can be accessed at www.sedar.com. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
View original content to download multimedia:
SOURCE PlantX Life Inc. | https://www.whsv.com/prnewswire/2022/09/06/plantx-announces-monthly-gross-revenue-14-million-august-2022-up-32-year-over-year/ | 2022-09-06T12:59:37Z |
LOS ANGELES, Sept. 6, 2022 /PRNewswire/ -- Maintaining its successful pattern of hiring experienced probate litigation talent, national probate and inheritance dispute law firm RMO LLP announced today that seasoned probate litigator Savannah Brutto has joined the firm to launch its Westlake Village, California office, and senior probate paralegal Tina Chavez has joined the firm in its Orange County, California office.
"We could not be happier to be able to welcome these talented, veteran probate professionals to our team," said RMO CEO Scott Rahn. "Like all our team members, Savannah and Tina have remarkable backgrounds and significant experience. Undoubtedly, our clients, referral sources and communities will benefit from the experience they bring to the firm."
Brutto joins the firm as a Senior Attorney. Her practice includes defending and prosecuting causes of action on behalf and against heirs, beneficiaries, fiduciaries, and creditors in probate, trust, guardianship, and power of attorney proceedings. Brutto also handles contested estate, probate, and trust administrations. Prior to joining RMO LLP, Brutto worked in the boutique law firm Wright Kim Douglas, ALC in Glendale, California.
Chavez is a seasoned probate paralegal with nearly 20 years of experience. She brings extensive knowledge in and supports the team with trust, estate and probate litigation matters and contested conservatorships.
RMO LLP provides personal, cost-effective litigation services to individual and institutional clients. The firm's attorneys focus on litigation contested trust, estate, probate, and conservatorship matters. RMO has offices throughout California, Florida, Texas, Missouri and Kansas. For more information, please visit https://rmolawyers.com/.
View original content:
SOURCE RMO LLP | https://www.whsv.com/prnewswire/2022/09/06/probate-dispute-law-firm-rmo-llp-continues-strategic-expansion/ | 2022-09-06T12:59:44Z |
Awarded 2022 Clinical Education Hall of Fame Award from Mercy College
MELVILLE, N.Y., Sept. 6, 2022 /PRNewswire/ -- Professional Physical Therapy, a leading provider of outpatient physical therapy and rehabilitation services in the Northeast, is proud to celebrate the recognition of their Clinical Affiliation Program. Now expanded to over 100 College and University partners, the program offers undergraduate students the opportunity to gain hands-on experience and receive mentorship with Professional's renowned clinical instructors.
The expansion has been recognized by a long-standing Clinical Affiliate, Mercy College. On July 21, 2022, Mercy College awarded Professional with the prestigious Hall of Fame award for exceptional clinical education for Physical Therapy. The award recognizes Professional's lifelong commitment to clinical education and mentorship of future professionals.
The Director of Clinal Affiliations, Kim Ciprian, was recognized for her hard work and dedication to the growth of the Clinical Affiliation Program. Kim has been with Professional since 2001, starting as a Certified Athletic Trainer and working in various departments learning all aspects of the business. After taking over the Clinical Affiliation Program in 2018, she developed a new internal management system to grow the program to what it is today.
Kim states, "Professional PT has some of the best clinicians in the Northeast. I am grateful for such an amazing Clinical team to work with. Professional prides itself in education, not only of our employees but in future clinicians as well."
For more information about participating in a clinical affiliation with Professional Physical Therapy, contact Professional at CAP@professionalpt.com or click here to learn more about the program.
Professional's Clinical Affiliation Program offers students an opportunity to gain hands-on experience with our patients and receive mentorship with our clinical instructors. Many of our instructors are Credentialed Clinical Instructors by the American Physical Therapy Association (APTA) and all are dedicated to ensuring that the student's experience at Professional is a rewarding one.
Students of the program often return to become a full-time member of our clinical staff, and many are now Clinical Directors and Partners in the company. We currently have contracts with over 100 colleges and universities that participate in our Clinical Affiliation Program.
View original content to download multimedia:
SOURCE Professional Physical Therapy | https://www.whsv.com/prnewswire/2022/09/06/professional-physical-therapy-celebrates-successful-growing-clinical-affiliation-program/ | 2022-09-06T12:59:50Z |
Event will showcase classroom engagement and management strategies facilitated by Promethean solutions for the new school year
SEATTLE, Sept. 6, 2022 /PRNewswire/ -- Promethean, a leading global education technology company, is hosting the Teacher Tailgate on Wednesday, September 7, 2022, from 6:00-9:00 p.m. EDT, to provide teachers with new ideas on how to leverage the Promethean panel and resources to improve engagement and inspire creativity in the classroom.
The event will provide educators with ways to access thousands of ready-made resources, including lessons, activities, courses, video tutorials, articles, tips, guides, and more. The tailgate event will also include prizes and a live demonstration of how to make interactive activities within the ActivPanel interactive display and ActivInspire lesson delivery software.
Keynote speaker Holly Clark is a recognized education and digital learning expert and a best-selling author. Her featured keynote at the Teacher Tailgate will focus on the new normal in education and how the future classroom must look different from the traditional classrooms of yesterday. She will explore the ways in which students' futures are digital and how their successes will depend on knowing how to use digital tools to build businesses, communicate effectively, and work productively from remote locations. She will discuss how the new classroom can better prepare our students for a future where technology will become even smarter and more prevalent. She is a twenty-plus-year educator who has spent over 15 years teaching in a 1:1 classroom and over five years as an administrator in both public and private schools. She specializes in helping teachers create classrooms where students want to learn and can become the agents of their own thinking and understanding.
In addition to showcasing low prep and high impact tech tools that can support differentiation in the classroom, the Teacher Tailgate will give attendees insight on how to:
- Improve classroom management and engagement across all content areas
- Inspire creativity with Promethean tools that can foster student-centered self-reflection
- Facilitate conversations centered around social-emotional skills with students
For more information on sessions and to register for the Teacher Tailgate, click here.
About Promethean
Promethean is a leading education technology company working to transform the way the world learns and collaborates. From our founding in Blackburn, England, more than 25 years ago to our global operations in 22 countries today, we've continued to explore, innovate, and inspire—designing learning and collaboration tools that are built for breakthroughs. Our award-winning interactive display, ActivPanel, and lesson delivery software, ActivInspire and ClassFlow, were designed to engage students, connect colleagues, and bring out the brilliance in everyone. With headquarters in Seattle, Washington, and offices worldwide, Promethean is a subsidiary of the NetDragon Websoft Holdings Limited (HKSE: 0777) group of companies. Visit us at PrometheanWorld.com.
©2022 Promethean. All Rights Reserved. Promethean, the Promethean logo, ActivPanel, ActivSync, ActivInspire, ActivConnect, ActivSound, ClassFlow, and Vellum are trademarks or registered trademarks of Promethean Limited in the United Kingdom, United States, and other countries around the world. All other product and company names are trademarks or registered trademarks of their respective holders. Unless specifically identified as such, Promethean's use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between Promethean and the owners of these trademarks.
View original content to download multimedia:
SOURCE Promethean | https://www.whsv.com/prnewswire/2022/09/06/promethean-hosts-teacher-tailgate-event-support-teachers-with-their-back-to-school-playbook/ | 2022-09-06T12:59:57Z |
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Rarecells, Inc. today announced the appointment of Dr. Neil Gunn, a recognized leader and expert in the diagnostic space, as an independent Board Director.
"We are delighted to welcome Neil as Board Director. With his broad understanding of diagnostics and the Liquid Biopsy space he is well-positioned to provide valuable perspectives and insight across a broad spectrum of topics, from strategic development to operational expertise and go-to- market potential for our products" said Pr. Patrizia Paterlini-Bréchot, Chairman and Chief Executive Officer of Rarecells, Inc.
"Neil will bring important experience to our Board, from strategic opportunities to business management, leadership, operations and sustainability. His nomination exemplifies Rarecells' commitment to best-in-class corporate governance. We look forward to his contribution to our Board," said Davide Bréchot, Rarecells' Deputy CEO and Secretary.
Dr. Gunn has recognized management experience in both large and small company settings, as well as within the liquid biopsy, sequencing, assay development, and go-to-market strategies. He has served as Chief Executive Officer at IDbyDNA, a metagenomics company acquired by Illumina in June of 2022. Dr. Gunn was the Head of Global Business at Roche Molecular Systems for 7 years followed by the position of President and Head of Roche Sequencing for further 5 years.
Dr. Gunn said "I'm thrilled to be joining the Board of Directors at Rarecells, a highly innovative company in the field of liquid biopsy where such disruptive molecular products will shape the future of predictive oncology. I look forward to contributing to the company's growth, strategic positioning and journey."
Rarecells Inc. is a leading company in the development of innovative non-invasive tests for very Early Cancer Diagnosis based on a proprietary hypersensitive AI-based Circulating Tumor Cells (CTCs) and CTC-DNA detection. Founded in 2012, the firm is headquartered in New York and maintains offices and laboratories in New York and Paris.
Logo: https://mma.prnewswire.com/media/1890062/Rarecells_logo.jpg
View original content to download multimedia:
SOURCE Rarecells, Inc. | https://www.whsv.com/prnewswire/2022/09/06/rarecells-inc-announces-appointment-new-director-board/ | 2022-09-06T13:00:03Z |
First Nordic company to launch a next-generation DEX to trade, swap, pool, win, farm and much more, anywhere in the world
OSLO, Norway, Sept. 6, 2022 /PRNewswire/ -- Reltime is developing and will soon be launching its Decentralised Exchange (DEX), cutting out any middlemen and providing businesses, traders and producers with freedom and attractive benefits through peer-to-peer (P2P) trading, swapping, pooling, winning, and farming of digital assets, commodities, precious metals, and foreign exchange world-wide.
"The Reltime DEX will liberalise and revolutionise the way trade is conducted around the globe," says Peter Michel Heilmann, CEO, Reltime. "Decentralisation is the fundamental principle of Web3 so for us, as a Web3 disruptor, developing a DEX for ourselves and for our partners globally is the most logical step forward. Our Reltime DEX could, for example, be used as a truly easy-to-trade platform for local fairtrade and premium cocoa producers to trade their quality beans directly with buyers on the other side of the plan, without the interference of any intermediaries. A smart contract inside the DEX enabling the transaction is automatically created. We are developing our own blockchain logistics management system that will be connected to the DEX. Reltime's instant smart contract could, for example, be between the seller (e.g. the grower or producer in Africa or Latin America), transporter (e.g. a shipping company), and buyer (e.g. the end user or merchant in Japan). The Reltime DEX is securing the buyer and seller until the goods have been delivered."
Reltime has already received serious interest and requests for its DEX from potential partners based in Europe, Africa, Middle East, Asia, and Latin America.
The Reltime DEX:
- is a one-click solution built on top of Reltime's global Web3 ecosystem and Layer 1, Proof of Authority blockchain;
- is easy to use, offering anyone the opportunity to trade anytime and anywhere;
- is much more trustworthy than a centralised exchange (CEX), which works with intermediaries;
- will be accessible to users from the Reltime App, MetaMask and other wallets;
- will support all EVM-compatible tokens and coins as well as Bitcoin;
- will be multi-lingual and inexpensive to use, since it will not have any internal transaction fees;
- will offerfarming—whereby DEX users can reclaim their funds whenever they wish, along with the "harvest," which the digital asset is earned from farming—swapping, pooling, winning, and earning opportunities.
When it comes to trading, Reltime will be able to secure the best delivery (shipping) solutions and will carry out electronic Know Your Customer—with proprietary eKYC technology, utilising Artificial Intelligence and Machine Learning—and Anti-Money Laundering checks.
Reltime's trusted B2B2C partners will be able to mint or create and list their own token on the DEX, e.g. via an Initial DEX Offering (IDO), and to pair it with other coins. Furthermore, the newly-launched Token Sale Platform, empowered by Reltime, can be used in order to raise capital off the market (e.g. through a pre-IDO). Reltime has its own token, RTC, and stablecoin, RTO (Reltime Oxygen).
As part of Reltime's FastTrack to Web3, B2B2C partners can build their own DEX with products, services, tokens and other tradable assets—with their unique identity (branding, mobile iOS and Android app and frontend), backend, onboarding (eKYC), settings, web domains, language(s), user experience (UX) and interface (UI) as well as monitoring and reporting (e.g. regulatory, customer onboarding, and black/white lists).
About Reltime
Reltime's mission is to liberalise, improve and protect people's lives, finances and assets. Aiming for one hundred million people and businesses to send, receive, withdraw, deposit, borrow, lend, earn, swap, trade, interact and transact on the Metaverses and in the real world by 2025, Reltime also protects people's identity through its global, game-changing Web3 technology.
A disruptive technology company with Nordic trust, honesty and transparency that is changing the game in the new world, Reltime has built the first global Web3 financial ecosystem on top of its Layer 1, Proof of Authority blockchain. Reltime offers cutting-edge, white-labelled B2B2C (FastTrack to Web3), Metaverse and Web3 solutions to trusted partners around the world. Headquartered in Oslo and with subsidiaries in Norway (Conax Technology AS, established in January 2010), Lithuania and El Salvador, Reltime recently secured a USD 50 million investment commitment from GEM Digital Limited.
Download Reltime's 24-page presentation at https://www.reltime.com/pitch/ and white paper 5.0 at https://www.reltime.com/whitepaper/.
#MoreThanMoney
CONTACT:
For any media or investor enquiries, please contact:
Cornelia S. van der Laak, International Relations Officer
Reltime AS
Tel.: +4740769988
cornelia@reltime.com
Peter Michel Heilmann, CEO
Reltime AS
pm@reltime.com
URL: https://www.reltime.com/
Twitter: https://twitter.com/reltime_rtc
Telegram: https://t.me/reltimedefiecosystem
Facebook: https://www.facebook.com/reltimeecosystem
LinkedIn: https://www.linkedin.com/company/reltimedefi
BitMart: https://www.bitmart.com/trade/en?symbol=RTC_USDT
CoinTiger: https://nomics.com/exchanges/cointiger/markets/rtc_usdt
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:
SOURCE Reltime AS | https://www.whsv.com/prnewswire/2022/09/06/reltime-liberalise-global-trade-cut-out-middlemen-with-new-decentralised-exchange-dex/ | 2022-09-06T13:00:10Z |
The brand inked agreements for 180+ franchises and renewed over 215 affiliated offices from April-June 2022
DENVER, Sept. 6, 2022 /PRNewswire/ -- RE/MAX, the global real estate franchisor, today announced over 180 new franchise agreements and over 215 renewals were signed worldwide between April and June 2022. This news comes on the heels of recently announced strategic growth initiatives at both RE/MAX, LLC and RE/MAX Holdings, Inc.
One of those initiatives – a renewed focus on conversions, mergers and acquisitions – is designed to help interested brokerages convert to the RE/MAX network or combine with an existing RE/MAX franchise. That's exactly the path Sal Montoya, Broker/Owner of RE/MAX Anela Realty in Tustin, CA, took when he aligned his brokerage with RE/MAX in June. Having once been an agent with RE/MAX, Montoya says he always wanted to return to the brand as a Broker/Owner.
Citing his agents' enthusiasm for affiliating with the balloon as a major draw, Montoya said, "My agents are happy to transition to RE/MAX because they know it means more opportunities to learn and grow. And for our clients, it means more resources for us to provide to them."
Peter Luft, RE/MAX Vice President of Franchise Sales, is excited about the new brokerages that have recently joined the RE/MAX network. He is looking forward to meeting other entrepreneurs who are drawn to the balloon as new state-of-the-art technology and resources roll out. "RE/MAX has a long-established reputation for delivering results, and our most recent announcements are proofpoints that this legacy is alive and well. The newest offering of MAX/TechSM powered by kvCORE consists of incredible technology that will help affiliates market themselves, generate leads, and automate many aspects of their business. We pride ourselves in helping entrepreneurs be extraordinary at what they do."
RE/MAX has a presence in more countries and territories than any other real estate brand. From a single office that opened in 1973 in Denver, Colorado, RE/MAX has grown into a global real estate network with more than 140,000 sales associates in almost 9,000 offices and a presence in more than 110 countries and territories.
For more information about RE/MAX, LLC, a business that builds businesses, visit remax.com. Each office independently owned and operated.
As one of the leading global real estate franchisors, RE/MAX, LLC is a subsidiary of RE/MAX Holdings (NYSE: RMAX) with more than 140,000 agents in almost 9,000 offices and a presence in more than 110 countries and territories. Nobody in the world sells more real estate than RE/MAX, as measured by residential transaction sides. RE/MAX was founded in 1973 by Dave and Gail Liniger, with an innovative, entrepreneurial culture affording its agents and franchisees the flexibility to operate their businesses with great independence. RE/MAX agents have lived, worked and served in their local communities for decades, raising millions of dollars every year for Children's Miracle Network Hospitals® and other charities. To learn more about RE/MAX, to search home listings or find an agent in your community, please visit www.remax.com. For the latest news about RE/MAX, please visit news.remax.com.
View original content to download multimedia:
SOURCE RE/MAX, LLC | https://www.whsv.com/prnewswire/2022/09/06/remax-reveals-strong-franchise-sales-results-high-retention-q2-2022/ | 2022-09-06T13:00:16Z |
SOUTH SAN FRANCISCO, Calif., Sept. 6, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference at 2:00 p.m. ET on Tuesday, September 13, 2022, in New York, NY.
To access the live and subsequently archived webcast, go to the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.
About Rigel
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe, the United Kingdom (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients.
Rigel's portfolio also includes olutasidenib, an oral, small molecule inhibitor of mutated IDH1 being investigated for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML) and other malignancies. Rigel in-licensed olutasidenib from Forma with exclusive, worldwide rights to develop, manufacture, and commercialize the investigational agent.
Rigel conducted a Phase 3 clinical trial (NCT03764618) evaluating fostamatinib for the treatment of warm autoimmune hemolytic anemia (wAIHA)1. Fostamatinib is also currently being studied in a Phase 3 clinical trial (NCT04629703) for the treatment of hospitalized high-risk patients with COVID-191 and an NIH/NHLBI-sponsored Phase 3 clinical trial (ACTIV-4 Host Tissue Trial, NCT04924660) for the treatment of COVID-19 in hospitalized patients.
Rigel's other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program, and a receptor-interacting serine/threonine-protein kinase (RIPK) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, Rigel has product candidates in development with partners BerGenBio ASA and Daiichi Sankyo.
For further information, visit www.rigel.com or follow us on Twitter or LinkedIn.
Please see http://www.tavalisseuspi.com/ for full Prescribing Information.
- The product for this use or indication is investigational and has not been proven safe or effective by any regulatory authority.
Contact for Investors & Media:
Rigel Pharmaceuticals
Phone: 650.624.1232
Email: ir@rigel.com
View original content to download multimedia:
SOURCE Rigel Pharmaceuticals, Inc. | https://www.whsv.com/prnewswire/2022/09/06/rigel-present-hc-wainwright-24th-annual-global-investment-conference/ | 2022-09-06T13:00:22Z |
Chicago Agency Sought 'Visionary' Partner to Reach More Clients, Take Business to Next Level
OMAHA, Neb., Sept. 6, 2022 /PRNewswire/ -- Senior Market Sales® (SMS), one of the industry's premier insurance marketing organizations, has acquired Medicare Solutions Network, a Lisle, Illinois, Medicare agency known for its engaging educational Medicare workshops and exceptional customer service in the Chicago area.
SMS President Jim Summers praised the success of husband-wife team David H. Wylly, President, Founder and Chief Executive Officer, and Lori L. Wylly, Chief Operations Officer, saying their production numbers outpace companies twice their size or even bigger.
"Their business model centers on doing what's right for the client, and their success is proof that when you do right by the client, your business will thrive," Summers said. "That focus on the customer also makes Medicare Solutions Network a perfect cultural fit with SMS as we grow through strategic acquisitions of companies."
David Wylly said SMS offers infrastructure support that will allow Medicare Solutions Network to focus even more on the client experience.
"We've partnered with a visionary company we believe gives us the best opportunity to help more people and to do more good without compromising our foundation of quality and customer service," Wylly said. "From the beginning, it felt right. Good people, shared mission, common passion."
In the past 15 years, Medicare Solutions Network has set the standard for Medicare health insurance education and customer service that is second-to-none in the Chicagoland area. Its educational workshops on Medicare are so effective and popular that the company cannot keep up with the demand.
"SMS was the first company that came to us with recommendations of how to expand and improve our business. We spoke with other companies who basically said 'whatever you want us to do, we can do' but never brought any ideas or concepts to the table," Wylly said. "We have a strong belief that SMS can help us expand our reach and help the ever-increasing number of folks that continue to come our way every day."
By partnering with SMS, Medicare Solutions Network will be able to leverage SMS' proprietary technology, industry-leading back-office support, proven marketing systems, and top health and wealth carrier product portfolio. Medicare Solutions Network also gains access to resources from Alliant Insurance Services, which acquired SMS in 2020. Alliant's recent organic growth and successful acquisitions enabled it to break into Business Insurance's ranking of the world's 10 largest brokerages for the first time this year, and to move up two spots to No. 8 in the list of largest brokers of U.S. business.
"With Alliant, SMS is able to help Medicare Solutions Network and other companies grow more than they ever envisioned," Summers said. "For companies who share our vision and want to continue to grow, SMS is an exciting place to be."
Senior Market Sales® (SMS) represents top Medicare Supplement, Medicare Advantage, annuity, life, long-term care, and travel insurance carriers in all 50 states. More than 70,000 independent insurance agents rely on SMS for proprietary technology, competitive insurance products, and expert training and service to help them leverage their time, make more money, and put their business in a position of distinction. Founded in 1982, SMS is headquartered in Omaha, Nebraska. In 2020, SMS joined the Alliant Insurance Services family of companies. Visit www.SeniorMarketSales.com or call 1.800.786.5566 for more information.
Alliant Insurance Services is one of the nation's leading distributors of diversified insurance products and services. Alliant operates through a network of specialized national platforms and local offices to offer clients a comprehensive portfolio of solutions built on innovative thinking and personal service. The business of managing risk is getting more complex, and Alliant is meeting this complexity head-on, not with more layers of management, but with more creativity and agility. Alliant is changing the way clients approach risk management and benefits, so they can capitalize on new opportunities to grow and protect their organizations. For more information, visit alliant.com.
Contact:
Dan Trumblee
Assistant Vice President
Divisional Director, Communications & Creative Services, Senior Market Sales®
402.343.3689
Dtrumblee@SeniorMarketSales.com
View original content to download multimedia:
SOURCE Senior Market Sales | https://www.whsv.com/prnewswire/2022/09/06/senior-market-sales-acquires-successful-senior-health-insurance-agency-medicare-solutions-network/ | 2022-09-06T13:00:29Z |
New apprenticeship software, Apprentix, can track and manage multiple programs and expand offerings to even more employees.
DENVER, Sept. 6, 2022 /PRNewswire/ -- Serial entrepreneur Andy Seth is excited to announce his latest initiative, Apprenticeships for All, by way of his two B corporations – Flow and Ravience.
Seth is expanding apprenticeship offerings in Flow, his content marketing business, and Ravience, his customer service business, to entry-level workers and existing managers interested in furthering their careers and skillsets.
The programs will run through Seth's newest startup, Apprentix, an online platform that helps companies create and manage their own apprenticeships. Business owners interested in creating their own apprenticeship program can contact an Apprenticeship Expert here or at support@apprentix.io for a free one-hour consultation.
Apprenticeships at Flow and Ravience are available for positions in Content Marketing and Quality Assurance for entry-level employees and Business Development and Operations for existing employees. All roles are 100% remote and apprentices are paid to learn.
"I want to inspire other modern leaders to take their existing training programs, make some tweaks, and turn them into apprenticeships," says Seth. "There are so many incredible business benefits to implementing this structure – including diversifying your candidate pool, lowering recruiting costs, and developing your employees' skills to your company's exact needs."
Seth developed Apprentix after organically offering apprenticeships in all of his businesses. He always intended on expanding his programs but needed capable software to manage and track their progress. After realizing such a product didn't exist, he set out to code one himself.
Apprentix allows users to design programs from scratch or select one of the 50,000 existing apprenticeships for their own use. Business owners can also designate appropriate wage schedules and register their program with the federal government, if they choose.
"Not everyone can take on debt to go to college, but that doesn't make them less deserving of a good job or less hard-working. In fact, 94% of apprentices continue their employment after graduating. That's something a four-year degree can't guarantee," says Seth.
Apprentix is the only apprenticeship platform that allows organizations to create apprenticeships from scratch and manage them, all in one tool.
Flow is one of the world's leading personal branding agencies and rated top 10% of all B-Corps worldwide. Flow delivers brand strategy, websites, content marketing, and book marketing.
Ravience is a US-based customer experience services company providing online businesses with responsive, affordable, and highly-skilled agents to turn customers into raving fans.
Contact Information:
Olivia Mancuso
Flow Marketing
olivia@feelmeflow.com
View original content to download multimedia:
SOURCE Apprentix | https://www.whsv.com/prnewswire/2022/09/06/serial-entrepreneur-andy-seth-launches-apprenticeships-all-via-new-apprenticeship-software/ | 2022-09-06T13:00:36Z |
Next generation of Smart Omix by Sharecare introduces scalable SaaS-based solution to empower independent researchers, clinicians, and academic institutions to conduct digitally enabled research studies
ATLANTA, Sept. 6, 2022 /PRNewswire/ -- Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced the evolution of Smart Omix by Sharecare, its proprietary digital clinical research solution that enables real-world data collection and digital biomarker creation through mobile research studies. By expanding Smart Omix's capabilities, Sharecare not only broadens the scope of its opportunity in life sciences beyond the point of commercialization but also plays an important role in advancing relevance, equity, and data integrity in clinical research across the healthcare continuum.
Building on Sharecare's work with leading life science companies to conduct decentralized custom research studies, the new intuitive software-as-a-service (SaaS) platform is purpose-built to address technological, economic, and talent barriers to remote observational studies more commonly encountered by members of the research community, in particular underserved independent and academic clinicians and researchers. The web-based Smart Omix platform is a no-code solution that gives researchers the ability to conduct studies independently; enabling them to design, launch, manage, and analyze clinical studies through a simple, easily accessible, self-service interface, and eliminating the need for design and engineering expertise to build and launch their studies.
"Smart Omix is designed for researchers by researchers to make high-quality, rigorous real-world data studies an accessible reality across the field – whether led from within a pharmaceutical company or by a 'citizen scientist' aiming to learn more about a condition," said Zeenia Framroze, Sharecare's vice president of strategy and operations for Smart Omix. "By combining a SaaS model and decentralized research methodologies, Smart Omix presents untapped and exceptional potential to aid in the democratization of research in a digital-first world."
With a tiered, license-based pricing model, Smart Omix enables all researchers – clinicians, academicians, students, and scientists – to implement a cost-effective solution that serves their independent research needs – from prototyping a study for Institutional Review Board approval to the full execution of a clinical study – for any length of time. Within the self-service platform, easy-to-use tools allow researchers to establish and manage processes for electronic informed consent (eConsent) and adherence-based compensation, build and refine study protocols, and gather electronic patient-reported outcomes (ePROs). Studies can be launched with participants through the companion app, Smart Omix by Sharecare – available for download in the App Store and Google Play – which enables researchers to conduct their studies and collect rich real-world data via smartphone.
By decentralizing clinical research, Smart Omix replaces brick-and-mortar trial sites, capitalizing on the efficiency and scalability of digital studies while also addressing socioeconomic barriers to patient and consumer participation such as transportation needs and time away from work. The platform also supports a transparent, user-friendly participant experience that engages individuals as they utilize their own devices to self-report and visualize their data, while allowing them to observe their own health metrics day-to-day and, with their consent, inform their care teams about their health status. To date, leading pharmaceutical and life sciences companies, including UCB, have used Smart Omix to advance relevance, equity, and data integrity in research across various disease states through smartphone-based bespoke studies.
"At UCB, our ambition is to deliver targeted solutions that can improve outcomes for people living with rare conditions, and real-world research – especially in these small patient populations – is critical," said Colin Lake, global head of digital transformation, neurology, at UCB. "We initially commissioned Sharecare to conduct a custom study using Smart Omix on mobile devices to see how we might develop objective symptom measures for people living with myasthenia gravis, a rare neuromuscular disease. We congratulate them on the public release of the full Smart Omix platform."
For more information about conducting research studies with Smart Omix by Sharecare, visit sharecare.com/smartomix.
Sharecare is the leading digital health company that helps people – no matter where they are in their health journey – unify and manage all their health in one place. Our comprehensive and data-driven virtual health platform is designed to help people, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by driving positive behavior change. Driven by our philosophy that we are all together better, at Sharecare, we are committed to supporting each individual through the lens of their personal health and making high-quality care more accessible and affordable for everyone. To learn more, visit www.sharecare.com.
Media Contact:
Sharecare PR Team
PR@sharecare.com
404.665.4305
View original content to download multimedia:
SOURCE Sharecare | https://www.whsv.com/prnewswire/2022/09/06/sharecare-launches-self-service-software-platform-enable-independent-decentralized-clinical-research/ | 2022-09-06T13:00:42Z |
Fastest-growing sparkling water brand in the US introduces a new taste for fall, made with real squeezed apples and cinnamon spice in both Sparkling and Spiked varieties
NEWTON, Mass., Sept. 6, 2022 /PRNewswire/ -- Spindrift®, the delicious sparkling water and hard seltzer brand made with real squeezed fruit, is adding warmth and comfort to its light, bright, and slightly pulpy beverage lineup with the brand's first-ever limited time, seasonal release. Spindrift's seasonal debut of Spiced Apple Cider is lighter and a more real-tasting version of the traditional fall flavor. It's not quite cider, not quite seltzer - it is a category-defying beverage and a completely new taste for Spindrift.
Spindrift challenges the idea that sparkling water and hard seltzer are just summertime beverages. "Fall is an ideal season for Spindrift. It's when the air is crisp, food turns heartier, and when many people return to where they feel the most at home to spend time with loved ones. Spiced Apple Cider pairs perfectly with fall and tastefully accompanies those homecoming moments," said Bill Creelman, founder and CEO of Spindrift.
"Spindrift Spiced Apple Cider is full of flavor, incredibly refreshing and drinkable. We created our version of apple cider because it's a fall-favorite beverage that evokes fond memories but something many may have stopped drinking because of the sugar, calories, and carbs," added Creelman. "With a Spindrift twist, we're giving people a modern alternative to cider – both a non-alcoholic version, and in a hard seltzer with 4% ABV from fermented cane sugar."
Spiced Apple Cider makes history as Spindrift's first limited release, uniquely crafted using real ingredients. "People have such strong associations matching flavors to times of year. That's why we're looking forward to exploring more seasonal offerings in the future. Real ingredients like fruit, grow by season – there is an optimal time for when they are best harvested. When we let nature guide us, the results are always incredible."
Spindrift Spiked Spiced Apple Cider is starting to hit stores now in 8-packs of 12-oz. cans. Each beverage is 97 calories and four percent ABV. The new flavor will be available in select regions and can be found in the hard seltzer section of quality grocery and liquor stores. For more information about Spindrift Spiked and where to buy, visit: www.spindriftspiked.com and follow @spindriftspiked.
Spindrift will launch its Spiced Apple Cider sparkling water in 24-packs available exclusively on its website in early November. Fans of the brand, known as 'Drifters' can also enter to win an 8-pack of the flavor before they can buy it on the company's website. For more information on Spindrift, visit www.drinkspindrift.com and follow @drinkspindrift.
About Spindrift
Spindrift® Beverage Co. is the maker of the first sparkling water made with real, squeezed fruit. Founded in 2010, Spindrift celebrates simplicity, transparency, and the superior taste that only real ingredients can deliver. Spindrift works directly with farms to source the best-tasting fruit for their products. All Spindrift products are free of added sweeteners or natural flavors, made of just sparkling water + real squeezed fruit – yup, that's it. The result is light, bright, and flavor-rich beverages that taste just like the fruit they're made of. Spindrift® sparkling water is available nationwide and new Spindrift® Spiked is available in select markets. The company donates to environmental not-for-profits through their membership to 1% For the Planet. Spindrift is headquartered in Newton, MA.
View original content to download multimedia:
SOURCE Spindrift | https://www.whsv.com/prnewswire/2022/09/06/spindrift-launches-first-ever-seasonal-flavor-spiced-apple-cider/ | 2022-09-06T13:00:49Z |
BLOOMINGTON, Ill., Sept. 6, 2022 /PRNewswire/ -- Today, State Farm announced a $1.2 billion equity investment in ADT Inc. resulting in State Farm owning approximately 15% of ADT after the equity investment and related transactions close. This partnership launches State Farm into a new category, allowing the company to reimagine the homeownership experience and innovate new ways to apply Smart Home technology to home insurance, with customer benefits that may include lowered costs, reduced claims, and smart home security devices that help to proactively mitigate loss caused by water, fire, or intrusion.
For more information, visit the State Farm Newsroom and ADT Newsroom.
About State Farm®:
For 100 years, the mission of State Farm has and continues to be to help people manage the risks of everyday life, recover from the unexpected, and realize their dreams. State Farm and its affiliates are the largest providers of auto and home insurance in the United States. Its 19,400 agents and nearly 55,000 employees serve over 87 million policies and accounts – which includes auto, fire, life, health, commercial policies and financial services accounts. Commercial auto insurance, along with coverage for renters, business owners, boats and motorcycles, is available. State Farm Mutual Automobile Insurance Company is the parent of the State Farm family of companies. State Farm is ranked No. 42 on the 2022 Fortune 500 list of largest companies. For more information, please visit http://www.statefarm.com.
About ADT Inc.:
ADT provides safe, smart and sustainable solutions for people, homes and businesses. Through innovative products, partnerships and the largest network of smart home, security and rooftop solar professionals in the United States, we empower people to protect and connect what matters most. For more information, visit www.adt.com.
View original content to download multimedia:
SOURCE State Farm | https://www.whsv.com/prnewswire/2022/09/06/state-farm-partners-with-adt-innovate-home-insurance-investing-smart-home-technology-helping-customers-prevent-detect-losses/ | 2022-09-06T13:00:56Z |
Extending the age range for children up to 12 years
ORLANDO, Fla., Sept. 6, 2022 /PRNewswire/ -- The Sunshine Flyer released new, lower ticket prices, and now allows children up to 12 years of age to receive the lower child price. By extending the child age range by three years, more families can enjoy Sunshine Flyer's unique and cost-effective transportation experience from Orlando International Airport (MCO) to Walt Disney World® Resorts.
The Sunshine Flyer offers an engaging transportation experience that allows guests to start the magic of their Walt Disney World® vacation from the moment they step off the plane.
The Sunshine Flyer's buses are late model, premium motorcoaches with themes that center around old-fashioned passenger cars and train engines. From the bus designs to staff dressed as 1920's rail conductors and engineers, the motorcoaches effectively serve as time-machines, offering a glimpse into 1920s rail travel.
"We listen to our guests, and we that know that extending the age range for children is very important to them. While we welcome passengers of all ages, we have a special focus on children. From coloring books and conductor hats to on-board video entertainment, the ride from the airport sets the tone for an exciting family vacation," says Tony Glibkowski, Vice President of the Sunshine Flyer.
The Sunshine Flyer is well-equipped for kids, including:
- Three-point harness seat belts at each seat
- Conductor hats for kids
- Stickers for kids
- Coloring/activity books for kids
- On-board video entertainment
When guests book a future trip, they can experience the following ticket prices at checkout:
- $10 per child
- $16 per adult
All Make-A-Wish® children and families receive complimentary service from the Sunshine Flyer for Disney wishes indefinitely.
For more information about the Sunshine Flyer, visit www.sunshineflyer.com.
About The Sunshine Flyer
The Sunshine Flyer is a unique motorcoach bus experience from Transportation Management Services (TMS) that provides seamless transportation for guests from the Orlando International Airport (MCO) to Walt Disney World® Resorts. Offering a convenient and cost-effective mode of transportation, The Sunshine Flyer is the perfect option for families, groups, and individuals looking to start their Disney vacation from the moment they step off the plane. For more information and to book tickets, visit www.sunshineflyer.com.
Media Contact
Ashley La Fleur
(618) 660-6963
343887@email4pr.com
View original content to download multimedia:
SOURCE The Sunshine Flyer | https://www.whsv.com/prnewswire/2022/09/06/sunshine-flyer-announces-new-ticket-prices-kids/ | 2022-09-06T13:01:02Z |
SOUTHFIELD, Mich., Sept. 6, 2022 /PRNewswire/ -- The SyBridge Technologies' Board of Directors is pleased to announce that Byron J. Paul has joined SyBridge Technologies ("SyBridge" or the "Company") as Chief Executive Officer and will also serve as a member of the Board of Directors. Mr. Paul will build upon the Company's strategic vision of becoming a global technological leader in value-added design and manufacturing solutions ranging from design and prototyping to production-as-a-service and aftermarket services for customers. Mr. Paul brings extensive experience in industrial technology and a 20+ year track record of driving profitable growth in complex, global enterprises.
Mr. Paul was most recently Group President at Signode Industrial Group where he led a global portfolio of businesses focused on end-of-line packaging technologies and warehouse automation solutions. He previously served as President of Destaco, a leading designer and manufacturer of precision engineered components for industrial automation and robotics applications. Mr. Paul has also held senior leadership roles at John Crane, a leader in rotating equipment solutions, and at the Boston Consulting Group. Mr. Paul holds an MBA from the Kellogg School of Management at Northwestern University and a Master of Public Administration from Harvard University's Kennedy School of Government. He also attended the University of Western Australia where he earned a Bachelor of Commerce with first class honors in accounting and finance.
Mr. Paul stated, "I am thrilled to be joining a world-class team at SyBridge Technologies. They have done an outstanding job expanding SyBridge Technologies' global reach, growing from three sites in 2019 to 16 locations today. I look forward to partnering with the Board and Crestview Partners as we embark on the next phase of growth to build an unrivaled leader in digital manufacturing."
Jason Luo, Chairman of SyBridge Technologies and Crestview Operating Executive noted, "Byron is a committed leader with a proven track record of successfully growing businesses and we are excited to partner with him as we plan to execute on the Company's next chapter of growth."
Mr. Paul succeeds Tony Nardone who has departed the company to pursue other interests. "We appreciate the many contributions Tony has made to SyBridge and wish him well in his future endeavors," said Mr. Luo.
About SyBridge Technologies
SyBridge Technologies was established in 2019 by Crestview Partners to create a global technology leader that provides value-added design and manufacturing solutions across multiple industries. SyBridge is the combination of 12 acquisitions made to combine different products, services and technologies into a singular technology enabled solution. SyBridge is based in Southfield, Michigan and has 16 locations throughout the United States, Canada and Mexico. For more information, please visit www.sybridgetech.com.
About Crestview Partners
Founded in 2004, Crestview is a value-oriented private equity firm focused on the middle market. The firm is based in New York and manages funds with approximately $10 billion of aggregate capital commitments. The firm is led by a group of partners who have complementary experience and backgrounds in private equity, finance, operations and management. Crestview has senior investment professionals focused on sourcing and managing investments in each of the specialty areas of the firm: industrials, media, and financial services. For more information, please visit us at www.crestview.com
For more information, please contact:
Jeffrey Taufield or Daniel Yunger
Kekst CNC
(212) 521-4800
jeffrey.taufield@kekstcnc.com / daniel.yunger@kekstcnc.com
View original content to download multimedia:
SOURCE SyBridge Technologies & Crestview Partners | https://www.whsv.com/prnewswire/2022/09/06/sybridge-technologies-board-directors-announces-byron-j-paul-ceo/ | 2022-09-06T13:01:09Z |
STAMFORD, Conn., Sept. 6, 2022 /PRNewswire/ -- Synchrony (NYSE: SYF) Chief Financial Officer, Brian J. Wenzel, will participate in a fireside chat at the Barclays Global Financial Services Conference on Monday, September 12, 2022 at 11:15 a.m. (Eastern Time).
A live webcast and replay will be made available on the Synchrony Investor Relations website at www.investors.synchronyfinancial.com.
About Synchrony
Synchrony (NYSE: SYF) is a premier consumer financial services company delivering one of the industry's most complete digitally-enabled product suites. Our experience, expertise and scale encompass a broad spectrum of industries including digital, health and wellness, retail, telecommunications, home, auto, outdoor, pet and more. We have an established and diverse group of national and regional retailers, local merchants, manufacturers, buying groups, industry associations and healthcare service providers, which we refer to as our "partners." We connect our partners and consumers through our dynamic financial ecosystem and provide them with a diverse set of financing solutions and innovative digital capabilities to address their specific needs and deliver seamless, omnichannel experiences. We offer the right financing products to the right customers in their channel of choice.
For more information, visit www.synchrony.com and Twitter: @Synchrony.
Contact:
Investor Relations
Kathryn Miller
(203) 585-6291
Media Relations
Sue Bishop
(203) 585-2802
View original content to download multimedia:
SOURCE Synchrony | https://www.whsv.com/prnewswire/2022/09/06/synchrony-participate-barclays-global-financial-services-conference/ | 2022-09-06T13:01:16Z |
CAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate in-person at the following upcoming investor conferences:
Conference: H.C. Wainwright 24th Annual Global Investment Conference
Date / Time: Tuesday, September 13th, 2022, 12:00pm ET
Format: Company Presentation
Conference: Morgan Stanley 20th Annual Global Healthcare Conference
Date / Time: Wednesday, September 14th, 2022, 3:30pm ET
Format: Fireside Chat
Conference: Cantor Fitzgerald's Oncology, Hematology & HemeOnc Conference
Date / Time: Wednesday, September 28th, 2022, 11:30am ET
Format: Panel Discussion
Live webcasts will be available in the Events section of the company's investor relations website at ir.theseusrx.com and archived for 30 days following the presentations.
Management will also be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Theseus management team should contact their H.C. Wainwright, Morgan Stanley, or Cantor Fitzgerald representatives.
About Theseus Pharmaceuticals, Inc.
Theseus is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is working to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors (TKIs) to target all known classes of cancer-causing and resistance mutations that lead to variants in a particular protein in a given type of cancer. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC). For more information, visit www.theseusrx.com.
Media Contact
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com
Investor Contacts
Christen Baglaneas
Theseus Pharmaceuticals
857-706-4993
christen.baglaneas@theseusrx.com
Josh Rappaport
Stern Investor Relations
212-362-1200
josh.rappaport@sternir.com
View original content:
SOURCE Theseus Pharmaceuticals | https://www.whsv.com/prnewswire/2022/09/06/theseus-pharmaceuticals-participate-upcoming-september-investor-conferences/ | 2022-09-06T13:01:23Z |
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ISEE, FWBI, HYRE, ADT, and RUBY.
To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.
- ISEE: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=ISEE&prnumber=090620221
- FWBI: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=FWBI&prnumber=090620221
- HYRE: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=HYRE&prnumber=090620221
- ADT: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=ADT&prnumber=090620221
- RUBY: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=RUBY&prnumber=090620221
(Note: You may have to copy this link into your browser then press the [ENTER] key.)
InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
View original content to download multimedia:
SOURCE InvestorsObserver | https://www.whsv.com/prnewswire/2022/09/06/thinking-about-buying-stock-iveric-bio-first-wave-biopharma-hyrecar-adt-inc-or-rubius-therapeutics/ | 2022-09-06T13:01:31Z |
MIAMI, Sept. 6, 2022 /PRNewswire/ -- Researchers at ThriveDX announced today a marked uptick in the utilization of cybersecurity awareness programs across all industries in the last year, resulting in a higher level of security at a majority of enterprises. The findings are part of the company's newly released 2022 Global Cybersecurity Awareness Training Study including 1900+ CISOs, security leaders, and IT professionals.
Almost all of the organizations surveyed, a total of 97%, reported implementing some type of cybersecurity awareness training measures this past year, with most now using a combination of both phishing simulations and security awareness training. However, of the 1,900 security professionals surveyed, just 42% reported involving their employees in security detection with the use of such measures as a Phishing Incident Button. It's an important distinction as this type of engagement is known to further security by creating a virtual 'human firewall' and accelerating the reporting of potential threats.
"These statistics tell us two things. The first is that cybersecurity awareness is now reaching its adolescence with almost universal agreement that regular training improves enterprise security in a way that technology alone cannot," said Aaron Bostick, CISO, North America at ThriveDX. "Secondly, these numbers show us that we still have a long way to go to reach maturity and an understanding that the only true way to mitigate modern cyber risks is by positively changing employee behavior and building positive security cultures within our companies."
65% of IT professionals surveyed did agree that their cybersecurity awareness training programs need expansion, and no one indicated a desire to reduce their current engagement.
The results of employee awareness efforts were impressive across the board with 19% reporting better awareness; 14% greater vigilance; 12% said they increased their human firewall; and 99% reporting an increase in corporate security. Ninety-six percent also noted a positive influence on their enterprise's overall working atmosphere. Survey participants reported that the most important success factors were training course duration, an entertaining nature, customization, and individualization.
"This really validates the human-centric approach that we take towards security awareness," Roy Zur, CEO of ThriveDX for Enterprise, said. "Involving employees, offering end-to-end customized security training 'beyond awareness', and gaining employees' commitment to security is the number one way to mitigate cyber risk."
Other key findings:
- Currently, the most popular training topics are courses on phishing and malware, password security, email security, social engineering and ransomware.
- 72% refrain from pre-announcing phishing campaigns to employees
- The biggest challenges cited in implementing awareness programs were achieving user acceptance (25%), workload and resources (22%) and program execution (14%)
- The use of mission statements, policies, guidelines, metrics and systematic training is increasing with 58% of respondents reporting some form of security awareness regulations in place.
The full 2022 Global Cybersecurity Awareness Training Study is available here.
ThriveDX's enterprise solutions specialize in the human side of cybersecurity, offering end-to-end cybersecurity training and talent solutions. Our team is comprised of military-trained cyber experts, industry veterans, and educators united under the mission of closing the worldwide skills and talent gap in cybersecurity. The ThriveDX enterprise suite was born out of the formation of best-in-class cyber companies: Cybint Solutions (Cybersecurity Professional Bootcamp), Kontra Application Security (Application Security Training), Lucy Security (Security Awareness Training + Phishing), ThriveDX Labs (Managed Cybersecurity Services), and HackerU Pro (Custom Training with an Expert Instructor). Learn more here: ThriveDX for Enterprise.
Follow ThriveDX for Enterprise:
LinkedIn: http://linkedin.com/company/thrivedx-enterprise/
Twitter: http://twitter.com/TDX_Enterprise
Facebook: http://facebook.com/thrivedxenterprise
View original content to download multimedia:
SOURCE ThriveDX | https://www.whsv.com/prnewswire/2022/09/06/thrivedx-2022-global-cybersecurity-awareness-training-study-shows-an-increased-maturity-awareness-programs-higher-level-security-most-companies/ | 2022-09-06T13:01:40Z |
CORAL GABLES, Fla. and AUSTIN, Texas, Sept. 6, 2022 /PRNewswire/ -- Trivest Partners (Miami, FL) and LP First Capital (Austin, TX) announced today the formation of OpenRoad, a family of leading brands within the collision repair industry. The announcement comes in combination with the acquisitions of four well-known collision repair centers including Car Crafters (Albuquerque, NM), Drury and Moss Body Shop (Amarillo, TX), 1st Choice Collision (Houston, TX), and Helotes Collision (Helotes, TX). Combined, the OpenRoad family of brands now operates 12 collision repair centers located across the Southwest.
OpenRoad's initial investment was Car Crafters, the largest independent collision repair center in the state of New Mexico. Across its five locations in Albuquerque and Rio Rancho, Car Crafters maintains strong relationships with all major insurance carriers and repairs more automobiles than any other shop in the state. Car Crafters is led by industry veterans Jim and Sean Guthrie, who will remain with the shop and continue to lead strategic and operational initiatives.
"For more than 40 years, Car Crafters has been known for quality repairs, excellent technician training, superior employee benefits, and stellar shop culture. Partnering with Trivest and LP First Capital will allow us to build upon this reputation, and their collective financial, operating, and strategic resources will enable us to expand across the greater Southwest while maintaining the Car Crafters culture and commitment to quality," said Jim Guthrie, Founder of Car Crafters and OpenRoad Chairman.
Led by industry veteran Tom Csekme, who will serve as Chief Executive Officer, OpenRoad is currently pursuing strategic acquisitions of leading collision repair centers across the United States.
"The collision repair industry remains highly fragmented despite recent consolidation efforts by a few large industry players. We look forward to expanding the OpenRoad initiative by partnering with shop owners who desire to preserve their shop's brand name and legacy, while not sacrificing repair quality or employee engagement," said Logan Lowery, Vice President at LP First Capital.
"OpenRoad is perfectly aligned with Trivest's strategy to partner with growing founder and family-owned businesses in fragmented markets. We believe we can leverage our experience in the automotive aftermarket space and with other buy and build success stories to help OpenRoad become one of the largest players in the collision repair industry," added Reid Callaway, Principal at Trivest.
To learn more about OpenRoad, please visit OpenRoadCollision.com
OpenRoad partners with and invests in leading collision repair centers across the United States. OpenRoad believes that quality repairs, excellent technician training, shop culture and a passionate employee base are the gears that create a best-in-class collision center. OpenRoad is currently pursuing additional acquisitions of leading collision repair centers across the United States. openroadcollision.com
Trivest Partners, with offices in Miami, Charlotte, Chicago, Los Angeles, Philadelphia, and Toronto, is a private investment firm that focuses exclusively on the support and growth of founder-led and family-owned businesses in the U.S. and Canada, in both control and non-control transactions. Since its founding in 1981, Trivest has completed more than 400 investments, totaling approximately $7 billion in value. The firm has roughly $4 billion in assets under management, with a growing team of over 60 professionals. Trivest is one of only 15 firms recognized by Inc. Magazine as one of the top founder-friendly private equity firms in three consecutive years. trivest.com
LP First Capital is a private investment firm with experience creating super-regional and national platforms by leveraging its expertise in mergers & acquisitions, profit center integration, and team building to drive performance. Headquartered in Austin, TX, LP First Capital maintains an active presence in much of the Southwest, Southeast, and Midwest markets as it continues to take interest in building best-in-class businesses within traditionally fragmented industries. lpfirstcapital.com
Contact: Tom Csekme; tom@openroadcollision.com
View original content:
SOURCE LP First Capital | https://www.whsv.com/prnewswire/2022/09/06/trivest-partners-amp-lp-first-capital-announce-formation-openroad-family-collision-repair-center-brands/ | 2022-09-06T13:01:48Z |
CHARLOTTE, N.C., Sept. 6, 2022 Truist Insurance Holdings, Inc., a subsidiary of Truist Financial Corporation (NYSE: TFC) and the sixth-largest insurance brokerage in the U.S., announced today that it has signed a definitive agreement to acquire BankDirect Capital Finance, a nationwide premium finance company, from Texas Capital Bancshares, Inc. (NASDAQ: TCBI).
After the closing, BankDirect will operate as a division of AFCO Credit Corporation, Truist Insurance Holdings' existing premium finance operation in the U.S.
The transaction will add over $3 billion in loans to Truist Insurance Holdings' premium finance business—which also includes CAFO Inc., its Canadian operation—while broadening its business into the life insurance arena. The transaction is expected to close in the fourth quarter of 2022, subject to satisfaction of customary closing conditions.
"This strategic investment increases the breadth of our insurance capabilities and demonstrates our continued commitment to the growth of Truist Insurance Holdings," said Truist Chairman and CEO Bill Rogers. "The addition of BankDirect expands our team, further diversifies the risk management solutions we can provide our clients and creates new opportunities to fulfill our purpose to inspire and build better lives and communities."
BankDirect Capital Finance was founded in 2005 and has grown through four acquisitions in the past 17 years. The company has a balanced portfolio of both property & casualty and life insurance products across a diversified national geographic footprint. With 122 employees, BankDirect operates in five offices across the U.S.
"BankDirect brings a strong track record of growth and success in the premium finance business, much like what we've achieved with our AFCO and CAFO organizations," said Truist Chief Insurance Officer John Howard. "With this acquisition, we'll extend our business into life insurance, a growing market for premium finance, as well as broaden our geographic reach, particularly on the West Coast. BankDirect's focus on technology and digitization to enhance client experience also mirrors our strategic initiatives at Truist Insurance Holdings, further demonstrating how well our operations are aligned. All in all, this is a key acquisition for our premium finance business, and we're excited to welcome BankDirect clients and employees to Truist."
RBC Capital Markets and Truist Securities served as financial advisors, and Willkie Farr & Gallagher LLP served as legal counsel to Truist Insurance Holdings in this transaction. Morgan Stanley & Co. LLC and Texas Capital Securities served as financial advisors, and Cravath, Swaine & Moore served as legal counsel to Texas Capital Bancshares in this transaction.
About Truist Insurance Holdings
Truist Insurance Holdings, Inc., the sixth-largest insurance broker in the U.S. and seventh-largest in the world, is a subsidiary of Truist Financial Corporation (NYSE: TFC). Headquartered in Charlotte, NC, Truist Insurance Holdings operates more than 240 offices through its subsidiaries: McGriff Insurance Services, Inc.; CRC Insurance Services, Inc.; Crump Life Insurance Services, Inc.; AmRisc, LLC; and its Insurance Services companies (AFCO Credit Corporation, CAFO Inc., and Kensington Vanguard Land Services, LLC). To learn more, visit www.truistinsurance.com.
About AFCO
As a pioneering leader in premium finance for more than 65 years, AFCO Credit Corporation works with insurance agents to provide customized premium finance solutions to insureds, with the objective of improving cash flow and working capital. AFCO is transforming its business to a digitized, dual premium collection and financing product powered by new digital portals designed to simplify the way its clients do premium financing and to improve the overall client experience.
Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the financial condition, results of operations, business plans and future performance of Truist Financial Corporation or its subsidiaries (collectively, "Truist"). Words such as "anticipates," "believes," "estimates," "expects," "forecasts," "intends," "opportunity," "plans," "projects," "could," "may," "should," "will" or other similar words or expressions are intended to identify these forward-looking statements. These forward-looking statements are based on Truist's current expectations and assumptions regarding Truist's businesses, the economy, and other future conditions. Because forward-looking statements relate to future results and occurrences, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Many possible events or factors could affect Truist's future financial results and performance and could cause actual results or performance to differ materially from anticipated results or performance. Except to the extent required by applicable law or regulation, Truist disclaims any obligation to update such factors or to publicly announce the results of any revisions to any of the forward-looking statements included herein to reflect future events or developments. Further information regarding Truist and factors which could affect the forward-looking statements contained herein can be found in Truist's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as updated by its Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.
View original content:
SOURCE Truist Financial Corporation | https://www.whsv.com/prnewswire/2022/09/06/truist-insurance-holdings-further-enhances-premium-finance-business-with-acquisition-bankdirect-capital-finance/ | 2022-09-06T13:01:54Z |
TALLAHASSEE, Fla., Sept. 6, 2022 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced planned participation in upcoming conferences and events in September.
- 3rd Annual Needham Virtual Cannabis Conference, September 7, 2022: Founder and CEO Kim Rivers will participate in a fireside chat and investor meetings.
- Benzinga Cannabis Capital Conference, September 13, 2022: Founder and CEO Kim Rivers will give a keynote speech.
- Wolfe Research Fall Consumer Conference, September 22, 2022: Founder and CEO Kim Rivers will participate in a fireside chat and investor meetings.
Information about our events, links to events where available, and slide presentations can be found at: https://investors.trulieve.com/events-presentations
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established hubs in the Northeast, Southeast, and Southwest, anchored by leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.
Facebook: @Trulieve
Instagram: @Trulieve_
Twitter: @Trulieve
Investor Contact
Christine Hersey, Executive Director of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
Media Contact
Rob Kremer, Executive Director of Corporate Communications
+1 (404) 218-3077
Robert.Kremer@Trulieve.com
View original content to download multimedia:
SOURCE Trulieve Cannabis Corp. | https://www.whsv.com/prnewswire/2022/09/06/trulieve-announces-september-2022-event-participation/ | 2022-09-06T13:02:01Z |
WATSONVILLE, Calif., Sept. 6, 2022 /PRNewswire/ -- The MILPA Collective releases "Truth Telling and Palabra: A Project at Rikers Island," a report that memorializes a transformative project that brought safety, stability, and healing to incarcerated young people [ages 18-21] and correctional staff at the RNDC jail at Rikers Island in Queens, New York.
From June 2021 through January 2022, at the request of Commissioner Vincent Schiraldi, MILPA and a team of expert consultants led a project at Rikers Island to stabilize conditions for incarcerated young adults and frontline staff. Like most jurisdictions across the country, rates of violence are nine times higher among young adults than any other group, making a focus on young adults key to stabilizing conditions agency-wide.
The MILPA approach of working in community and carceral settings across the U.S via the leadership of formerly incarcerated Chicano Indigenous and Black relatives uniquely positioned them to guide this project. "Our work wasn't about flooding Rikers with more programs. Our work was about making systemic change. Organizing with those who live and work inside, to challenge the systemic racism and toxic culture that sustains the status quo at Rikers," says Juan Gomez, Executive Director of MILPA. "And while we always try to balance urgency with the process, at Rikers, we had to treat every day like a war zone with a disaster relief mission."
In just seven months MILPA led a team of expert consultants and accomplished the following:
- Completed a participatory planning process in partnership with frontline staff and incarcerated young adults
- Designed a new model of jail operations for young adults
- Opened four transformed pilot living units using the new operations model
- Trained upwards of 50 correctional staff to work in the units
- Facilitated healing-engaged workshops
- Crafted a new antiracist policy to codify the new model with an eye toward scale.
Planning and preparation began in June 2021, and on November 1st the first pilot units opened, with the second two opening in mid-December 2021. From then through January 2022, only one fight occurred, while the other RNDC units experienced a total of 47 stabbings and slashings during the same period. Using a unique combination of facility-based organizing tactics, a participatory planning process, and a disaster relief approach, the team built an "inside" coalition of Black and Chicano Indigenous frontline staff and incarcerated people aligned in purpose, process, and hope for the future.
In January 2022, the project ended when Commissioner Schiraldi and his administration were ousted by the incoming Mayor. "While this story has an equivocal ending, the report has been written to memorialize the heart and hard work that staff and incarcerated people put into making this vision a reality while reflecting on its implications for the field."
You can access the full report, "Truth Telling and Palabra: A Project at Rikers Island," here and the Executive Summary here.
About MILPA: MILPA is a non-profit organization that is founded and led by formerly incarcerated Chicano Indigenous people. MILPA is a movement space dedicated to Cultivating Change Makers for The Next Seven Generations. For more, visit milpacollective.org
MEDIA CONTACT:
Dayanna Macias- Carlos
Email: pressoffice@milpacollective.org
Phone: (559)289-9885
View original content to download multimedia:
SOURCE MILPA Collective | https://www.whsv.com/prnewswire/2022/09/06/truth-telling-palabra-project-rikers-island-report-released-by-milpa-collective/ | 2022-09-06T13:02:07Z |
Grant supports study of expanded HyBryte™ treatment, including in the Home Use Setting
PRINCETON, N.J., Sept. 6, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has awarded an Orphan Products Development grant to support the evaluation of HyBryte™ (synthetic hypericin) for expanded treatment in patients with early-stage CTCL. The grant, totaling $2.6 million over 4 years, was awarded to a prestigious academic institution that was a leading enroller in the recently published positive Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study in the treatment of early stage cutaneous T-cell lymphoma (CTCL).
"We are pleased the FDA is supporting the HyBryte™ program and giving patients an opportunity to access the therapy in an open-label setting," stated Christopher J. Schaber, President and CEO of Soligenix, Inc. "CTCL is an incredibly difficult to treat orphan disease and remains an area of unmet medical need with a very limited number of safe and effective treatment options. The Phase 3 results provide the basis for our upcoming marketing application and this study will serve to embark on potential home-use of the therapy, augment the safety database as well as provide further real-world evidence into the practical use of HyBryte™ once commercially available."
The clinical study RW-HPN-MF-01, "Assessment of Treatment with Visible Light Activated Synthetic Hypericin Ointment in Mycosis Fungoides Patients" is designed as an open-label, multicenter clinical trial enrolling approximately 50 patients at up to six of the highest enrolling clinical centers that participated in the Phase 3 FLASH study. Patients have the potential to be treated for up to 12 months with twice a week dosing (visible light activation to follow ointment application by 24 ± 6 hours). The primary endpoint for the study will be evaluating the number of treatment successes defined as ≥50% reduction in the cumulative CAILS (Composite Assessment of Index Lesion Severity) score from baseline to end of the treatment. Study initiation is planned for the fourth quarter of 2022.
About HyBryte™
HyBryte™ (research name SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by visible light 16 to 24 hours later. The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. This treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging drugs and other phototherapy that are dependent on ultraviolet exposure. Combined with photoactivation, hypericin has demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients. In a published Phase 2 clinical study in CTCL, patients experienced a statistically significant (p=0.04) improvement with topical hypericin treatment whereas the placebo was ineffective. HyBryte™ has received orphan drug and fast track designations from the FDA, as well as orphan designation from the European Medicines Agency (EMA).
The recently published Phase 3 FLASH trial enrolled a total of 169 patients (166 evaluable) with Stage IA, IB or IIA CTCL. The trial consisted of three treatment cycles. Treatments were administered twice weekly for the first 6 weeks and treatment response was determined at the end of the 8th week of each cycle. In the first double-blind treatment cycle, 116 patients received HyBryte™ treatment (0.25% synthetic hypericin) and 50 received placebo treatment of their index lesions. A total of 16% of the patients receiving HyBryte™ achieved at least a 50% reduction in their lesions (graded using a standard measurement of dermatologic lesions, the CAILS score) compared to only 4% of patients in the placebo group at 8 weeks (p=0.04) during the first treatment cycle (primary endpoint). HyBryte™ treatment in the first cycle was safe and well tolerated.
In the second open-label treatment cycle (Cycle 2), all patients received HyBryte™ treatment of their index lesions. Evaluation of 155 patients in this cycle (110 receiving 12 weeks of HyBryte™ treatment and 45 receiving 6 weeks of placebo treatment followed by 6 weeks of HyBryte™ treatment), demonstrated that the response rate among the 12-week treatment group was 40% (p<0.0001 vs the placebo treatment rate in Cycle 1). Comparison of the 12-week and 6-week treatment groups also revealed a statistically significant improvement (p<0.0001) between the two groups, indicating that continued treatment results in better outcomes. HyBryte™ continued to be safe and well tolerated. Additional analyses also indicated that HyBryte™ is equally effective in treating both plaque (response 42%, p<0.0001 relative to placebo treatment in Cycle 1) and patch (response 37%, p=0.0009 relative to placebo treatment in Cycle 1) lesions of CTCL, a particularly relevant finding given the historical difficulty in treating plaque lesions in particular.
The third (optional) treatment cycle (Cycle 3) was focused on safety and all patients could elect to receive HyBryte™ treatment of all their lesions. Of note, 66% of patients elected to continue with this optional compassionate use / safety cycle of the study. Of the subset of patients that received HyBryte™ throughout all 3 cycles of treatment, 49% of them demonstrated a positive treatment response (p<0.0001 vs patients receiving placebo in Cycle 1). Moreover, in a subset of patients evaluated in this cycle, it was demonstrated that HyBryte™ is not systemically available, consistent with the general safety of this topical product observed to date. At the end of Cycle 3, HyBryte™ continued to be well tolerated despite extended and increased use of the product to treat multiple lesions.
Overall safety of HyBryte™ is a critical attribute of this treatment and was monitored throughout the three treatment cycles (Cycles 1, 2 and 3) and the 6-month follow-up period. HyBryte's™ mechanism of action is not associated with DNA damage, making it a safer alternative than currently available therapies, all of which are associated with significant and sometimes fatal, side effects. Predominantly these include the risk of melanoma and other malignancies, as well as the risk of significant skin damage and premature skin aging. Currently available treatments are only approved in the context of previous treatment failure with other modalities and there is no approved front-line therapy available. Within this landscape, treatment of CTCL is strongly motivated by the safety risk of each product. HyBryte™ potentially represents the safest available efficacious treatment for CTCL. With no systemic absorption, a compound that is not mutagenic and a light source that is not carcinogenic, there is no evidence to date of any potential safety issues.
The Phase 3 CTCL clinical study was partially funded by the National Cancer Institute via a Phase II SBIR grant (#1R44CA210848-01A1) awarded to Soligenix, Inc.
About Cutaneous T-Cell Lymphoma (CTCL)
CTCL is a class of non-Hodgkin's lymphoma (NHL), a type of cancer of the white blood cells that are an integral part of the immune system. Unlike most NHLs which generally involve B-cell lymphocytes (involved in producing antibodies), CTCL is caused by an expansion of malignant T-cell lymphocytes (involved in cell-mediated immunity) normally programmed to migrate to the skin. These malignant cells migrate to the skin where they form various lesions, typically beginning as patches and may progress to raised plaques and tumors. Mortality is related to the stage of CTCL, with median survival generally ranging from about 12 years in the early stages to only 2.5 years when the disease has advanced. There is currently no cure for CTCL. Typically, CTCL lesions are treated and regress but usually return either in the same part of the body or in new areas.
CTCL constitutes a rare group of NHLs, occurring in about 4% of the approximate 700,000 individuals living with the disease. It is estimated, based upon review of historic published studies and reports and an interpolation of data on the incidence of CTCL that it affects over 25,000 individuals in the U.S., with approximately 3,000 new cases seen annually.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Development programs in this business segment also include our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203).
Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, and SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease, and our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.
This press release may contain forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, such as experienced with the COVID-19 outbreak. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that a marketing authorization from the FDA or EMA will be successful. Further, there can be no assurance that RiVax® will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax®. Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
View original content to download multimedia:
SOURCE Soligenix, Inc. | https://www.whsv.com/prnewswire/2022/09/06/us-food-drug-administration-awards-26-million-orphan-products-development-grant-expanded-study-hybryte-treatment-cutaneous-t-cell-lymphoma/ | 2022-09-06T13:02:13Z |
SAN JOSE, Calif., Sept. 6, 2022 /PRNewswire/ -- Whatfix today announced that it has been named a Leader for the third consecutive year in the Digital Adoption Platform (DAP) PEAK Matrix® Assessment 2022 released by Everest Group, a global research and analyst firm.
Despite an influx of new players entering the space, Whatfix was one of only two designated as a Leader, and saw a sharp improvement in its overall analytics offerings from the 2021 assessment. Whatfix also noted a strengthened position in the PEAK Matrix® from 2021, and a more distinct differentiation from competitors, especially on industry verticalization.
"We're excited to be recognized again as a Leader among digital adoption platforms," said Khadim Batti, CEO and co-founder, Whatfix. "Consistency and sustained excellence are baseline targets for Whatfix. We look forward to maintaining our leadership position by continuing to pursue technical excellence combined with relentless customer focus."
Everest Group highlighted Whatfix's ability to deliver scalable success for its clients by removing barriers between users and productivity. They lauded Whatfix's extensive partner ecosystem that spans across independent software vendors, system integrators and technology, analytics & AI vendors. Further, the report mentions personalized recommendations, automated testing, easy content creation & maintenance and flexible content delivery as some of Whatfix's key strengths. Everest Group also recognized the company's investment in its product analytics capabilities during the last year, which allows enterprises to track application utilization and recognize drop-offs, before or without creating any DAP content. This helps further drive adoption and efficiency by measuring gaps at an enterprise level.
"Whatfix is positioned as a Leader in the DAP Products PEAK Matrix® Assessment 2022, as a result of its investments in product capabilities and sustained market growth. It has deepened its capabilities in industry-specific solutions, element detection, product analytics, and support for mobile and desktop applications. Whatfix's strong roadmap and focus on innovation and customer experience places it well to serve the DAP buyers," said Sharath Hari N, Practice Director at Everest Group.
Everest Group's PEAK Matrix® is a proprietary framework used to assess the market impact and overall vision & capability of technology vendors. For the 2022 report, Everest Group evaluated 20 digital adoption platform (DAP) software providers.
"Whatfix does what all the competitors can but with better training, customer service, and price," said Brandon Copeland, Senior Director of Product Design at GlobalTranz, a leading provider of technology-driven transportation and supply chain management solutions. "Whatfix can do what the others cannot. The ability to utilize intelligent segmentation and the ability to have the walkthrough in multiple formats was a game changer for us. The training team is always available to help and very friendly."
Everest Group is a research firm focused on strategic IT, business services, and engineering services. Everest Group's PEAK Matrix® is compiled annually to provide the analysis and insights enterprises need to make critical selection decisions about global services providers, locations, and products and solutions within various market segments.
A complimentary custom copy of the report can be downloaded here.
Whatfix empowers anyone, anywhere to have scalable success with technology they use everyday, achieving greater knowledge, expanding capability, and unlocking productivity for themselves and their organizations. Whatfix's Digital Adoption Platform (DAP) integrates seamlessly with applications to enable users, providing in-context information and guidance to immediately increase individual capability and collectively amplify productivity. The organization has six offices globally in the US, India, UK, Germany, and Australia, and works with Fortune 500 companies around the world. Whatfix has raised $140 million to date, and is backed by marquee investors including Softbank Vision Fund 2, Sequoia Capital India, and Cisco Investments. For more information, visit Whatfix's website.
Media contact:
Dex Polizzi
Lumina Communications for Whatfix
Whatfix@luminapr.com
View original content to download multimedia:
SOURCE Whatfix | https://www.whsv.com/prnewswire/2022/09/06/whatfix-named-category-leader-third-consecutive-year-digital-adoption-platform-dap-peak-matrix-assessment-2022-by-everest-group/ | 2022-09-06T13:02:19Z |
Ground-breaking partnership set to deliver a new standard of multi-disciplinary care for back, neck, hip, knee, shoulder pain, and more.
NASHVILLE, Tenn., Sept. 6, 2022 /PRNewswire/ -- WholeHealth Living, Inc. (formerly known as WholeHealth Networks, Inc.) a Tivity Health® company, has secured an agreement with Vori Health®, an award-winning, nationwide innovative medical practice focused on whole-person musculoskeletal care, to power a revolutionary and comprehensive pain management solution.
More than half of the U.S. population, ages 18 and over, reports having a musculoskeletal condition, with at least 33% of people requiring or seeking medical care. Low back and neck pain account for the highest amount of health care spending, with an estimated $134.5 billion in annual costs, of which 33.7% is paid by Medicare and Medicaid.
To address these growing problems, the collaborative pain management solution will provide the millions of Americans suffering from muscle and joint pain with both convenient access to appropriate, world-class medical care as well as a full-suite of preventive and rehabilitative services.
"The current musculoskeletal patient pathway is often costly and ineffective, and these challenges are compounded by inflation and rising healthcare costs," said Richard Ashworth, president and CEO, Tivity Health. "We expect this industry-leading pain care solution to drive down inappropriate opiate utilization, surgery, imaging, ER steerage, injections, and total costs of care. Our ultimate goal is to help members reach their goals, reduce their pain, and return to a life they love without unnecessary procedures or costs."
According to the World Health Organization, musculoskeletal conditions significantly limit mobility and dexterity, leading to early retirement from work, lower levels of well-being and reduced ability to participate in society.
"When we created Vori Health, we wanted to revolutionize musculoskeletal care by surrounding a patient with a dedicated team who puts the patient first," said Ryan Grant, M.D., founder and CEO, Vori Health. "The right care given at the right time by the right clinical experts is critical to providing patients with access to appropriate, evidence-based care that minimizes the rate of unnecessary surgeries, poor outcomes, and patient dissatisfaction."
The partnership's effective end-to-end solution integrates Vori Health's nationwide virtual-first medical services for musculoskeletal care and pain management with WholeHealth Living's on-the-ground network of chiropractic, acupuncture, and massage therapy practitioners. Each patient receives support from a Vori Health care team, which includes a non-operative physical medicine physician, a health coach navigator, and a physical therapist who work collaboratively to assess, diagnose, and coordinate all aspects of care. In addition to leveraging WholeHealth Living's ecosystem of practitioners, Tivity Health offers eligible SilverSneakers members the opportunity to engage in movement therapy via fitness centers, community classes and online social platforms.
When people with musculoskeletal (MSK) pain seek health care, they often receive treatment not aligned with best practices, including initial management options such as opioids. Inadequate care for MSK pain conditions can have tremendous societal consequences leading to decreased quality of life and increased costs. It is the primary reason for 1 in 8 persons reporting lost workdays due to MSK pain conditions and direct costs equate $796.3 billion dollars annually. WholeHealth Networks and Vori Health's partnership will transform the delivery of musculoskeletal care in a choreographed, calibrated fashion, ensuring that patients benefit from a higher quality, lower cost of care.
At WholeHealth Living®, Inc. we promote nonpharmacologic options earlier in the care continuum because they are less invasive and can be less expensive. Also, they typically pose a lower risk than drugs or surgery and can help reduce opioid use. We recognize that musculoskeletal conditions are a major contributor to medical spend, and we are committed to bridging the gap between members, practitioners, health plans, and the broader medical community to increase the understanding and acceptance of physical medicine and integrative health solutions. We partner with regional and national health plans, managing benefits for Medicaid, Commercial, and Medicare members spanning a variety of specialties that include chiropractic, acupuncture, physical therapy, occupational therapy, therapeutic massage, and naturopathy.
Tivity Health®, Inc. is a leading provider of healthy life-changing solutions, including SilverSneakers® and Prime® Fitness. We help adults improve their health and support them on life's journey by providing access to in-person and virtual physical activity, social, and mental enrichment programs. We continue to enhance the way we direct members along their journey to better health by delivering an insights-driven, personalized, interactive experience. Our suite of services support health plans nationwide as they seek to reduce costs and improve health outcomes. At Tivity Health, we deliver the resources members need to live healthier, happier, more connected lives. Learn more at www.tivityhealth.com
Vori Health® is an all-inclusive medical and health provider practicing a holistic, integrated approach to musculoskeletal care. The organization offers full-service physical medicine and rehabilitation care, physical therapy, prescriptions, imaging & lab ordering, health coaching, nutritional guidance, community support, and premium instructional content. The Vori Health team consists of carefully selected, board-certified physicians and licensed healthcare providers, and provides health services that are accessible at the click of a button from the comfort, convenience, and privacy of a patient's home. Learn more at www.vorihealth.com.
Media Contacts:
Jill Meyer (Tivity Health), Jill.Meyer@TivityHealth.com
Carrie McCulloch (Vori Health), pr@vorihealth.com
View original content to download multimedia:
SOURCE Tivity Health, Inc. | https://www.whsv.com/prnewswire/2022/09/06/wholehealth-living-partner-with-vori-health-provide-industry-leading-musculoskeletal-solution/ | 2022-09-06T13:02:25Z |
Konishiki Yasokichi, born Saleva'a Fuauli Atisano'e is a Hawaii-raised, American former sumo wrestler. He explained that, “Sumo is bigger than anybody, sumo becomes your life. Sumo is 24/7, 365 days and if you do it for 16 years, it's your life...period.”
He describes being a part of the sport as, “100% committed. Because once you join the world of sumo, you are sumo.”
On June 18, 1982, Konishiki left Hawaii to become a sumotori. “Let’s go back 40 years because where I’m sitting right now...that’s where I started my career...40 years ago, a place called Nagoya.” From staying in temples to sleeping on the floor he shared, “I was lucky to have the mentality of a crazy Waianae boy, Nanakuli boy. I had no way to explain what I was getting myself into... because I knew nothing about the sport.”
Konishiki’s advice is, “It’s a matter of committing. Once you get the courage to commit, you can conquer. That’s the three C’s I always tell the kids... have courage to commit. Once you commit, you can conquer. It’s all or nothing.”
The sport of sumo has a rich history. Konishiki shared, “I think sumo was the first contact sport ever. It’s very hard for anybody to picture it because it’s not normal...but that’s the part a lot of people don’t understand...is sumo is mixed martial arts...it’s a mix of Aikido, Karate, Judo, and wrestling.”
In celebration of his 40th Anniversary, Konishiki feels it's important to show his gratitude. “Part of our Polynesian culture is to give back and be thankful for all the support...that’s the biggest reason why I’m doing this 40th anniversary. It’s a kind of Japanese thing too... It’s the respect that we have for each other.”
Throughout his years, Konishiki has seen the culture of sumo grow. “When I joined sumo, sumo is a cool culture. Your life actually kind of changes for the best. There’s so much interest in sumo that it’s crazy. On the world level, sumo’s just gonna get big.”
This segment was aired in conjunction with The Giants documentary on KITV and KIKU. The Giants is a three-part documentary chronicling the rise of Hawaiians/Samoans Konishiki, Akebono and Musashimaru to the top two ranks of ozeki and yokozuna in the world of sumo wrestling in Japan.
Interested in featuring your business or organization? Email IslandLife@kitv.com
As Miss Hawaii 2019 & 2020, Nikki was a representative for the Aloha State and was highly involved with the community as she promoted the importance of service. Nikki is the host of KITV's entertainment and culture platform, ISLAND LIFE. | https://www.kitv.com/island-life/konishiki-celebrates-the-40th-anniversary-of-his-sumo-legacy/article_f6bd88a0-28ab-11ed-ae3d-5f35fa46488a.html | 2022-09-06T13:09:48Z |
MICHEL MARTIN, HOST:
If you love fashion, as many of us do, then you know September is a big month. It's when New York, London, Paris and Milan hold their fashion weeks, where designers show off their upcoming collections. And that's when fashion magazines drop their coveted and lucrative September issues, even though, yes, the book generally comes out in the summer.
Earlier this year, Kenya Hunt became editor-in-chief for one of the top fashion books, the U.K. edition of Elle magazine - the first Black woman to be in that role. And this month's issue is the first to be edited entirely under her supervision. So not surprisingly, she used this month's issue to make a statement. She introduced new features, new contributors and put a new fashion icon on the cover - Lizzo, the pop star who's breaking new ground for larger-sized women in fashion and culture. Given all that, we thought this would be a great time to hear from Kenya Hunt about her vision for the magazine and, of course, new looks for the season. And she is kind enough to take time out from her busy schedule to talk to us now. Kenya Hunt, welcome. Thank you so much for talking with us.
KENYA HUNT: Oh, thank you for having me. It's a pleasure to be here.
MARTIN: Well, you know, obviously, your appointment is notable for so many reasons - I mean, in part, because you are the first Black woman to lead the U.K. edition of Elle magazine, and you're also an American. And I'm just wondering how you feel that you have been received in that role.
HUNT: I have to say it's been very positive, and it's been quite a heartwarming experience because I do feel that I'm a part of a wave of editors and creatives and image makers who have broken through in recent years. So there is a real sense of kinship and community among us, which has been really beautiful to see. But I've always loved Elle as a title, and it's always resonated with me. I'll never forget watching a show that used to air called "Style With Elsa Klensch," and she was interviewing the editor of Elle at the time about her choice to put a Black model on the cover, and this was Naomi Campbell. And she, you know, questioned her and asked her, you know, about her feelings about making this bold and courageous decision to put this woman of color in the cover.
And, you know, her reply was quite, you know, simple. She just thought she was - she didn't think it was this courageous move at all. She just thought it was - you know, that she was the woman who reflected the moment. And, you know, she just felt she was the best woman for the cover. And so I think that resonated with me, and it never left me. So even now, just, you know, having this role as editor-in-chief, I often think about that. And having Lizzo on the cover for September, it was - you know, it was such - it was thrilling for so many reasons. But also, I was quite tickled because the fact that she was a Black woman was not the headline because we've evolved.
MARTIN: Well, I will have to say, there are so many things about Lizzo as the cover that is remarkable for - first of all, it is September. You know, like, I remember when Beverly Johnson was the first Black model on the cover of Vogue, and it was deliberately chosen to be August...
HUNT: Yep.
MARTIN: ...Because August is the small book that precedes the big book, which is September. And it was deliberately chosen because it was - there was a feeling that some of the buyers and subscribers and advertisers would rebel. So there is that history, and that's not when dinosaurs walked the earth, you know? This is...
HUNT: It was recent. Yeah.
MARTIN: ...In our lifetimes. It was in our lifetime. So tell me about Lizzo. Why was she so important for you to choose?
HUNT: She is - she represents so many things to so many different people. I like how she uses her platform to really speak out and celebrate Black women, women of size. You know, I love that she is not afraid to speak out about issues like women's reproductive rights. You know, she talked a lot about how she really wanted to use her new album, "Special," to speak to this experience that we all collectively had during the lockdown period and also inspire people to feel a sense of hope and optimism. But also, most of all, I think we all know that the history of women's magazines has been very insular and exclusive and the opposite of inclusive. You know, there's that sense of there being historically a very, very narrow standard of beauty. And, you know, I'm excited to open that up and to really sort of look at the expansiveness of what womanhood looks like. And I thought Lizzo was a really great starting point for that.
MARTIN: Well, you know, speaking of inclusion, I was really struck by your editor's note where you don't shy away at all from the uncertainty, frankly, of - that a lot of people are living with right now. I mean, I think some people have seen, you know, fashion in the way that some people have seen sports. It's like their escape. You are very much not taking that approach, and I was curious about that. You specifically referenced the sense of unease that many people feel with the politics of the moment, whatever side they are on, you know, as it were, and the war in Ukraine, obviously. You are there in Europe. I was just curious, like, why you took that approach. And did you ever second-guess yourself and think, maybe not? You know what I mean?
HUNT: Yeah.
MARTIN: Like, how did you come to that?
HUNT: For me personally, I've always admired those journalists who drew those connections between fashion and culture and politics and really sort of contextualized fashion. But also, I think we've witnessed fashion sort of evolve to a place that's more purposeful. I think we're in a moment in time and in history that requires us to be much more honest and expansive in the way that we look at fashion and beauty, and to look at it against the backdrop of, you know, value systems and identity. Like, I don't think we can solely look at clothing in a bubble.
But that said, I do think it does have the power to inspire hope. And, you know, I do think there is power in a really beautiful and gorgeous fashion shoot that can make you dream. And we definitely still give you that. I think it's the most modern approach is to sort of speak to the world that we're living in - also because our readers are so savvy, and that's what we're talking about. And I think we - it's an exchange. Like, it's an - a dialogue exchange as opposed to before, I guess historically, when you look at women's magazines in the historic sense, where it's a monologue. Like, they're telling you how to live, how to dress, how to be.
MARTIN: So, you know - forgive me. I have to ask, are there any looks in particular you're excited about for fall? Now, I know you said, you know, fashion used to be top down and now it's more of a dialogue. And it's no longer the designers, you know, pointing the finger and saying, this is the color, this is what you're going to wear, this is the silhouette. But having said that, are there any key trends that you can point to that our listeners should be on the lookout for at whatever price point they're comfortable with?
HUNT: Yes. Hot pink is not a color I would ever normally gravitate towards, but it emerged as this dominant color story that came out of the collections. And it looks very sharp and intelligent and dynamic and cool. And so for me, as a color, I'm really interested in that. And then also, I'm really into heels again, which I didn't expect because I love my Jordans. I love a flat. I love a sandal. I broke a couple toes during the lockdown period, and so I had like, collected a whole range of like, you know, flats. And all of a sudden, I'm like, really enjoying wearing a heel again and dressing up.
And so I think it's the looks from the catwalks that really inspire you to - you know, to dress up, to wear some color, to go out and have an experience. That's what's really resonating with me. And I'm seeing it, you know, here as well. Like, during the summer, people were just getting their life - like, going out, traveling all over the place. So for me, it's, like - it's those pieces that inspire you to dress up. So I think there's a lot to get excited about right now in terms of, you know, options for what to wear.
MARTIN: That's Kenya Hunt. She's the editor-in-chief of the U.K. edition of Elle magazine. Her book, "Girl Gurl Grrrl: On Womanhood And Belonging In The Age Of Black Girl Magic," is also out now. Kenya Hunt, thanks so much for joining us.
HUNT: Thank you for having me. Transcript provided by NPR, Copyright NPR. | https://www.keranews.org/2022-09-04/the-new-editor-in-chief-of-elle-uk-is-shaking-up-the-magazine | 2022-09-06T13:35:20Z |
A federal judge ruled in favor of former President Trump on Monday, ordering an independent review of materials seized by the FBI at Trump's Florida home. It's a temporary setback for investigators.
Copyright 2022 NPR
A federal judge ruled in favor of former President Trump on Monday, ordering an independent review of materials seized by the FBI at Trump's Florida home. It's a temporary setback for investigators.
Copyright 2022 NPR | https://www.keranews.org/2022-09-06/a-judge-grants-trumps-special-master-request-to-review-mar-a-lago-materials | 2022-09-06T13:35:26Z |
American Frances Tiafoe, 24, has reached the quarterfinals for the first time. Of the eight men left at the U.S Open, six are ranked outside of the top 10.
Copyright 2022 NPR
American Frances Tiafoe, 24, has reached the quarterfinals for the first time. Of the eight men left at the U.S Open, six are ranked outside of the top 10.
Copyright 2022 NPR | https://www.keranews.org/2022-09-06/no-22-seed-ends-rafael-nadals-22-match-grand-slam-streak-at-the-u-s-open | 2022-09-06T13:35:32Z |
NPR's A Martinez talks to Cardozo Law School professor of law Jessica Roth, who analyzes a federal judge's decision to grant former President Donald Trump's request for a special master.
Copyright 2022 NPR
NPR's A Martinez talks to Cardozo Law School professor of law Jessica Roth, who analyzes a federal judge's decision to grant former President Donald Trump's request for a special master.
Copyright 2022 NPR | https://www.keranews.org/2022-09-06/the-probe-into-trumps-seized-documents-raises-executive-privilege-questions | 2022-09-06T13:35:38Z |
Members of BTS already received a special deferment. Instead of serving the mandatory 18 months by the time they turn 28, they can wait until they're 30. The two oldest members are now 29.
Copyright 2022 NPR
Members of BTS already received a special deferment. Instead of serving the mandatory 18 months by the time they turn 28, they can wait until they're 30. The two oldest members are now 29.
Copyright 2022 NPR | https://www.keranews.org/2022-09-06/will-south-koreans-get-a-say-in-whether-a-boy-band-is-exempt-from-military-service | 2022-09-06T13:35:44Z |
I've always liked silos. Exotic, to this Manhattanite. But artist Guido van Helten is obsessed with them. He's made them canvases for giant murals in Iowa, Arkansas, Finland, Jordan, Denmark and his native Australia. He often turns to old, abandoned silos in small towns. The latest — in McKinney, Texas — stored grain once. Now, the silo's eight canisters introduce passers-by (and locals) to the spirit and people of the place.
Van Helten starts by interviewing and photographing residents. "I meet people, try to get a bit of character of the place." He sorts through hundreds of black and white photos, "seeing which ones will fit the space." And then he chooses maybe 20 pictures, and combines parts of them, to paint on a 90-foot high silo.
Photos of his project prompt thoughts about silos. They're landmarks. They stand for safe-keeping, sustenance, security. They're storing the future. And by painting some with strong, evocative images, he's made them literal signs of home.
Van Helten's Texas mural shows several McKinneyans at a town celebration of Juneteenth. "People interacting," he says, "and moving and walking. It shows layers."
A major figure is a pretty young African American woman, an arm behind her back, looking over her shoulder at viewers. It's an unselfconscious look. She's comfortable where she stands.
The muralist has themes for his silo art: public housing, education, desegregation. For McKinney the theme is "Community." The town is changing. Its population jumped from 35,000 to 210,000 in just a few years. Mostly Republican, with lots of civic pride. It sits some 30 miles from Dallas, off Highway 5 — once the main way to go north or south. Mayor George Fuller and other town leaders think the silos could bring together McKinney's white, Black and Hispanic population. And attract tourists. "We saw this as a tremendous opportunity" the mayor says.
McKinney's economy is diverse: it includes Raytheon, a big copper wire company, hospitals, tech. Plus a proud history of production. There once was a flour mill, a cotton mill. "We were the lollipop capital," Mayor Fuller points out, with pride. "We were the blue jean capital of the world at one point." More Mayoral pride. "We've done it all here in McKinney, Texas."
In the historic downtown now you'll find lots of owner-run businesses and restaurants plus a concentration on the arts. Galleries. Musicians. And now Guido van Helten's really stunning painted silos — a salute to the place's past, and a new and powerful act of artistic preservation.
Almost done, save for a question this reporter just had to ask.
"Do you make a nice bourbon?"
"Yes we do! We make some great beer too."
Sounds as if they really have done it all in McKinney, Texas.
Copyright 2022 NPR. To see more, visit https://www.npr.org. | https://www.keranews.org/news/2022-09-06/a-north-texas-town-gets-its-portrait-on-a-silo | 2022-09-06T13:35:50Z |
Tuesday is the first day back to school in Uvalde, Texas since a gunman killed 19 children and two teachers in May.
The shooting at Robb Elementary School shook the town and the nation when news of the high death toll first broke, and then again when people learned it took law enforcement more than an hour to confront the shooter.
The return to school is a chance for students to see friends and get back into routines. But it also brings back the fear and trauma for those touched by the tragedy.
Going virtual
Adam and Raquel Martinez have four children and another on the way. Their 8-year-old son Zayon was at Robb Elementary during the shooting.
“They went on lockdown, and he was under his desk for quite a while waiting and he was crying and kids were crying. And apparently, they heard some shots that sounded like fireworks,” said Adam Martinez, sitting at his dining room table the week before school started.
For the first few weeks afterwards, Zayon was somber and didn’t play much. To help him cope, his parents got him a guinea pig.
“He had been wanting some type of pet,” said Martinez. “It’s really helped him because he’s always playing with it.
Zayon named the guinea pig Max. As the summer passed, Martinez said his son started joking again and playing more.
“But there are some things that trigger him, like loud noises. He wants the door locked all the time and before he never really worried about the doors being locked,” Martinez said.
Zayon also has nightmares and trouble sleeping. And he’s not alone. Many kids and parents are still scared.
To help the community feel safer, the Uvalde school district is putting up 8-foot fences around the schools. They’ve hired campus monitors to roam the halls and check doors to make sure they’re locked and 33 state troopers will be stationed at the schools this year to provide extra security.
Those measures made Martinez feel better about sending his kids back. But Analiyh and Zayon told their parents they’re scared because they don’t trust the police to protect them.
“They're worried that if it happens again, it's going to be the same scenario where they don't go in there, they don't protect them. So, it doesn't matter how high the fencing is, or how many police officers are there. They don't feel comfortable right now,” said Martinez.
The Uvalde school board fired the school police chief who was in command during the shooting, but the district’s other officers are still on the job. And it’s likely some of the state troopers assigned to guard Uvalde schools this year were also on the scene in May.
“I wish I could tell them ‘Well, those cops are gone, son. They won't be back,’ you know? But I can't. They're the same cops, those same cops are gonna be there,” Martinez said.
So, Adam and Raquel decided to enroll Zayon and their 12-year-old daughter Analiyh in the district’s new virtual option instead.
“If you're scared, you can't learn,” Adam Martinez said. “When you're in an unsafe environment it's going to be hard to interact with other children. When you're constantly looking around making sure that nothing happened.”
The Martinezes plan to reassess whether to return for in-person classes after the first semester. A lot of the Uvalde school district’s security upgrades aren’t done — fences are only up around two of the eight campuses, for instance. And the district’s own investigation into its officers’ actions that day hasn’t even begun.
Returning to school
On May 24, Angeli Gomez fought her way past the police line at Robb to get to her sons during the shooting.
This summer, she joined a group of women who call themselves Fierce Madres. They organized after the shooting to help push for change.
Sitting outside her grandma’s house on Friday, Gomez said she was originally planning to keep her kids home from school, but towards the end of the summer her sons said they wanted to return.
“I can't hold them back, because they just want to go catch up with friends and really do sports again,” said Gomez.
But the decision weighs on her.
“Just thinking about it feels like I’m going to cry,” said Gomez. “It feels like I'm letting them go and they could not come home tomorrow. And it would be my fault for letting them go back.”
Gomez is a single mom and works long hours in the field harvesting onions and cucumbers and chiles. She said it would have been really hard to figure out child care if she signed her sons up for virtual instruction. And a lot of parents are just like her.
“(I’m like a lot of single moms.) I can't stay home. I have to work,” Gomez said. “So, then who's gonna watch our kids?”
The first day of school brings back all the fear she experienced during the shooting. Earlier that day, it was a celebration. The school held an awards ceremony to honor students. Families were there, taking pictures of smiling kids.
Gomez knows those pictures could have been the last ones she ever took of her children.
“Not even 30 minutes later, you're getting a call that they're shooting up the school. It's just I don't know, it was just crazy. It was just bad,” Gomez said. “And it's just so hard to think about school again now and not think about what happened.”
As classes start Tuesday, the Uvalde school district will have comfort dogs on campus to help kids when they get overwhelmed. Teachers and staff have been trained how to respond to children experiencing grief and trauma.
But it just may be the parents who have the hardest time letting go. Especially those who should have one more child going back to school.
Copyright 2022 Texas Public Radio. To see more, visit Texas Public Radio. | https://www.keranews.org/texas-news/2022-09-06/uvalde-students-return-to-school-for-the-first-time-since-mays-deadly-shooting | 2022-09-06T13:35:57Z |
Airlines count on business travelers to keep recovery going
DALLAS (AP) — With summer vacations winding down, airlines are counting on the return of more business travelers to keep their pandemic recovery going into the fall.
Air travel in the United States, bolstered by huge numbers of tourists, has nearly recovered to pre-pandemic levels.
Inflation — and especially this year’s sharp rise in airfares — raises concern about how long vacationers can afford to keep flying at their current pace. Airlines say they see no signs of a slowdown in leisure travel.
Business travel, however, remains about 25% to 30% below 2019 levels, according to airlines and outfits that track sales.
And it is not clear when — or if — road warriors will return to their old travel habits.
“The whole challenge for the industry is around the return of the corporate traveler, and whether he is going to come back in enough volume and frequency that is going to help these airlines,” says John Grant, an analyst with travel-data provider OAG.
The Global Business Travel Association recently predicted that corporate travel won’t fully return until mid-2026, 18 months later than the trade group had previously forecast.
Business travelers generally pay higher fares, so their absence has an outsized impact on airline revenue and profit.
Business travel is slower to return because it is more complicated than somebody deciding they want to take a vacation after staying home during the first two years of the pandemic, says Chuck Thackston, who leads data research at the Airlines Reporting Corp., a ticket-settlement firm that operates as a middleman between airlines and travel agents.
“On the corporate side, it just takes a little more to restart that because there are so many moving parts,” Thackston said. “If you want to go visit clients in New York, it could be that nobody is in the office in New York. That is slowly building back.”
Conventions and other big meetings are another key driver of business travel, and also seem to be coming back, Thackston said.
Airline officials say that travel by small-business operators has recovered nearly fully, but that many corporate travelers have not returned to the road or skies.
The chief commercial officer of Southwest Airlines, Andrew Watterson, said that since business travel began picking up this spring, “it was skewed toward smaller businesses and government and education were traveling. Our largest corporates are the ones that are lagging, particularly banking, consulting and technology.”
Watterson said that among Southwest’s biggest corporate accounts, they all have employees traveling — but not as many of them, and not as often.
The nature of business travel is changing as companies become accustomed to smaller travel budgets. Some trips are being replaced by video calls, perhaps permanently. Speculative sales trips could be especially easy for companies to cut.
Conventions now routinely offer a “hybrid” format with an option to stay behind and watch online — although that means missing the hallway conversations and other opportunities to network.
Standard & Poor’s said this week that many convention center operators are running summer and fall schedules similar to those in 2019, but a recession or new COVID-19 variant are still risks.
Vasu Raja, the chief commercial officer at American Airlines, said demand has dropped for one-day business trips in which someone leaves in the morning and flies home that evening.
“But interestingly, we’ve seen more demand for blended trips where somebody leaves on a Thursday from Dallas to go to New York, they don’t return on the Friday — they stay through the weekend and they come back on Sunday,” he said. Sometimes a spouse goes with them, he added.
Business travel is big business worldwide. The Global Business Travel Association estimates that it was worth more than $1.4 trillion in 2019, then plummeted by more than half each of the next two years. The trade group estimates that after being hindered by the omicron variant early this year, business travel will hit $933 billion in 2022 — still 35% below the pre-pandemic mark.
The widespread availability of vaccines and better treatment of COVID-19 — along with relaxation of mandatory quarantines and other travel restrictions — have boosted leisure and corporate travel. However, travel is now threatened by deteriorating economic conditions including surging inflation and labor shortages. New COVID-19 variants remain a concern among travel managers, particularly in Asia.
The cost of travel is expected to keep rising, putting pressure on corporate budgets. A recent report from travel-management company CWT predicted that fares paid by business travelers will rise nearly 50% this year and 8% next year, and hotel rates will rise 19% this year and 8% in 2023.
Most U.S. airlines reported profits for the April-through-June second quarter. For American and United, it was their first profitable quarter excluding government aid since the pandemic started, and they should be in the black for the third quarter, which ends with vacation-heavy July and August.
Business travel traditionally enjoys a peak in the spring and another in September and October. Airlines are about to find out whether that happens this year.
“There has been a lot of discussion about, yeah, business travel is coming back, and U.S. airline CEOs being quite bullish about it,” said Grant, the OAG analyst. “But the hard evidence now needs to come forward.”
Copyright 2022 The Associated Press. All rights reserved. | https://www.whsv.com/2022/09/06/airlines-count-business-travelers-keep-recovery-going/ | 2022-09-06T14:24:54Z |
Canada police hunt remaining suspect in stabbing attacks
WELDON, Saskatchewan (AP) — Canadian police hunted for the remaining suspect in the stabbing deaths of 10 people in an Indigenous community and nearby town in the province of Saskatchewan after finding the body of his brother amid a massive manhunt for the pair.
Damien Sanderson, 31, was found dead Monday near the stabbing sites and authorities believe his brother and fellow suspect, Myles Sanderson, 30, is injured, on the run and likely in the provincial capital of Regina, said police chief Evan Bray. The series of stabbings also wounded 18 people.
RCMP Commanding Officer Assistant Commissioner Rhonda Blackmore said authorities are not sure of the cause of death yet but the injuries were not self-inflicted.
Damien Sanderson’s “body was located outdoors in a heavily grassed area in proximity to a house that was being examined. We can confirm he has visible injuries,” said Blackmore. Asked if Myles Sanderson was responsible for his brother’s death, Blackmore said police are investigating that possibility, but “we can’t say that definitively at this point in time.″
Leaders of the James Smith Cree Nation, where most of the stabbing attacks took place, blamed the killings on the drug and alcohol abuse plaguing the community, which they said was a legacy of the colonization of Indigenous people.
James Smith Cree Nation resident Darryl Burns and his brother, Ivor Wayne Burns, said their sister, Gloria Lydia Burns, was a first responder who was killed while responding to a call. Burns said his 62-year-old sister was on a crisis response team.
“She went on a call to a house and she got caught up in the violence,” he said. “She was there to help. She was a hero.”
He blamed drugs and pointed to colonization for the rampant drug and alcohol use on reserves.
“We had a murder-suicide here three years ago. My granddaughter and her boyfriend. Last year we had a double homicide. Now this year we have 10 more that have passed away and all because of drugs and alcohol,” Darryl Burns said.
Ivor Wayne Burns also blamed drugs for his sister’s death and said the suspect brothers should not be hated.
“We have to forgive them boys,” he said. “When you are doing hard drugs, when you are doing coke, and when you are doing heroin and crystal meth and those things, you are incapable of feeling. You stab somebody and you think it’s funny. You stab them again and you laugh.”
Blackmore said police were still determining the motive, but the chief of the Federation of Sovereign Indigenous Nations echoes suggestions the stabbings could be drug-related.
“This is the destruction we face when harmful illegal drugs invade our communities, and we demand all authorities to take direction from the chiefs and councils and their membership to create safer and healthier communities for our people,” said Chief Bobby Cameron.
Blackmore said the criminal record of Myles Sanderson dates back years and includes violence. Last May, Saskatchewan Crime Stoppers issued a wanted list that included him writing that he was “unlawfully at large.”
While authorities believe Myles Sanderson is in Regina, about 335 kilometers (210 miles) south of where the stabbings happened, they have issued alerts in Canada’s three vast prairie provinces — which also include Manitoba and Alberta — and contacted U.S. border officials. The manhunt entered its third day Tuesday.
Before Damien’s body was found, arrest warrants were issued for the suspects and both men faced at least one count each of murder and attempted murder.
The stabbing attack was among the deadliest mass killings in Canada, where such crimes are less common than in the United States. The deadliest gun rampage in Canadian history happened in 2020, when a man disguised as a police officer shot people in their homes and set fires across the province of Nova Scotia, killing 22 people. In 2019, a man used a van to kill 10 pedestrians in Toronto.
Deadly mass stabbings are rarer than mass shootings, but have happened around the world. In 2014, 29 people were slashed and stabbed to death at a train station in China’s southwestern city of Kunming. In 2016, a mass stabbing at a facility for the mentally disabled in Sagamihara, Japan, left 19 people dead. A year later, three men killed eight people in a vehicle and stabbing attack at London Bridge.
Police in Saskatchewan got their first call about a stabbing at 5:40 a.m. on Sunday, and within minutes heard about several more. In all, dead or wounded people were found at 13 different locations on the sparsely populated reserve and in the town, Blackmore said. James Smith Cree Nation is about 30 kilometers (20 miles) from Weldon.
Among the 10 killed was Lana Head, who is the former partner of Michael Brett Burns and the mother of their two daughters.
“It’s sick how jail time, drugs and alcohol can destroy many lives,” Burns told the Aboriginal Peoples Television Network. “I’m hurt for all this loss.”
Weldon residents have identified one of the dead as Wes Petterson, a retired widower who made he coffee every morning at the senior center. He loved gardening, picking berries, canning, and making jam and cakes, recalled William Works, 47, and his mother, Sharon Works, 64.
“He would give you the shirt off his back if he could,” William Works said, describing his neighbor as a “gentle old fellow” and “community first.”
Sharon Works was baffled: “I don’t understand why they would target someone like him anyway, because he was just a poor, helpless little man, 100 pounds soaking wet. And he could hardly breathe because he had asthma and emphysema and everybody cared about him because that’s the way he was. He cared about everybody else. And they cared about him.”
____
Gillies reported from Toronto.
Copyright 2022 The Associated Press. All rights reserved. | https://www.whsv.com/2022/09/06/canada-police-hunt-remaining-suspect-stabbing-attacks/ | 2022-09-06T14:24:54Z |
Ruby Bridges, desegregation trailblazer, writes kid’s book
(AP) - Ruby Bridges was a 6-year-old first-grader when she walked past jeering crowds of white people to become one of the first Black students at racially segregated schools in New Orleans more than six decades ago. Now, with teaching about race in America more complicated than it’s ever been, she’s authored a picture book about her experience for the youngest of readers.
Bridges, along with three other Black students at a different school, were the first to integrate what had been all-white schools in New Orleans in 1960.
“I Am Ruby Bridges,” featuring illustrations by Nikkolas Smith, goes on sale Tuesday. Published by Orchard Books, an imprint of Scholastic Inc., it’s aimed at readers as young as 4.
Complete with a glossary that includes the words “Supreme Court” and “law,” the book is an uplifting story about opportunities and kids being able to make a difference, Bridges said in an interview with The Associated Press.
“It’s a true reflection of what happened through my own eyes,” she said.
But books by or about Bridges have been challenged by conservatives in several school districts amid complaints over race-related teaching. Bridges said she hopes the new book winds up in elementary school libraries.
“I’ve been very, very fortunate because of the way I tell my story that my babies come in all shapes and colors, and my books are bestsellers, and maybe banned in schools,” she said. “But I think parents really want to get past our racial differences. They’re going to seek out those books.”
Bridges was born in 1954, the same year the U.S. Supreme Court ruled that racial segregation of public schools was unconstitutional. Southern school districts, including New Orleans, continued resisting integration for years.
But on Nov. 14, 1960, Bridges — carrying a plaid book satchel and wearing a white sweater — was escorted by four federal marshals past a taunting white crowd into segregated William Frantz Elementary School. The scene was made famous in the Norman Rockwell painting “The Problem We All Live With,” which hung in the White House near the Oval Office during the tenure of former President Barack Obama.
The book’s theme plays off the author’s name: “Ruby” is a precious stone, and “Bridges” are meant to bring people together. Told with a touch of humor from the vantage point of a first-grader, the book captures the wonder of Bridges’ experience — rather than just the scariness of that raucous first day at the school.
“It really looks like Mardi Gras to me, but they aren’t throwing any beads. What’s Mardi Gras without beads?” Bridges writes.
The only parade that day was out of the school. White parents immediately began withdrawing their children, so Bridges spent the entire year by herself with white teacher Barbara Henry, who is still alive and a “very best friend,” Bridges said. Henry’s acceptance and kindness during a fraught time taught her an important lesson, she said.
“That shaped me into a person that is not prejudiced at all. And I feel like that little girl is still inside of me, and that’s it’s my calling to make sure kids understand that you can’t look at someone and judge them,” Bridges said.
Elsewhere in New Orleans on the same day Bridges went to school, Gail Etienne, Leona Tate and Tessie Prevost entered the previously all-white McDonogh No. 19 elementary school. Last year, New Orleans held a weekend of events to remember Bridges and other women.
Bridges, a Mississippi native, still lives in metro New Orleans and has authored or co-authored five books. Two years she published “This Is Your Time,” which is intended for older children than her new book.
___
Reeves is a member of AP’s Race and Ethnicity Team.
Copyright 2022 The Associated Press. All rights reserved. | https://www.whsv.com/2022/09/06/ruby-bridges-desegregation-trailblazer-writes-kids-book/ | 2022-09-06T14:24:57Z |
Video fills in details on alleged Ga. election system breach
ATLANTA (AP) — Two months after the 2020 presidential election, a team of computer experts traveled to south Georgia to copy software and data from voting equipment in an apparent breach of a county election system. They were greeted outside by the head of the local Republican Party, who was involved in efforts by then-President Donald Trump to overturn his election loss.
A security camera outside the elections office in rural Coffee County captured their arrival. The footage also shows that some local election officials were at the office during what the Georgia secretary of state’s office has described as “alleged unauthorized access” of election equipment.
Security footage from two weeks later raises additional alarms — showing two people who were instrumental in Trump’s wider efforts to undermine the election results entering the office and staying for hours.
The security video from the elections office in the county about 200 miles southeast of Atlanta offers a glimpse of the lengths Trump’s allies went to in service of his fraudulent election claims. It further shows how access was facilitated by local officials who are entrusted with protecting the security of elections while raising concerns about sensitive voting technology being released into the public domain.
Georgia wasn’t the only state where voting equipment was accessed after the 2020 presidential election. Important information about voting systems also was compromised in election offices in Pennsylvania, Michigan and Colorado. Election security experts worry the information obtained — including complete copies of hard drives — could be exploited by those who want to interfere with future elections.
“The system is only as secure as the people who are entrusted to keep it secure,” said lawyer David Cross, who represents plaintiffs in a long-running lawsuit over Georgia’s voting machines.
The Coffee County security footage was obtained through that lawsuit, which alleges that Georgia’s touchscreen voting machines are vulnerable to attack and should be replaced by hand-marked paper ballots. The suit long predates and is unrelated to false allegations of widespread election fraud pushed by Trump and his allies after the 2020 election.
The alleged breach in Coffee County’s elections office also has caught the attention of Fulton County District Attorney Fani Willis, who is overseeing an investigation into whether Trump and his allies illegally tried to influence the 2020 election results in Georgia.
Last month, Willis cited the Coffee County activity, among other things, when she sought to compel testimony from Sidney Powell, an attorney who was deeply involved in Trump’s effort to undo the election results.
Emails and other records show Powell and other attorneys linked to Trump helped arrange for a team from data solutions company SullivanStrickler to travel to Coffee County, which Trump won by nearly 40 percentage points.
The surveillance video, emails and other documents that shed light on what happened there in January 2021 were produced in response to subpoenas issued in the voting machine lawsuit and were obtained by The Associated Press. Parts of the security video appear to contradict claims by some of the local officials:
— Footage captures Cathy Latham, then chair of the Coffee County Republican Party, arriving at the elections office shortly after 11:30 a.m. on Jan. 7, 2021, the day after the violent assault on the U.S. Capitol. Just a few weeks earlier, she was one of 16 Georgia Republicans who signed a certificate falsely stating that Trump had won the state and declaring that they were the state’s “duly elected and qualified” electors.
A few minutes after her arrival, she is seen outside greeting SullivanStrickler chief operating officer Paul Maggio and two other people. Less than 10 minutes later, she escorts two other men into the building.
The video shows her leaving the elections office just before 1:30 p.m., roughly two hours after she greeted the SullivanStrickler team. She returns a little before 4 p.m. and then leaves around 6:15 p.m.
Latham said under oath during a deposition in August that she stopped by the elections office that evening for “Just a few minutes” and left before 5 p.m. Pressed on whether she had been there earlier in the day, Latham said she couldn’t recall but suggested her schedule as a teacher would not have allowed it.
A lawyer for SullivanStrickler said in an email attached to a court filing that Latham was a “primary point of contact” in coordinating the company’s work and “was on site” while that work was done.
Robert Cheeley, a lawyer for Latham said in an emailed statement that his client doesn’t remember all the details of that day. But he said she “would not and has not knowingly been involved in any impropriety in any election” and “has not acted improperly or illegally.”
— The video also shows Eric Chaney, a member of Coffee County’s election board, arriving shortly before 11 a.m. the same day and going in and out several times before leaving for the night around 7:40 p.m. Lawyers for the plaintiffs in the voting machine lawsuit wrote in a court filing that a photo produced by SullivanStrickler’s COO shows Chaney in the office as the copying is happening.
During a deposition last month, Chaney declined to answer many questions about that day, citing the Fifth Amendment. But when an attorney representing the county reached out to him in April regarding questions from The Washington Post, Chaney wrote, “I am not aware of nor was I present at the Coffee County Board of Elections and Registration’s office when anyone illegally accessed the server or the room in which it is contained.” Chaney resigned from the elections board last month, days before his deposition.
Attempts to reach Chaney by phone were unsuccessful, and his lawyer did not respond to an email seeking comment.
— About two weeks after the initial breach, video shows Misty Hampton — then the county elections director — arriving at the elections office at 4:20 p.m. on Jan. 18, when it was closed for Martin Luther King Jr. Day. She unlocked the door and let in two men — Doug Logan and Jeff Lenberg, who have been active in efforts to challenge the 2020 election results.
Logan founded Cyber Ninjas, which participated in a partisan and ultimately discredited review of the 2020 election in Maricopa County, Arizona. The two men remained inside until just after 8 p.m. and then spent more than nine hours there the next day. Lenberg returned for brief visits on at least three more days later that month.
Hampton resigned as elections supervisor in February 2021 after elections board officials said she falsified her timesheets. Attempts by the AP to reach her were unsuccessful.
In a statement released by its attorney, SullivanStrickler said the company was retained by attorneys to forensically copy voting machines used in the 2020 election and had no reason to believe they would ask its employees to do anything improper.
The Georgia secretary of state’s office said it opened an investigation in March and asked the Georgia Bureau of Investigation for assistance last month. State officials have said the system remains secure because of multiple protections in place.
Copyright 2022 The Associated Press. All rights reserved. | https://www.whsv.com/2022/09/06/video-fills-details-alleged-ga-election-system-breach/ | 2022-09-06T14:24:58Z |
White House health officials to hold COVID-19 briefing as boosters roll out
(Gray News) - The White House COVID-19 Response Team and federal public health officials will hold a virtual briefing on Tuesday to provide updates on the COVID-19 response effort.
Participants will include Health and Human Services Secretary Xavier Becerra, National Institute of Allergy and Infectious Diseases Director Anthony Fauci, White House COVID-19 Response Coordinator Ashish Jha and Centers for Disease Control and Prevention Director Rochelle Walensky.
Federal health officials on Thursday approved a new booster designed to battle the dominant omicron variant. People can get booster shots this week at pharmacies or other designated locations.
The shots “can help restore protection that has waned since previous vaccination and were designed to provide broader protection,” Walensky said in a statement.
The Pfizer-BioNTech booster is available for people ages 12 years and older. The booster from Moderna is approved for people ages 18 years and older.
The CDC said it expects to recommend updated COVID-19 boosters for other pediatric groups in the coming weeks.
The booster shots are combination or “bivalent” shots — half the original vaccine and half protection against the BA.4 and BA.5 omicron versions now causing nearly all COVID-19 infections.
Copyright 2022 Gray Media Group, Inc. All rights reserved. CNN Newsource and The Associated Press contributed to this report. | https://www.whsv.com/2022/09/06/white-house-health-officials-hold-covid-19-briefing-boosters-roll-out/ | 2022-09-06T14:25:04Z |
Over 38 million Americans struggle with food insecurity.
"This is a problem we just cannot turn our back on."
CORONA, Calif., Sept. 6, 2022 /PRNewswire/ -- Advanced Container Technologies, Inc (Ticker: ACTX), announced that it has partnered with the Clean Food Initiative and Produce Now to provide fresh, healthy food to disadvantaged youth.
ACTX said it will allocate space in one or more of its GrowPods to grow leafy greens, which will be donated to the Clean Food Initiative for distribution to various hunger-related charities. The food will be grown, packaged and distributed by workers from Produce Now.
Hunger is an enormous and often under-reported problem in the United States. According to National Geographic, millions of working Americans don't know where their next meal is coming from. One in six Americans don't have enough food to eat.
The Food Research and Action Center states that over 38 million Americans live in households that struggle with food insecurity or lack of access to an affordable, nutritious diet. This represents a 9 percent increase from 2019.
"This is a problem we just cannot turn our back on," said Douglas Heldoorn, CEO of Advanced Container Technologies, Inc. "There are hungry people in towns throughout America. These are our neighbors, our sisters and brothers. We have a moral obligation to help those in need."
GrowPods are hydroponic modular farms that can be located almost anywhere, and can replace approximately 1-acre of farmland in a pesticide-free, automated, and controlled setting.
The company has worked previously with Caterina's Club, a non-profit organization established by noted chef Bruno Serato. Caterina's Club donates over 25,000 nutritional meals to underprivileged children each week around the world.
GrowPods offer a way for non-profit organizations to grow clean, nutritious food virtually anywhere. Organizations can place a system in an urban environment, and teach young people how to grow food - providing valuable skills, job training, instilling pride, and invoking a sense of responsibility, in addition to helping meet the nutritional needs of the community.
CONTACT:
For more information on Advanced Container Technologies or GrowPods, call: (951) 381-2555 or visit: www.advancedcontainertechnologies.com or www.growpodsolutions.com.
This press release contains forward-looking statements made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-Looking Statements about ACTX' beliefs and expectations, involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words such as "may," "expect," "anticipate," "estimate," "intend," "plan," "believe," "potential," or other similar expressions. All information is as of the date of this press release, and ACTX undertakes no duty to update such information, except as required under applicable law.
View original content:
SOURCE Advanced Container Technologies, Inc. | https://www.whsv.com/prnewswire/2022/09/06/actx-partners-with-clean-food-initiative-produce-now-provide-healthy-food-hungry-americans/ | 2022-09-06T14:25:14Z |
Taiwanese conglomerate looks to utilize the technology behind Airovation's patented air purification solutions to reform the development of its hardware and consumer electronics.
NESS ZIONA, Israel, Sept. 6, 2022 /PRNewswire/ -- Airovation Technologies, a cutting-edge climate tech company based in Israel, and ASUSTek Computer Inc., the Taiwan-based world leader in computer hardware and consumer electronics' applications and markets, this week signed a Memorandum of Understanding for the megacorporation to explore utilizing Airovation's air purification technology in the development, manufacturing and sale of products and solutions in Taiwan and Greater China.
Airovation's air purification technology prevents the negative impacts of CO2 on the environment, while simultaneously improving people's productivity and wellbeing. The company's patented solutions include its "Air-O" device, which treats CO2, VOCs, airborne viruses and bacteria, deploying unique sensing ability and cloud processing to customize the personal indoor environment and ensure wellbeing and productivity; and "Airosphera" device, which uses multi-sensors to measure and reflect environmental conditions for infants as well as their own bodily conditions, and treats the air to improve infants' wellbeing indoors and outdoors.
Developed over a decade of research at the Hebrew University of Jerusalem, the company's core innovation is the in-situ generation of Superoxide Radical, the most powerful oxidizer in nature. The patented technology is capable of purifying indoor air spaces by oxidizing dangerous microbiological threats such as viruses and bacteria, while converting harmful gasses into clean air.
Clinical trials have shown that CO2 accumulation while sleeping causes decreased cognitive performance the next day. Utilized in tandem, Air-O and Airosphera aim to create a customizable personal indoor environment that ensures wellbeing and productivity.
In the newly signed MOU, the two companies agree to cooperate on further developing Air-O and Airosphera, as well as ASUS' planned products and solutions. Furthermore, the Taiwanese conglomerate will look to utilize its digital expertise to explore data-driven solutions which support and enhance the purifying performance of the companies' joint products. The agreement was signed by Marat Maayan, Founder & CEO at Airovation Technologies and Joe Hsieh, COO and Senior Corporate Vice President at ASUS, in the presence of Abby Ya-Ping Lee, Representative of the Taipei Economic and Cultural Office in Tel Aviv and Roni Shafran, CEO of IP2 Israel.
"This landmark partnership empowers Airovation Technologies to take tremendous steps toward our goal of igniting a cleantech revolution — a movement that stands poised to benefit the environment, productivity and wellbeing of countless individuals not only in Taiwan and Greater China, but across the globe," said Marat Maayan, Founder & CEO at Airovation Technologies. "We are gratified to be working alongside industry leaders such as ASUS as we continue to commercialize our technology and further the indoor air quality (IAQ) solutions market."
In addition to developing air purification productions and solutions, Airovation utilizes its Superoxide Radical technology to pursue breakthroughs in the carbon capture, utilization and storage (CCUS) industry — specifically by using its patented chemical invention to transform carbon dioxide emissions into valuable minerals and products that can be used in the food, feed, glass and fertilizer industries.
Airovation completed a $16 million funding round to transform the air purification industry utilizing its groundbreaking technology, bringing its total raised funds to $19 million. This latest round of investments, which was largely secured in Q4 2021, was led by Dreamstone Partners and also included the Yozma Group Korea as well as the Unid Global Corporation.
Media Contact:
James Fattal
James@jcubedpr.com
347-497-6900
View original content to download multimedia:
SOURCE Airovation Technologies | https://www.whsv.com/prnewswire/2022/09/06/airovation-technologies-asus-sign-mou-expand-air-purification-solutions-taiwan-greater-china/ | 2022-09-06T14:25:21Z |
EDINBURGH, Scotland, Sept. 6, 2022 /PRNewswire/ - Amp X, a division of Amp Energy, has partnered with Smartcar to offer smart charging management solutions to electric vehicle (EV) owners who want to save money and reduce their carbon footprint without sacrificing comfort while allowing the grid to be more flexible. This partnership follows a successful integration of the Smartcar's technology into the Amp X behind-the-meter energy management system, which was recently deployed within the Energy Systems Catapult (ESC) Living Lab.
The Amp X behind-the-meter digital energy assistant (DEA), Alice, manages EV charging through a combination of machine learning, advanced data analytics, and a decentralised control architecture to help consumers take advantage of low-cost, low-carbon energy, as well as participate in demand-side-response opportunities. Through the Amp X platform, EV owners are empowered to make the grid more flexible.
Alice is one of several Amp X offerings catered by its digital energy platform. The ultimate goal of Amp X is to unlock flexibility from the edge of the grid at a large scale to help fully decarbonize the energy system.
Smartcar allows software applications to integrate with connected cars through the cloud. The Smartcar platform enables Amp X to provide electric vehicle owners with a seamless smart charging experience across an ever-growing range of EV brands.
With Alice's autonomous decisions, users can reduce their EV charging costs and carbon footprint. Alice optimizes energy consumption against a number of constraints, while being aware of user preferences and grid needs in real-time.
"At Smartcar, we are passionate about EV adoption and its influence on the future of mobility," said Sahas Katta, CEO of Smartcar. "We are excited to partner with Amp X to help EV owners make smarter charging decisions and reduce the strain on today's electric grid."
With EVs' significantly growing impact on energy demand, giving EV owners the tools to optimize their charging will be of the utmost importance to preserve the stability of the grid. Dr. Irene Di Martino, Head of Amp X, said: "Our vision of the future revolves around smart energy solutions that move from automated to autonomous, turning the edge of the grid into the locus of provision of flexibility for the grid."
"Consumer engagement is a key barrier to demand‐side-management as a scalable non‐wire‐alternative. The Amp X digital energy assistant will simultaneously cater for consumer preferences and grid needs, delivering demand-side management at a very large scale through artificial intelligence and machine learning. Our behind-the-meter technology will allow for optimal energy management and dynamic load shaping in residential, commercial, and industrial premises, enabling cost and carbon savings, though with no adverse impact on the needs and lifestyle of the end users."
Founded in 2015, Smartcar is the leading developer platform for mobility businesses. From auto insurance and car sharing to EV charging and fleet management, businesses of all kinds use Smartcar's APIs to integrate their apps and services with vehicles. By making it easy to connect to their customers' cars, Smartcar enables companies to build the future of mobility.
Smartcar has raised $36M to date and is backed by Andreessen Horowitz (a16z), New Enterprise Associates (NEA), and Energize Ventures. For more information, visit https://smartcar.com.
Amp X is a UK-registered subsidiary of Amp.
Amp develops, owns and operates clean energy assets throughout a number of strategic markets around the world.
Amp X was created to deliver a disruptive grid edge digital platform allowing all forms of distributed generation and load to make a dynamic contribution in the relevant power markets, whether as an individual unit or as an aggregated group of assets, providing flexibility, resilience and system stability at the lowest possible price. Amp X has developed a proprietary smart transformer to address the challenges of the increased presence of Distributed Energy Resources in the distribution network - this will soon be rolled out in the U.K. Amp X has also a Virtual Power Plant solution in commercial operation in North America, and is in the process of commercializing its user-centric energy management system to harness behind-the-meter flexibility at a very large scale.
View original content:
SOURCE Amp Energy | https://www.whsv.com/prnewswire/2022/09/06/amp-x-smartcar-partner-bring-smart-charging-ev-owners-lower-energy-bills-while-making-grid-more-flexible/ | 2022-09-06T14:25:27Z |
CAPE CORAL, Fla., Sept. 6, 2022 /PRNewswire/ -- In recent years, anonymous donations have become the single best way for people to donate money to the charitable projects and causes they care about, while maintaining full protection of their privacy. The Anonymous Donor initiative, created by The Community Foundation (TCF), a global center for generosity, founded in Cape Coral, Florida, allows individuals and companies to easily send donations to charitable organizations they are passionate about while enjoying the full protection of their privacy. Donors also enjoy the benefit of remaining private and keeping their names and information off any call or email lists.
TCF helps donors carry out their charitable donations without anyone calling, texting, emailing, or interrupting their day to ask of them something they already plan to do; donate. How, might you ask? It's a relatively simple process.
First, a donor sends the donation to TCF, and TCF sends it straight along to the organization of their choice anonymously. By acting as the middleman, TCF can protect the privacy of the donor, as well as take the heavy lifting off their hands. There is a small fee for this service, but it is completely worth it, given this anonymous process ensures the donation gets to where it needs to go without any unwanted attention or possible associated backlash to the donor themselves.
Now that the donation has made it to the organization of choice, what happens next? At this point, the donor's work is already done. If the receiving organization wants to extend their gratitude to the donor, they can send a thank you note to TCF and have it passed along to the donor; again, acting as that middleman to keep everyone's privacy protected. TCF is sworn to secrecy, and no matter how many times an organization asks, the name and information of that anonymous donor will not be divulged.
The Community Foundation firmly believes in generosity and giving to others, but also understands the publicity and attention that can come along with the nonprofit world. With this anonymous donor service, you can ensure you are helping your favorite charity without any of the potential side-affects. Don't believe us? In recent years, The Community Foundation has passed along over $600,000 in anonymous donations. That's a lot of private generosity! Anonymous donors are the fastest growing segment of givers to nonprofits and charities; are you ready to join the movement?
The Community Foundation is ready to partner with you and ready to send an anonymous donation on your behalf. Anonymous donations can be sent to nonprofits, churches, ministries, universities, and more.
If you would like to make an anonymous donation or start a private conversation, contact The Community Foundation, Global Center for Generosity, in private at: Alison@capecoralcf.org.
View original content to download multimedia:
SOURCE The Community Foundation | https://www.whsv.com/prnewswire/2022/09/06/anonymous-donor-secretly-give-your-favorite-charity-while-enjoying-full-protection-your-privacy/ | 2022-09-06T14:25:33Z |
Fann brings a strong track record in private markets and will oversee business development and investor relations and serve on investment committees
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Apogem Capital LLC ("Apogem"), a leading alternatives investment firm, today announced that David Fann, former Vice Chairman and Partner of Aksia LLC, has joined Apogem as Senior Managing Director and Vice Chairman. Fann is a highly regarded veteran in the institutional private alternatives industry.
In this newly created role, Fann will serve as a Senior Managing Director and Vice Chairman, managing Business Development and Investor Relations at Apogem as well as serving on several of the firm's investment committees.
"I'm excited to be a part of Apogem's leadership team and to help grow the firm's well established middle market focused investment platform. The middle market represents an important portfolio exposure for institutional investors but has been a segment that has been difficult to navigate due to the sheer number of firms and the wide dispersion of outcomes. Apogem is uniquely positioned as it applies decades of collective investment experience through multiple business cycles, key market relationships and proprietary data to its investment programs in middle market private equity and private credit," said David Fann.
Prior to joining Apogem, Fann served as Vice Chairman and Partner of Aksia, where he was involved with the firm's private markets offering and provided senior advisory support to Aksia's client advisory and private market investment activities. Prior to Aksia's acquisition of TorreyCove Capital Partners, Fann was co-founder, President and Chief Executive Officer of TorreyCove Capital Partners. Previously, Fann was the President and Chief Executive Officer of Pacific Corporate Group Asset Management.
Fann received a BAS in Industrial Engineering and Economics (dual degree) from Stanford University. He currently serves on the Honorary Advisory Board for the Association of Asian American Investment Managers and on the advisory board for the Robert H. Toigo Foundation.
Apogem Capital was formed in April 2022 through the combination of PA Capital, Madison Capital Funding and GoldPoint Partners to create a singular and unified, world class private markets alternative investment firm. With approximately $39 billion in assets under management as of March 30, 2022, Apogem has the deep relationships, data, and history in the middle market to deliver innovative solutions to both clients and sponsors. Apogem Capital offers investors access to the middle market's growth engine through investments in leading private companies and funds. The Firm manages a streamlined suite of capital solutions, including direct lending, junior debt, primary fund investments, secondary investments, equity-co-investments, GP stakes, private real assets and long/short equity. Apogem Capital is a wholly owned subsidiary of New York Life Insurance Company ("NYLIC"), through New York Life Investment Management Holdings, LLC ("NYLIM").
Allison Scott
allison_scott@nylim.com
Zef Vataj
zvataj@sloanepr.com
View original content:
SOURCE Apogem Capital | https://www.whsv.com/prnewswire/2022/09/06/apogem-capital-announces-private-markets-leader-david-fann-joins-firm/ | 2022-09-06T14:25:40Z |
LONDON, Sept. 6, 2022 /PRNewswire/ -- Arbolus, the knowledge-sharing platform, has strengthened its leadership team with the appointment of Dolly DeNyse, a senior executive with 25 years of continuous experience successfully scaling revenues and leading large commercial teams.
Arbolus was founded in 2018 with a mission to make human knowledge digital. Their platform is a disruptor to traditional expert networks, and allows for more flexible knowledge sharing, for example through the medium of video via their new Canopy tool. Following significant growth in recent years, particularly in the US, the role of CRO is a timely addition to Arbolus's leadership team.
As Chief Revenue Officer at Arbolus, Dolly will be responsible for global revenue across all product groups, setting the strategy for continued and increased growth and maintaining a best-in-class culture across all parts of the company.
She will have overall ownership of Sales and Marketing, Customer Success, Account Management and Professional Services, ensuring alignment and performance of all of Arbolus's revenue-generating departments to drive continued growth. She will also be instrumental in growing Arbolus's footprint in North America, and serve as a member of Arbolus's Executive Committee, partnering with the founders to define and execute Arbolus's vision and strategic plan.
Prior to joining Arbolus, Dolly was the Chief Revenue Officer at Kantar, the $4bn+ market research firm owned by Bain Capital. In her role at Kantar, she led Sales and Marketing across North America. Prior to her role as CRO, she held various roles at Kantar, including Chief Sales Officer for Kantar Insights, the company's largest division within North America, and Head of Sales for Kantar Millward Brown.
Sam Glasswell, CEO of Arbolus, said:
"Dolly is such an exciting hire for us at the perfect time.
"Arbolus has evolved from its roots of improving the user experience in the expert network industry, towards a full-scale insight and market data platform. Our customers today use the platform not just for gathering individual expert insights, but also to deliver surveys or gather customer sentiment analysis (through our Canopy product) or as an improved way to carry out secondary research instead of using static industry reports (through our Channels product).
"Dolly's experience at Kantar, one of the most diversified global research groups, will accelerate this evolution of the company.
"Plus, she has the rare virtues of absolute authenticity and humility. We can't wait to start working with her."
Regarding her new role, Dolly DeNyse said:
"Our industry is undergoing rapid change, and Arbolus is well positioned to further transform the global knowledge network space and beyond, providing meaningful connections for our clients in a seamless and tech-enabled way.
"I am excited to join Arbolus at this important juncture, to help accelerate the strategy and plans for the company, continuing their journey operating at the intersection of expert knowledge, technology, data, and analytics.
"Sam and Will have set forth an inspirational and ambitious roadmap for Arbolus, and I am honored to join them in pursuing the next chapters of transformation, growth and success for the company."
Contact:
Federico D'Amico
Communications & Social Media Manager
federico.damico@arbolus.com
+34 661 045 196
View original content:
SOURCE Arbolus | https://www.whsv.com/prnewswire/2022/09/06/arbolus-announces-dolly-denyse-former-kantar-cro-their-new-chief-revenue-officer/ | 2022-09-06T14:25:46Z |
SAN FRANCISCO , Sept. 6, 2022 /PRNewswire/ -- Arturo Perez-Reyes is the latest addition to Newfront, a tech-enabled, full service brokerage. As Senior Vice President, Cyber Lead Strategist, Arturo joins from HUB, where he spent the last nine years leading the Cyber and Technology Practice.
Arturo has worked for 22 years as a risk consultant and broker helping firms identify, quantify, and transfer the liability and losses from technology, professional services, value chains, intellectual property, and regulatory compliance, as well as privacy and security.
As a broker, Arturo has placed coverage for industries such as retail, financial institutions, law firms, healthcare organizations, travel-hospitality, utilities, manufacturers, telecom, gambling, pharmaceutics, manufacturing, web-services, and technology. In addition, he also developed the first privacy policies and hybrid products that provide both insurance and information-security services.
"The Cyber market continues to be very challenging for companies," said Rod Sockolov, Executive Vice President and Property & Casualty Leader at Newfront. "With the addition of Arturo to our growing Cyber practice, we are ensuring our clients will obtain the best results."
Arturo performs enterprise-risk consulting for mid-cap to Fortune 50 companies and has also presented at industry conferences nationally and internationally.
Arturo is a member of the professional faculty at the Haas School of Business, UC Berkeley where he has lectured for more than 34 years on subjects such as e-commerce, communication, insurance, sales, and green business.
Newfront is transforming the delivery of risk management, employee experience, insurance, and retirement solutions by building the modern insurance platform. Transparent data delivered real-time translates into a lower total cost of risk and greater insights. Newfront makes insurance work for you. Headquartered in San Francisco, Newfront has offices throughout the country and is home to more than 750 employees who serve clients across the United States and globally.
Contact Information
Bethany Hale
Chief Marketing Officer
Newfront
press@newfront.com
View original content to download multimedia:
SOURCE Newfront | https://www.whsv.com/prnewswire/2022/09/06/arturo-perez-reyes-brings-more-than-20-years-experience-newfront-cyber-team/ | 2022-09-06T14:25:54Z |
AQUA's first celebrity stylist collaboration debuts a bold, sexy and of-the-moment fall capsule collection as part of the leading retailer's 150th Anniversary celebration
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Bloomingdale's today announces AQUA x Maeve Reilly, a limited-edition collaboration between the retailer's best-selling exclusive brand and the leading celebrity stylist. The collection features fashion-forward mix-and-match pieces in rich, colorful tweed prints and sleek satin separates that embrace this year's hottest fall trends. The AQUA x Maeve Reilly collection launches on September 6th at Bloomingdale's stores nationwide and on Bloomingdales.com.
AQUA, which features of-the-moment ready-to-wear apparel and accessories for a stylish head-to-toe look at an approachable price point, has previously partnered with cultural figures and top brands, including Pendleton, Scout the City, Mary Katrantzou, Zendaya, Helen Owen, Mary Lawless Lee, Yigal Azrouël, Maddie & Tae, Zadig & Voltaire, Madeleine Thompson, and Studio 189. AQUA x Maeve Reilly joins the brand's growing list of successful partnerships this fall as AQUA's first exclusive stylist collaboration.
"Maeve's style empowers and gives women confidence to embrace the trends of the season in an original and authentic way," explained Erica Ruff Hatfield, Creative Director Private Brands, Bloomingdale's. "AQUA's goal is to do just that - offer on-trend and fashion-forward collections that customers can mix, match, and make their own. Maeve's aesthetic and personalized approach to fashion aligns perfectly with the AQUA style and philosophy. This vibrant collection will bring exciting, trend-driven new looks to our best-selling AQUA portfolio this fall."
Maeve Reilly, whose clients include music icons, runway models, pop stars and A-list celebrities and who has worked with the likes of Megan Fox, Hailey Bieber, Ciara, La La Anthony, The Chainsmokers, Lori Harvey and more, translated dramatic looks into easy-to-wear pieces that are authentic to AQUA's fun, playful and approachable identity. The 33-piece collection includes dresses, jackets, coats, tops, bottoms, sets and a catsuit, as well as shoes, handbags, and accessories. Sexy, feminine accents such as mesh, corsets and feathers are juxtaposed with structured blazers and tailored wide leg trousers, blending the perfect mix of soft and striking.
"This collaboration is so exciting for me because I actually worked at Bloomingdale's when I was 19," explained Maeve Reilly. "I'm such a fan of the AQUA brand and I'm so grateful to have the chance to be part of Bloomingdale's 150th anniversary celebrations. My inspiration was to create a collection full of staples that has something for everyone who wants to feel strong, feminine, and sexy in their own skin. And because I am a stylist, I was conscious of creating super wearable pieces that can be styled in so many different ways."
To pay homage to AQUA's longstanding line of chic tweed blazers and suiting separates, Maeve put her spin on the classic with a selection of bold tweed pieces in bright magenta and rich kelly green – two of the season's hottest colors. Additionally, Maeve designed a selection of shoes and bags so that every customer can perfect their look like a professional stylist.
View and shop the AQUA x Maeve Reilly collection here.
About Bloomingdale's
Bloomingdale's is America's only nationwide, full-line, upscale department store. A division of Macy's, Inc., it currently operates 33 Bloomingdale's stores and 21 Bloomingdale's, The Outlet Stores, in California, Connecticut, Florida, Georgia, Hawaii, Illinois, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Texas, and Virginia, along with 1 Bloomie's location in Virginia. In addition, Bloomingdale's has an international presence with a location in Dubai. Founded in 1872, the iconic retailer is celebrating its 150th anniversary this year. Be sure to follow @bloomingdales on social media, become a Loyallist, and for more information, or to shop any time, visit www.bloomingdales.com
Bloomingdale's Public Relations
Bloomingdales@FinnPartners.com
View original content:
SOURCE Bloomingdale's | https://www.whsv.com/prnewswire/2022/09/06/bloomingdales-launches-exclusive-aqua-x-maeve-reilly-collection/ | 2022-09-06T14:26:01Z |
When You Put on a Better Fit, You Put on a Show
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Bonobos, the menswear brand that started with a perfect pair of chinos, introduces its new Fall 2022 campaign featuring celebrated actor, comedian, and producer, Nick Kroll.
In a homage to television programming of yesteryear, the viewer follows Kroll as he finds himself (barely) breaking a sweat in a fitness/workout infomercial, answering tough questions from a surprisingly familiar talk show host and even posing in some steamy late night programming - viewers can text the number in the spot for a fun surprise too.
Kroll fits into a number of roles professionally – from co-creating, producing, and performing in Netflix's animated series "Big Mouth", to co-starring in the critically acclaimed Broadway show, "Oh, Hello" and being featured in Olivia Wilde's upcoming film, "Don't Worry Darling." In the same way, he finds himself in the perfect fitting Bonobos pants, no matter the scenario. With up to five fits to choose from, each pant style moves with your body – from the Slim Taper fit, for those who want a little extra hug in their calf, to Athletic Fit, for the guy who never skips leg day, to those who want something in-between.
"Bonobos has always been, and will always be focused on finding your best fit," says David Sasson, Chief Operating Officer at Bonobos. "Our campaign showcases the jolt of joy and confidence you feel when you not only look good, but also fit well in the clothes you wear; and our friend Nick certainly emulates that energy."
"This is such a natural fit, just like their line of pants...LOL LOL LOL LOL," joked Kroll. "Bonobos politely asked me never to repeat such a lame joke or say LOL that many times," he continued. "Now, I've probably caused irreparable harm to our relationship - which is a shame, because I genuinely like wearing their clothes."
In addition to pants, the campaign features key items from Bonobos's Fall 2022 line that are perfect for the modern guy — from tuxedos for your friend's nth rescheduled wedding, Riviera short sleeve shirts for crisp 90 degree Fall days, to performance t-shirts comfortable for watching the game on the couch or in a crowded bar.
The campaign will run digitally on web, social media and paid social, through linear TV and OTT and will be featured prominently in Bonobos Guideshop locations across the United States from September 6 through mid-November. The creative concept was developed and produced in partnership with Transport New York.
Pieces featured in the 'Famous for Fit' Campaign include:
Fitness Infomercial
Bonobos Jetsetter Performance Tee in White and Stretch Washed Chino 2.0 in Fall Leaf
Talk Show
Bonobos Italian Stretch Wool Flannel Suit in Sage Green and Washable Merino Mock Neck Sweater in Olive
Love Hotline
Bonobos Stretch Riviera Short Sleeve Shirt in Eastling Floral and Stretch Washed Chino 2.0 in Pink Salmon
MISC
- Bonobos Stretch Denim Shirt in Bleach Wash and Stretch Washed Chino 2.0 in Pageant Blue
- Bonobos Velvet Tuxedo Blazer in Dark Gold and Capstone Italian Wool Tuxedo Pant in Black
Link to Press Kit: HERE
Bonobos wants to give every guy the chance to feel good about his own fit, to feel as comfortable in his clothes as he is in his own skin, to have confidence in his place in the world, and to use that confidence to help others along the way. Because we believe in a world where all men fit. Check out more at www.Bonobos.com.
Walmart Inc. helps people around the world save money and live better - anytime and anywhere - in retail stores, online, and through their mobile devices. Each week, approximately 230 million customers and members visit approximately 10,500 stores and clubs under 46 banners in 24 countries and eCommerce websites. With fiscal year 2022 revenue of $573 billion, Walmart employs 2.3 million associates worldwide. Walmart continues to be a leader in sustainability, corporate philanthropy and employment opportunity. Additional information about Walmart can be found by visiting https://corporate.walmart.com, on Facebook at https://facebook.com/walmart and on Twitter at https://twitter.com/walmart.
View original content to download multimedia:
SOURCE Bonobos | https://www.whsv.com/prnewswire/2022/09/06/bonobos-is-famous-fit-with-nick-kroll-new-fall-campaign/ | 2022-09-06T14:26:07Z |
SHANGHAI, Sept. 6, 2022 /PRNewswire/ -- Boqii Holding Limited ("Boqii" or the "Company") (NYSE: BQ), a leading pet-focused platform in China, today announced that it will release its unaudited financial results for the quarter ended June 30, 2022, before the U.S. market opens on Thursday, September 15, 2022.
Boqii's management will hold an earnings conference call to discuss the financial results at 8:00 AM on Thursday, September 15, 2022, U.S. Eastern Time (8:00 PM on Thursday, September 15, 2022, Beijing/Hong Kong Time). Please dial in 15 minutes before the conference is scheduled to begin using numbers below.
A replay of the conference call may be accessed by phone at the following numbers until September 22, 2022.
A live and archived webcast of the conference call will be available on the Company's investor relations website at http://ir.boqii.com/.
About Boqii Holding Limited
Boqii Holding Limited (NYSE: BQ) is a leading pet-focused platform in China. We are the leading online destination for pet products and supplies in China with our broad selection of high-quality products including global leading brands, local emerging brands, and our own private label, Yoken and Mocare, offered at competitive prices. Our online sales platforms, including Boqii Mall and our flagship stores on third-party e-commerce platforms, provide customers with convenient access to a wide selection of high-quality pet products and an engaging and personalized shopping experience. Our Boqii Community provides an informative and interactive content platform for users to share their knowledge and love for pets.
For investor and media inquiries, please contact:
Boqii Holding Limited
Investor Relations
Tel: +86-21-6882-6051
Email: ir@boqii.com
DLK Advisory Limited
Tel: +852-2857-7101
Email: ir@dlkadvisory.com
View original content:
SOURCE Boqii Holding Limited | https://www.whsv.com/prnewswire/2022/09/06/boqii-announce-fiscal-2023-first-quarter-unaudited-financial-results-september-15-2022/ | 2022-09-06T14:26:14Z |
The free online event will connect cancer patients and caregivers with the latest promising research findings shared by top immunotherapy experts, patient success stories, and clinical trial updates, on September 22, 2022, at 2 p.m. ET
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- The Cancer Research Institute (CRI), a nonprofit organization spearheading transformative research to harness the immune system's power to control and potentially cure all cancers, will offer its second annual CRI Virtual Immunotherapy Patient Summit in Spanish on September 22, 2022, 2-5 p.m. ET. This free virtual event, moderated by TV Host and Entrepreneur Ana Patricia Gámez, and presented completely in Spanish, will connect Hispanic cancer patients and caregivers with groundbreaking research updates from leading immunotherapy experts driving scientific breakthroughs and advancements that impact patient care.
According to the Center for Disease Control (CDC), cancer is the leading cause of death among Hispanic people, with current cancer research and statistics indicating a higher incidence of liver cancer, stomach cancer, and cervical cancers in the Hispanic population. With harrowing statistics like, 1 in 3 Hispanic men and women will be diagnosed with cancer in their lifetime, and 1 in 5 men and 1 in 7 women will die from the disease1, CRI continues its commitment to empower the U.S. Hispanic cancer community and help create a world immune to cancer.
Cancer immunotherapy is a form of cancer treatment that uses the body's own immune system to control and eliminate cancer. CRI is bringing the promise of immunotherapy to the underserved Spanish-speaking U.S. Hispanic community with in-language research, information, and direct access to clinical trials, to ultimately improve treatment outcomes for this patient group. CRI offers free clinical trial consultations where a professional will walk patients and their families through their immunotherapy clinical trial options. In addition, CRI will be developing content and news bites in Spanish from leading members of the CRI scientist community, sharing Hispanic-relevant information and patient stories.
"Understanding a cancer diagnosis and treatment options are a vital part of a patient success story, said Dr. Kurt Schalper, associate professor of pathology and medicine (medical oncology), Yale School of Medicine, director of the Translational Immuno-Oncology Laboratory, Yale Cancer Center, and CRI Virtual Immunotherapy Patient Summit keynote speaker. "There is an undeniable need to make information available in-language for Spanish-speaking cancer patients and caregivers. Knowledge and access to data are key components for patients to advocate for themselves and make informed choices. I am honored to be a part of CRI's second annual Cancer Immunotherapy Summit to help benefit the U.S. Hispanic cancer community."
An early diagnosis can make the difference between life and death, and overall Hispanic men and women are generally less likely to be diagnosed at an early stage, when treatment is usually less intensive and more successful. Over the past two years, the Cancer Research Institute has launched several initiatives to engage Spanish-speaking Hispanic patient and caregiver communities including the development of an immunotherapy patient information hub in Spanish we well as the first all-Spanish language CRI Virtual Immunotherapy Patient Summit, which included an informative session devoted to overcoming racial and ethnic inequalities in access to health information and care.
"Here at the Cancer Research Institute, we continue to work to address barriers that hinder scientific progress and access to Spanish-language health information and care by creating a platform for scientists and patients to share their firsthand experiences at the forefront of cancer immunotherapy research and connect with clinical trials," said Jill O'Donnell-Tormey, Ph.D., CEO and director of scientific affairs at CRI. "We hope to reach and positively impact the U.S. Hispanic cancer community via our in-language CRI Virtual Immunotherapy Patient Summit, and with the integral participation of our media sponsor TelevisaUnivision and host Ana Patricia Gámez.
"I am so very honored to be asked back to moderate the second annual CRI Virtual Immunotherapy Patient Summit in Spanish," said Ana Patricia Gámez, TV host and entrepreneur. "It is a privilege to support Hispanic cancer patients and caregivers in their healthcare journey once again, connecting the community with potentially lifesaving information and access to clinical trials. I do this in loving memory of my father, and I know he would be proud to be a part of such an important program."
"As a journalist, it is my duty to serve my community, and I am deeply grateful for the opportunity to moderate a panel and be a part of the CRI mission to better serve U.S. Hispanic cancer patients and caregivers," said Teresa Rodríguez, host of Univisionarios (Univision News).
"There is a need to engage and help our community overcome barriers to better care and treatments."
From the comfort and safety of home, attendees of the free CRI Virtual Immunotherapy Patient Summit in Spanish can expect to:
- Learn the basics of cancer immunotherapy and how it may help them or their loved one.
- Hear from and interact with leading physician-scientists with expertise in cancer immunotherapy.
- Gain valuable insight into how clinical trials work and to understand whether they are a good option for patients to explore with their healthcare team.
- Learn more about the latest research on cancers most affecting the U.S. Hispanic community.
- Discover issues specific to U.S. Hispanic communities regarding overall health care and how doctors, organizations, advocates, and individuals are addressing these challenges.
- Hear real patients who have undergone immunotherapy treatment tell their story.
Support for the Spanish-language 2022 CRI Virtual Immunotherapy Patient Summit is generously provided by the following sponsors:
Official Media Sponsor: TelevisaUnivision
- Gold:
- Silver:
- Contributor:
- Friend:
- Host Institutions
The Cancer Research Institute has pledged to help close the information and research gap and better serve the Spanish-speaking U.S. Hispanic community. Visit cancerresearch.org/es to see the robust and helpful offering of information now available in Spanish. Visit cancerresearch.org/es/conferencia to register for the free Spanish-language 2022 CRI Virtual Immunotherapy Patient Summit.
About the Cancer Research Institute
The Cancer Research Institute (CRI), established in 1953, is a top‐rated U.S. nonprofit organization dedicated exclusively to saving more lives by fueling the discovery and development of powerful immunotherapies for all cancers. Guided by a world‐renowned Scientific Advisory Council that includes four Nobel laureates and 27 members of the National Academy of Sciences, CRI has invested $500 million in support of research conducted by immunologists and tumor immunologists at the world's leading medical centers and universities and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment. To learn more, go to cancerresearch.org/es.
1 American Cancer Society. Cancer Facts & Figures for Hispanic/Latino People 2021-2023. Atlanta: American Cancer Society, Inc. 2021.
View original content to download multimedia:
SOURCE Cancer Research Institute | https://www.whsv.com/prnewswire/2022/09/06/cancer-research-institute-host-second-annual-spanish-language-virtual-immunotherapy-patient-summit-moderated-by-ana-patricia-gmez-connect-us-hispanic-cancer-community-with-information-that-can-save-lives/ | 2022-09-06T14:26:21Z |
PALM BEACH GARDENS, Fla., Sept. 6, 2022 /PRNewswire/ -- Carrier Global Corporation (NYSE:CARR) Chairman & CEO David Gitlin will speak at the 10th Annual Morgan Stanley Laguna Conference on Wednesday, Sept. 14, 2022 at 3:50 p.m. ET.
The event will be broadcast live at ir.carrier.com. A webcast replay will be available on the website following the event.
About Carrier
As the leading global provider of healthy, safe, sustainable and intelligent building and cold chain solutions, Carrier Global Corporation is committed to making the world safer, sustainable and more comfortable for generations to come. From the beginning, we've led in inventing new technologies and entirely new industries. Today, we continue to lead because we have a world-class, diverse workforce that puts the customer at the center of everything we do. For more information, visit www.Corporate.Carrier.com or follow Carrier on social media at @Carrier.
CARR-IR
View original content to download multimedia:
SOURCE Carrier Global Corporation | https://www.whsv.com/prnewswire/2022/09/06/carrier-present-morgan-stanleys-10th-annual-laguna-conference/ | 2022-09-06T14:26:27Z |
Catalyst Housing Group further demonstrates its commitment to delivering equitable social and environmental impact with new certification
LARKSPUR, Calif., Sept. 6, 2022 /PRNewswire/ -- Today, Catalyst Housing Group, a mission-driven investment firm, announced that it has officially become a Certified B Corporation, documenting its commitment to effective and sustainable change, and demonstrating its continued leadership in developing innovative, scalable pathways to delivering housing affordability for all.
Over the past two years, Catalyst has participated in rigorous B Corporation certification and assessment processes requiring tangible documentation of its mission-aligned business practices. Having formally obtained B Corporation certification, Catalyst joins a growing community of mission-driven businesses adopting rigorous social and environmental impact standards and committed to fostering effective and sustainable change. Prioritizing transparency, sustainability and the common good, Catalyst was built on ideals that remain fully aligned with the requirements for B Corporation certification, further demonstrating its relentless pursuit of a more inclusive, equitable, and affordable housing market.
"Catalyst was founded with the belief that a mission-driven investment firm, fueled by innovation and impact, could radically alter the delivery of desperately needed affordable housing," said Jordan Moss, Founder and CEO of Catalyst Housing Group. "Obtaining Certified B Corporation status is a direct reflection of our team's successes to date and continued dogged pursuit of scalable solutions to the lack of quality affordable housing across the socioeconomic spectrum."
Catalyst's financial innovations include the formation of an entirely new asset class, which Catalyst coined "Essential Housing," to provide affordable rental housing to California's essential workforce - the nurses, teachers, and first responders who earn too much to qualify for traditional affordable housing, yet not enough to live directly within the communities they serve. Catalyst's leadership in the development of an open-sourced Essential Housing framework have resulted in the creation of approximately 14,000 units of governmentally owned, income-restricted rental housing throughout California.
Catalyst Housing Group is a mission-driven housing provider investing at the intersection of innovation and impact. We bridge wealth and opportunity gaps through the scaled delivery of pioneering capital solutions that empower generational change for our residents, our communities, and our environment. For more information, please visit www.catalysthousing.com.
Media Contact:
Anna Sugg
asugg@actumllc.com
View original content:
SOURCE Catalyst B Corp | https://www.whsv.com/prnewswire/2022/09/06/catalyst-housing-group-announces-b-corp-certification/ | 2022-09-06T14:26:33Z |
Acquisition Expands Cost Reducing Energy Supply Options for the Underserved Middle-Market Commercial and Industrial Customer
ROCHESTER, N.Y., Sept. 6, 2022 /PRNewswire/ -- Catalyst Power Holdings LLC ("Catalyst Power"), an integrated provider of cleaner energy solutions for the commercial and industrial sector, acquired the assets of Northeast Expense Reduction Services, a New York-based energy advisor. The acquisition deepens Catalyst Power's role in Central and Western New York State's energy transition allowing it to expand on its mission of helping its commercial and industrial customers to decarbonize their electricity consumption.
"This is a tremendous fit. We're excited to be able to expand the mix of commercial and industrial customers that can now have access to Catalyst Power's decarbonizing solutions," said Gabriel Phillips, CEO of Catalyst Power Holdings. "The middle market has been underserved for too long – by combining Northeast Expense Reduction Services' territories, customers and supplier relationships with our novel energy supply options including community solar products and proprietary Connected Microgrid solutions, we are expanding access for our customers to more environmentally friendly, money saving energy supply options."
"New York's C&I sector is getting hit by rising energy bills driven by volatile fossil fuel prices–and the clean energy solutions offered by Catalyst Power offer a reliable, cost-saving solution for these businesses. The team at Catalyst Power is fantastic and provides a wide range of clean energy solutions that can help small and mid-sized businesses," said Clark Taylor, founder of Northeast Expense Reduction Services.
Catalyst Power develops innovative energy supply solutions for commercial and industrial companies, with a focus on a first-of-its-kind network of Connected Microgrids, a no-up-front-cost custom solution using onsite solar panels and with back-up generators, as well as retail power and gas supply. Catalyst Power provides small- to industrial-sized businesses access to distributed generation through our network of Connected Microgrids. The company utilizes a proprietary technology platform that provides a fresh perspective on data to identify, underwrite, fund, and provide solutions to customers while operating more cost-effective onsite energy projects for our retail energy clients.
Catalyst Power continues to pursue additional strategic REP and advisor acquisition opportunities. Businesses interested in partnering with Catalyst Power or learning more can visit: https://catalystpower.com/about-us/
Catalyst Power Holdings LLC is an independent, integrated provider of cleaner energy solutions for the commercial and industrial sector through commercial energy, customized Connected Microgrid solutions, and community solar to underserved middle-market commercial and industrial end-use customers, improving the overall efficiency and environmental impact of their supply. Catalyst Power is a portfolio company of BP Energy Partners, LLC. More info: www.catalystpower.com
BP Energy Partners, LLC (BPEP), is a Dallas, Texas based growth-oriented private equity firm. Since inception, BPEP has focused on a lower carbon future by establishing and growing sustainable and responsible companies in the natural gas value chain including infrastructure, power, logistics, transportation, environmental services, renewable natural gas, midstream, and distribution. BPEP will also invest in low carbon energy solutions and renewables. BPEP collaborates with entrepreneurs, family-owned businesses, project developers, and experienced management teams to provide patient capital, financial and operating expertise, and deep industry relationships. BPEP currently manages over $560 million in committed capital and is actively investing in new opportunities. More information can be found at www.bpenergypartners.com
View original content:
SOURCE Catalyst Power | https://www.whsv.com/prnewswire/2022/09/06/catalyst-power-announces-acquisition-northeast-expense-reduction-services/ | 2022-09-06T14:26:39Z |
ST. LOUIS, Sept. 2, 2022 /PRNewswire/ --
Landing 750 and Setting the Course for More
Chapman Foundation for Caring Communities is excited to announce that it has completed 750 (seven hundred and fifty) training courses in communication skills. The powerful three-day communication course "Our Community Listens" is conducted in partnership with communities, organizations, and businesses from around the globe to improve the communication skills of people from all walks of life. "We would like to thank our alumni, collaborators, and partners for being a part of this successful milestone," said Misty Janks, Foundation CEO.
A Decade of Dedication
In 2012, Chapman Foundation for Caring Communities began offering communication skills training to communities across the United States. A decade later, more than 13,000 individuals have healed relationships and grown as leaders through this unique learning experience. Our most recent alumni, photographed above, took the Our Community Listens course in Charleston, South Carolina. Participants included law enforcement officers, first responders, military personnel, corporate executives, social workers, graphic designers, software developers, and healthcare professionals—all from the same community.
What is Our Community Listens and how can it help you in your personal and professional life?
The Our Community Listens course is designed to help participants learn how to listen effectively, become more empathetic, and build better relationships. These skills are essential for success in both personal and professional contexts. In addition, the experience offered by Chapman Foundation for Caring Communities will help you to learn what motivates your team members and improve self-awareness.
Who is eligible to participate in Our Community Listens and Other Courses Offered by Chapman Foundation for Caring Communities?
Chapman Foundation for Caring Communities offers communication skills training courses to anyone who wishes to deepen their connections at work or home through people-centered relationships. The for-good organization seeks opportunities for collective impact to create communities of care. Join dozens of partners and collaborators that have already chosen Chapman Foundation for Caring Communities as their provider of transformational learning experiences.
How can you sign up for a communication skills training course near you?
To sign up for a virtual online course or in-person course near you, visit the foundation's website (chapmancommunities.org) and sort by location, date, class type, or learning experience. You can also contact the foundation directly to learn more.
Media Contact: Joshua Gale
joshua.gale@chapmancommunities.org
View original content to download multimedia:
SOURCE Chapman Foundation for Caring Communities | https://www.whsv.com/prnewswire/2022/09/06/chapman-communities-celebrates-decade-dedication/ | 2022-09-06T14:26:46Z |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.